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Gastric cancer is the second most common cancer world-wide. Patients with 
gastric cancer often presented with advanced stage and the prognosis is extremely 
poor. Despite the introduction of new treatment modality, like various 
chemo-irradiation regimen, the mortality rate has remained relatively unchanged over 
the past 30 years and the overall 5-years survival rate is only 10-20%. Thus new 
therapeutic approaches are urgently needed. Advances in the understanding of 
carcinogenesis may provide insights in development of new treatment options. 
Recent researches indicated that histone acetylation represents an important 
epigenetic mechanism that controls gene expression, including silencing of cancer 
related genes or tumor suppressor genes. The control of histone acetylation depends 
on activities of two sets of enzymes, histone acetyltransferase (HAT) and histone 
deacetylase (HDAC). HDAC inhibitors, which inhibit the HDACs activities, have 
been implicated as a new treatment strategy. However, data related to HDAC 
inhibitors on gastric cancer is limited. In the current study, a gastric cancer cell line 
AGS model is used to investigate the potential anti-cancer effect of HDAC inhibitors, 
Suberoylanilide Hydroxamic Acid (SAHA) and Trichostatin A (TSA). The results 
indicated that both SAHA and TSA exhibited anti-proliferative effect, apoptosis 
induction and G2/M phase cell cycle arrest in AGS cells. These observations 
suggested that HDAC inhibitors may have anti-cancer effects in gastric cancer. We 
further investigated the gene expression alterations upon treatment with SAHA and 
TSA in gastric AGS cell line to explore the potential mechanism underlying the 
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anti-cancer effect. By microarray expression analysis, a small subset of genes were 
altered after treatment with HDAC inhibitors: around 2% in SAHA (at 4|liM 
concentration and 24 hours treatment) and around 3% in TSA (at lOOng/ml 
concentration and 24 hours treatment) experiments. Overlapping genes altered after 
treatment of SAHA and TSA constitute more than 1% of genome. Among these 
altered overlapping genes, more than half were hypothetical genes with unknown 
functions while the remaining genes were related to various cellular pathways 
including anti-proliferation and apoptosis. Selected up-regulated genes after treatment 
of HDAC inhibitors were further confirmed by real time RT-PCR. In particular, after 
SAHA and TSA treatments, pro-apoptotic or apoptosis induction genes including 
BCL-2 interacting killer {BIK), BCL-2 antagonist/killer 1 (BAKl), cell 
death-inducing DFFA-like effector b (CIDEB), thioredoxin interacting protein 
(TXNIP) were up-regulated while B-cell CLL/lymphoma 2, alpha (BCL-2) and 
BCL2-associated X protein (BAX) were unaltered. Anti-proliferating genes including 
B-cell translocation gene 1 (BTGl), quiescin 6 (QSCN6), cysteine-rich, angiogenic 
inducer, 61 (CYR61) and metallothionein 2A (MT2A) were up-regulated. Cell-cycle 
related genes including and signal-induced proliferation-associated gene 1 
(SIPAl) were up-regulated but cyclin A and cyclin E were not induced. 
Furthermore, we also identified potential tumor suppressor genes that are known to 
be silenced by gene promoter methylation, like TSLCl and SOCS-1 which may also 
controlled by histone acetylation. In summary, selected subsets of genes were 
up-regulated after treatment of HDAC inhibitors in AGS cells, which may correlate 
with the anti-cancer effects. The observations suggested that further animal or clinical 
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studies are warranted to further investigate and document the potential anti-cancer 
effect of HDAC inhibitors for the deadly gastric cancer. The results also suggested 
that specific sets of genes are suppressed by histone modification and this may be 
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我們選出部分去乙酰酶抑制劑處理後表達增加的基因，用real time RT-PCR的方 
法進行確認。結果顯示TSA和SAHA處理後，細胞凋亡或前細胞凋亡基因 
BIKJBAKl, CIDEB, 表達增加可是BCL-2,万的表達並沒有改變；抑制細 
胞增殖基因BTG1, QSCN6, CYR61，MT2A表達增加；細胞週期控制基因p21誦， 
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Chapter 1 Introduction 
Gastric cancer is the second most common cancer world-wide (Bozzetti R, 
Marubini E. et al. 1999). Patients with gastric cancer often presented with 
advanced stage and the prognosis is extremely poor. Surgical resection remains 
the primary treatment for patients with gastric cancer. However, surgical 
resection only can apply on patients with resectable gastric cancer and greater 
than 50% of patients suffered from unresectable locally advanced or metastasis 
disease (Dicken B. J., Bigam D. L. et al. 2005). Despite the introduction of new 
treatment modality, like various chemo-irradiation regimen, the mortality rate has 
remained relatively unchanged over the past 30 years and the overall 5-years 
survival rate is only 10-20% (Msika S.，Benhamiche A. M. et al. 2000; Green D.， 
Ponce de Leon S. et al. 2002). Thus new therapeutic approaches are urgently 
needed. Advances in the understanding of carcinogenesis may provide insights in 
development of new treatment options. Recent researches indicated that histone 
acetylation represents an important epigenetic mechanism that control gene 
expression, including silencing of cancer-related genes or tumor suppressor 
genes. Histone acetylation depends on the enzyme activities of histone 
acetyltransferase (HAT) and histone deacetylase (HDAC). Inhibition of HDAC 
leads to relaxation of chromatin structure and facilitate genes transcription. 
HDAC inhibitors subsequently found to have anti-cancer effects. Some of the 
HDAC inhibitors have been entered into phase I and phase II clinical trials for 
certain cancers. The observations suggested that HDAC inhibitors represent an 
emerging new treatment approach to combat cancer. However data on the 
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potential anti-cancer effect of HDAC inhibitors for gastric cancer is limited. Thus, 
in my study, I would like to investigate the potential anti-cancer effects of HDAC 
inhibitors in a gastric cancer cell model. In addition, gene expression alterations 
after treatment with HDAC inhibitor will be studied to provide further insights in 
the underlying mechanism(s) associated with the potential anti-cancer effects. 
2 
Chapter 2 Literature Review 
2.1 Gastric cancer-overview 
2.1.1 Epidemology 
Gastric cancer is the second most common fatal cancer worldwide and 
accounts for 3% to 10% of all cancer related deaths, with a frequency that varies 
greatly across different geographic locations (Dicken B. J., Bigam D. L. et al. 
2005). In mainland China, gastric cancer is the second most common 
gastrointestinal cancer. The incidence of stomach cancer in Hong Kong is about 
1000 new cases per year. The incidence rate ranked sixth of all cancer in Hong 
Kong and the mortality rate ranked forth of all cancers in 2002. Most patients are 
diagnosed at age between 60s to 70s. Gastric adenocarcinoma comprises 90% to 
95% of all malignant gastric tumors, while the remainder consists of lymphomas, 
stromal tumors and other rare tumors (Master S. S. 2004). 
2.1.2 Pathology 
Gastric adenocarcinoma (GCA) more commonly arising from gastric 
antrum, followed by gastric body and fundus. Adenocarcinoma arising from 
gastric cardiac is less common. GCA can be divided into two main histology 
types, namely intestinal and diffuse types. Mixed type including both intestinal 
and diffuse histology is also not uncommon. Other histological types including 
3 
undifferentiated carcinoma are rare. The intestinal type composes of malignant 
glands while diffuse type composes of dis-cohesive infiltration of individual 
cancer cells. The cancer cells in diffuse type can contain large cytoplasmic mucin 
vacuoles compressing the nuclei and producing signet ring appearance. When 
GCA is confined in the mucosa or submucosa, it is considered as early gastric 
cancer with a better prognosis. When GCA invade the gastric muscular wall or 
beyond, it represents advanced gastric cancer and carry very poor prognosis. The 
cancer can spread via lymphatic to regional lymph nodes or invades serosa and 
spread through peritoneal cavity. Distant haematogenous spread usually 
developed in later phase of disease. 
2.1.3 Etiologies and Risk Factors 
In gastric cancer, both environmental and genetic factors are implicated. 
I. Environmental factors 
a, Helicobacter pylori infections 
Helicobacter pylori (HP) infection is regarded as type I carcinogen by WHO. 
H. pylori are highly host-adapted bacterial pathogens that establish a chronic 
infection in the human stomach and have no known animal and environmental 
reservoirs. This chronic infection has high degree genetic heterogeneity caused 
by mutations and frequent recombination (Shang J. and Pena A. S. 2005). H. 
pylori infection is more common in Asian population and which may link to 
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higher incidences of gastric cancer in Asian. H. pylori infection is often 
associated with intestinal type gastric adenocarcinoma (GCA). H. pylori 
infection could result in gastritis, gastric atropy, intestinal metaplasia and may 
followed by dysplasia and development of GCA. Certain strains, like cagA strain 
of H. pylori have been implicated as having higher risk of GCA. 
H. pylori alter the expression of genes encoding growth factors and 
cytokine/chemokines and their receptors, apoptosis proteins, transcription factors 
and metalloprotease-disintegrin proteins and tissue inhibitors of 
metalloproteinases (Shang J. and Pena A. S. 2005). It has been postulated that H. 
pylori increased DNA damage in epithelial cells which in turn may increase 
apoptosis (Chan A. O., Luk J. M. et al. 1999). It also suggested that H. pylori 
stimulate endothelical cells to induce adhesion molecule expression, increase 
neutrophil-recruiting chemokines production which in turn cause tissue damage 
and ulcer formation (Shang J. and Pena A. S. 2005). In patients with normal 
gastric mucosa, gastritis, gastric ulcer and duodenal ulcer, down-regulation of 
E-cadherin protein was found to be significantly correlated to H. pylori infection 
(Chan A. O., Luk J. M. et al. 1999). Previous studies also demonstrated that the 
degree of H. pylori infection was portion to the level of human telomerase RNA 
expression and telomerase positivity in gastric carcinoma (Chan A. O., Luk J. M. 
et al 1999). Studies also suggested that p53 alterations were associated with H. 
pylori-^osiiivQ gastric (Shang J. and Pena A. S. 2005). These findings suggested 
that H. pylori may predispose to carcinogenesis by increasing the likelihood of 
DNA mutagenesis. 
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During infection, a wide variety of antigens were produced which lead to 
immune response involving a complex of inflammatory mediators including 
cytokines such as interleukin-7y^ and tumor necrosis factor-a. The expressions of 
these cytokines have also been implicated in gastric carcinogenesis. 
b. Epstein-Barr virus (EBV) 
Epstein-Barr virus (EBV) is a gamma herpesvirus which was discovered 40 
years ago. A subset of gastric adenocarcinoma (GCA) is associated with clonal 
proliferation of EBV, which appears more common in oriental population. In 
south-east Asia and Japan, EBV associated GCA constitute ~ 5 to 10 % of GCA. 
EBV-associated gastric carcinoma is observed both intestinal and diffuse type 
GCA. The tumor cells carry latent EBV infection. The EBV is clonal in nature 
and suggested that EBV infection may not be just by stander but pathogenically 
important. 
c. Dietary factors 
Diet rich in vitamin A and C, grains and anti-oxidants may decrease the risk 
of gastric cancer. Whereas foods that rich in salted, pickled foods and complex 
carbohydrates are associated with higher risks in gastric cancer. 
d. Smoking 
Smoking is associated with increased risk of gastric cancer (Shang J. and 
PenaA. S. 2005). 
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II. Genetic Factors 
a. Hereditary Gastric Cancer 
Although most gastric adenocarcinomas occur sporadically without 
inherited predisposition, a small proportion of gastric cancers arise in clearly 
identified inherited gastric cancer predisposition syndromes. These include 
Hereditary Diffuse Gastric Cancer Syndrome (HDGC), Hereditary Nonpolyposis 
Colorectal Cancer Syndrome (HNPCC), Li-Fraumeni Syndrome (LFS) and 
Familial Adenomatous Polyposis (FAP). The understanding of these genetic 
abnormality underlying hereditary gastric cancer not only offers the opportunity 
for prevention and surveillance for affected individuals, but also offer clues to the 
molecular pathology of gastric cancer. 
Hereditary Diffuse Gastric Cancer Syndrome (HDGC) is a distinctive 
autosomal dominant inherited gastric cancer susceptibility syndrome and results 
from germline mutations in E-cadherin (CDHl) gene that involved in cellular 
adhesion (Lynch H. T., Grady W. et al 2005). Defect in CDHl gene has been 
linked to the diffuse type of gastric cancer (Caldas C. 1999). Gastric cancer 
families with E-cadherin mutation have been reported. Affected individuals 
inherit one copy of the defective gene. Somatic mutation or deletion inactivates 
the other copy. In addition, MADH4, CHK2, and caspase-10 germline mutations 
have also been analyzed in HDGC families (Lynch H. T., Grady W. et al 2005). 
Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC) is a 
syndrome caused by germline mutations in mismatch repair genes such as MSH2, 
MLHl，MSH6, PMSl, and PMS2. Defects in these genes result in microsatellite 
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instability (MSI), which will be discussed in later section. Stomach cancers arise 
in � l io /o f HNPCC families and have been shown to occur in families with 
MSH2, MLHl or MSH6 germline mutations (Vasen H. R, Wijnen J. T. et al 1996; 
Aamio M., Salovaara R. et al 1997). 
Li-Fraumeni Syndrome (LFS) is characterized by multiple primary 
malignancies. It is caused by germline mutations of TP53 and predispose to 
soft-tissue sarcomas, leukemia, brain cancer, adrenal cortical carcinoma, breast 
cancer and gastric cancer in some families. Gastric cancers, both intestinal and 
diffuse types, can occur in LFS (Oliveira C.，Ferreira P. et al. 2004). 
Familial Adenomatous Polyposis (FAP) is caused by germline mutations in 
APC gene. This disorder is inherited in an autosomal dominant pattern with high 
penetrance. FAP is associated with gastric fundic gland polyposis and increased 
risks of gastric adenocarcinoma. Gastric adenocarcinomas in FAP family 
members are generally believed to arise from adenomas, but there is evidence 
suggesting that fundic gland polyps have the potential to transform into 
adenocarcinomas (Hofgartner W. T., Thorp M. et al 1999). 
b. Genetic polymorphism 
Cytokines are important mediators that participated in inflammatory 
response which associated with both innate immunity and acquired immune 
responses. Genes harbor polymorphic regions that would alter gene transcription 
and thereby influence inflammatory response to infectious diseases (Perez-Perez 
G. L, Garza-Gonzalez E. et al. 2005). Polymorphisms in human interleukin-7y^ 
(IL-lp), interleukin-10 (IL-10), TNF-A, IFN-G and IL-IRN genes have been 
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reported to influence cytokine expression. 
Cytokines such as IL-ip, TNF-a and INF-y are up-regulated in the presence 
of H. Pylori infection. In gastric cancer, several cytokine polymorphisms which 
include IL-ip, IL-10, TNF-a have been evaluated as risk factors. Interleukin-1 
(IL-1) gene emcompasses a gene cluster on chromosome 2q. This cluster 
includes three related genes IL-1 A, IL-IB and IL-IRN that encode the 
proinflammatory cytokines, IL-1 a, IL-1/3 and their endogeneous receptor 
antagonist, IL-lra (Roberts-Thomson 1. C. and Butler W. J. 2005). Polymorphism 
of IL-ip and IL-IRN genes may increase susceptibility of gastric cancer (Shang J. 
and Pena A. S. 2005). TNF-a is closely related to epithelial injury and plays a 
crucial role in host defense against infection. However high concentration of 
TNF-a may cause severe pathology (Shang J. and Pena A. S. 2005). The 
increased concentrations of TNF-a alter the immune response which confers 
susceptibility to gastric disease with H. Pylori-cdigA subtype infection (Shang J. 
and Pena A. S. 2005). 
Gene polymorphism of some metabolizing enzymes such as 
N-acetyltransferase 1 (NATl) and glutathione S-transferase were also implicated. 
Environmental genotoxic chemical agents arising from the diet, smoking and air 
pollution are potential carcinogenic to humans. The NATl allele, NATl-10 is 
associated with enhanced acetylation that may promote the genotoxicity of 
carcinogens in cigarette smoker (Roberts-Thomson I. C. and Butler W. J. 2005). 
Higher risks have been found in smoker with deletion of glutathione 
S-transferase genotype (null variants) (Roberts-Thomson 1. C. and Butler W. J. 
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2005). 
III. Cyclooxygenases (COX) enzymes 
Cyclooxygenases are rate-limiting enzymes in the synthesis of 
prostaglandins. There are two COX isoenzymes: COX-1, which is ubiquitously 
expressed and responsible for physiologic functions and COX-2, which is an 
inducible enzyme and is linked to inflammation and carcinogenesis (Mrena J., 
Wiksten J. P. et al. 2005). Overexpression of COX-2 has been reported in various 
types of gastrointestinal malignancies, including gastric, colorectal, pancreatic 
and esophageal cancers (Kikuchi T., Itoh F. et al 2002). Overexpression of 
COX-2 is shown in human gastric cancer tissues and selective COX-2 inhibitor, 
like celecoxib, can suppress tumor formation in a trefoil factor 1-deficient mouse 
model of gastric carcinogenesis (Mrena J., Wiksten J. P. et al 2005). Previous 
studies reported that transgenic expression of COX-2 and microsomal 
prostaglandin E synthase could induced hyperplasia or tumors in mouse stomach 
and celecoxib could reduced chemically-induced gastric carcinogenesis in rat 
(Mrena J., Wiksten J. P. et al 2005). However, the regulation of COX-2 
expression in gastric cancer is poorly known. Recent studies indicated that 
COX-2 is associated with loss of apoptosis, enhancement of proliferation and 
tumorgenesis (Yu J., Leung W. K. et al. 2003). In gastric cancer, lack of 
overexpression of COX-2 is related to gene methylation and histone 
deacetylation (Kikuchi T., Itoh F. et al 2002; Yu J., Leung W. K. et al 2003). 
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IV. Molecular carcinogenesis 
There is proposal suggesting that gastric cancer may develop along three 
pathways: an intestinal metaplasia - adenoma - carcinoma sequence, an intestinal 
metaplasia -carcinoma sequence and de novo (Tahara E. 2004). Molecular 
alteratons in gastric adenocarcinoma are summarized in following paragraphs. 
a. Activation of proto-oncogenes 
Several proto-oncogenes have been implicated in gastric carcinogenesis. 
Three genes located at 17q21 locus, namely HER2/NEU, T0P2A, and DARPP32 
are overexpressed in human primary gastric cancers (Varis A., Zaika A. et al 
2004). Only elevated expression of HER2/NEU was observed in intestinal type 
gastric adenocarcinoma (GCA) while only TOP2A expression was detected in 
diffuse type GCA. In contrast, overexpression of DARPP32 was detected in both 
histological subtypes (Varis A., Zaika A. et al 2004). Enhanced expression of 
Ras oncogene has been demonstrated in gastric cancers (Noguchi M., Hirohashi 
S. et al 1986) and more often in intestinal type GCA (Yoshida K., Hamatani K. 
et al 1988). Yamamoto's group studied 174 gastric cancers and showed that 
co-expression of Ras and TGF-a correlated with stage, grade, depth of invasion, 
presence of lymphatic metastases and poor prognosis (Yoshida K., Hamatani K. 
et al 1988). In addition, overexpression of c-myc gene has been reported in 
gastric cancer (Shibuya M., Yokota J. et al 1985) and correlated with the stage of 
disease, depth of invasion and peritoneal dissemination (Ninomiya L, Yonemura 
Y. et al 1991). 
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b. Candidate tumor suppressor genes 
Tumor suppressor genes may be altered by mutation or silenced by deletion 
or epigenetic mechanism. 
1. Gene mutation and deletion 
p53 
p53 protein expression is related to regulation of cell growth, initiation of 
programmed cell death or apoptosis. Studied by loss of heterozygosity (LOH) 
analyses, allelic deletions involving the p53 locus have been detected in more 
than 60% of gastric cancers (Chan A. O., Luk J. M. et al. 1999). Investigators 
have noted that p53 mutation would be an early event in intestinal gastric cancer, 
and it does not correlate with stage progression (Wu M. S., Shun C. T. et al. 
1997). 
Adenomatous polyposis gene (APC) 
Deletion 5q and somatic mutation of APC gene have been observed in 8% 
of gastric cancers. Moreover, APC may also be silenced by promoter methylation. 
APC protein is located in the cytoplasm and binds to the adherent junction 
proteins, a- and p-catenin (Chan A. O., Luk J. M. et al 1999). APC protein 
interacts with E-cadherin and p-catenin and plays an important role in cell 
signaling. 
Delection in Colon Cancer (DCC) 
DCC is also frequently involved in gastric cancer. This tumor suppressor 
gene is located on chromosome 18q. DCC could be inactivated by allelic deletion 
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and promoter hypermethylation. DCC expression is more often down-regulated 
in well-differentiated as compare to poorly-differentiated GCA (Chan A. O.，Luk 
J. M. etal. 1999). 
RUNX3 
RUNX2 is normally expressed in gastric epithelia. In an animal model 
experiment, RUNX3 knockout mice exhibited gastric epithelial hyperplasia with 
suppression of apoptosis (Li Q. L.，Ito K. et al 2002). RUNX3 is frequently 
down-regulated in gastric cancer cell lines and primary gastric cancer tissues by 
gene mutation or promoter hypermethylation. Further investigations into the role 
of RUNX3 in gastric carcinogenesis are underway. 
2. Epigenetic Silencing 
Cancer-related genes or tumor suppressor genes can be silenced by 
epigenetic mechanisms which appeared frequently in human cancers. The two 
most well known mechanisms are gene promoter hypermethylation and histone 
acetylation. Increasing lists of cancer-related genes silenced by such mechanisms 
have been reported in GCA. A more in depth discussion will be presented in 
section of "Epigenetics" (please refer to section 2.2). 
Microsatellite instability (MSI) 
Microsatellites are tandem repeats found throughout the human genome 
(Eshleman J. R. and Markowitz S. D. 1996). Any changes in the repetitive 
sequence caused by insertion or deletion in tumor tissue as compared to the 
normal are called microsatellite instability (MSI). Germline mutations in DNA 
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repair genes (MSH2, MLHl, MSH6, PMSl, and PMS2) would lead to 
microsatellite instability and hereditary HNPCC phenotype as describe in 
previous section. Apart from mutation, DNA-repair genes, like MHLl can also 
be silenced by promoter hypermethylation. Altered lengths of microsatellite 
marker is the hallmark of replication errors (RERSs) phenotype and has been 
described in a number of human malignancies, including gastric cancer (Semba 
S., Yokozaki H. et al. 1998). Sporadic gastric cancers may be classified as 
microsatellite stable (MSS), microsatellite instability-low (MSI-L) or 
microsatellite instability-high (MSI-H). The frequency of MSI (MSI-H and 
MSI-L) is about 20 to 30% in gastric cancers (Yasui W., Oue N. et al 2005). 
Many studies demonstrated that MSI gastric cancer is associated with less 
aggressive behavior and more favorable prognosis. (Yasui W., Oue N. et al 
2005). 
2.2 Epigenetics 
In 1942, Biologist Waddington defined epigenetics as “the branch of 
biology which studies the causal interactions between genes and their products 
which bring the phenotype into being" (Slack J. M. 2002). However, in modem 
view, epigenetic is defined as heritable changes in gene expression that does not 
involve changes in the sequence of nuclear DNA and can persist through one or 
more than one generations (Lengauer C. and Issa J. P. 1998; Mai A., Massa S. et 
al. 2005). In recent years, rapid progress has been made in understanding 
epigenetic mechanisms in regulation of gene expression. Epigenetic regulations 
involve changes in the structure (remodeling) of chromatin through covalent 
modifications of histone proteins and DNA methylation (Li E. 2002). Such 
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epigenetic control mechanism is important in normal development as well as in 
various diseases. It play important roles in various biological processes, 
including X chromosome inactivation (Avner P. and Heard E. 2001), genomic 
imprinting (Feinberg A. P. 2001), developmental abnormalities (Feinberg A. R 
2001), activity of mobile genetic elements (Hagan C. R. and Rudin C. M. 2002) 
and also implicated in cancer biology (Baylin S. B. 1997), viral latency 
(Robertson K. D.，Ait-Si-Ali S. et al. 2000; Takacs M., Salamon D. et al. 2001), 
somatic gene therapy (El-Osta A. and Wolffe A. P. 2000; Rideout W. M., 3rd, 
Eggan K. et al. 2001), cloning and transgenic technologies. 
The two important epigenetic mechanisms include gene promoter 
hypermethylation and histone modification will be discussed in following 
sections. 
2.2.1 DNA methylation 
DNA methylation is a complex process which has profound effects on the 
mammalian genome. It affects CpG dinucleotide where DNA methyltransferases 
(DNMTs) catalyze the addition of a methyl group from the universal methyl 
donor S-adenosyl-L-methionine to the 5-carbon position of cytosine. It is widely 
spread throughout the genome that accounts for 70% of all CpG dinucleotides 
(Figure 1). There are three major catalytically active mammalian DNMTs, 
include DNMT 1, DNMT 3a and DNMT 3b (Bestor T. H. 2000). DNMTl is 
essential for maintaining DNA methylation patterns in proliferating cells (Li E., 
Bestor T. H. et al. 1992). Whereas DNMT 3a and DNMT 3b are required for the 
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initiation of de novo methylation in vivo and for establishing new DNA 
methylation patterns during development (Hsieh C. L. 1999). This finding 
suggests that these three enzymes may have different targets or requirements 
during methylation. 
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Figure 1 DNA methylation in the human genome occurs nearly exclusively at 
cytosine residue within CpG dinucleotide (Worm J. and Guldberg P. 2002). 
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Figure 2 Gene promoter hypermethylation associated with cancer progression. 
Completely unmethylated state of a promoter CpG island (white dots) is 
associated with transcriptional activity, whereas hypermethylation (black dots) 
causes transcriptional silencing (Worm J. and Guldberg P. 2002). 
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There are two major types of DNA methylation changes have been observed 
in human cancers. On one hand, the amount of methylated cytosine is reduced 
and referring to hypomethylation (Feinberg A. R，Gehrke C. W. et al 1988). Or 
on the other hand, genes are transcriptionally silenced by promoter 
hypermethylation (Figure 2) (Jones P. A. and Laird P. W. 1999). Cancer-related or 
tumor suppressor genes silenced by gene promoter hypermethylation is a very 
common observation in human cancer and has been described in almost every 
tumor types. However, the methylation patterns appear different in different 
cancers. Moreover, methylation phenotypes have been described in certain types 
of cancers, like colorectal cancer. Nevertheless, some of the genes appear more 
frequently silenced by gene hypermethylation (Table 1). For examples genes 
involved in cell cycle (pi6•’ pi5麵，職 pi严),DNA repair (BRCAl’ 
hMLHl, MGMT), carcinogen-metabolism (GSTPl), cell-adherence (CDHl, 
CDHI3) and apoptosis (DAPK, TMSI). 
Gene promoter hypermethylation is also commonly identified in gastric 
cancer. A selected set of genes that frequently reported to be inactivated by gene 
promoter hypermethylation will be presented in following paragraphs. 
Both pi严 and p l G ^ Q (CDKN2A) are located on chromosome 9p21 that 
encodes two unique proteins which share an exon in different reading frames. 
Chromosome 9p21 demonstrated a high frequency of loss of heterozygosity in 
gastric cancers (lida S.’ Akiyama Y. et al 2000). Inactivation of •如 by 
mutations, homozygous deletions or gene methylation was observed in many 
tumors (Song S. H., Jong H. S. et al 2000). pl6i融 specifically inhibits the 
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interactions between CDK4/CDK6 and cyclin D1 which result in blockage of the 
progression of cell cycle from G1 to S phase (Song S. H., Jong H. S. et al. 2000). 
The frequency of 卩16狐4“ methylation in gastric cancer ranging from 10 % to 
65.4 % (lida S., Akiyama Y. et al. 2000; Leung W. K., Yu J. et al 2001; To K. F., 
Leung W. K. et al. 2002; Sarbia M., Geddert H. et al 2004). pl4層 functions as 
a stabilizer of the tumor suppressor protein p53 as it can interact and induce 
degradation of the MDM2 protein that responsible for the degradation of p53 
(lida S., Akiyama Y. et al. 2000). Methylation of pi4層 have been reported in 
gastric cancer, with a frequency ranging from 10 % to 32 % in gastric tumors 
(lida S., Akiyama Y. et al. 2000; To K. R, Leung W. K. et al. 2002; Sarbia M., 
Geddert H. et al. 2004). 
gene jg an inhibitor of cyclin-dependent kinase 4 which is an 
important mediator of cell cycle control especially in the pathway stimulated by 
transforming growth factor. In previous study, the frequency of hypermethylation 
ofp][5iNK4B was found to be 73.1% in 26 gastric carcinomas (Leung W. K., Yu J. 
et al. 2001). In addition, previous study demonstrated from our team indicated 
that tumor tissues had significantly more frequent methylation than intestinal 
metaplasia (To K. R, Leung W. K. et al 2002). These finding suggested that 
aberrant methylation of 口15腿48 ^^g frequently detected in gastric cancer and 
is involved in the multistep progression of gastric carcinogenesis. 
Hymethylation of Human MutL homolog 1 QiMLHl) is DNA 
mismatch-repair gene whereas mutation and promoter methylation are found to 
contribute to a substantial proportion of sporadic gastric cancer which displays 
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microsatellite instability phenotypes (Leung W. K., Yu J. et al 2001). Studies 
have demonstrated that hMLHl had comparable methylation frequency in gastric 
cancer (29%; 9 of 31) and intestinal metaplasia (22%; 8 of 36) (Leung W. K.，Yu 
J. et al 2001). 
Ras association domain family 1 {RASSFl) gene has more than seven 
isoforms including RASSFIA, RASSFIB and RASSFl Q which are derived from 
different mRNA alternative splicing and span about 7.6 kb (Byun D. S.，Lee M. G. 
et al 2001). Among the seven isoforms, RASSFIA is the most commonly studied 
isoform for promoter hypermethylation in a variety of tumors. Transcriptional 
silencing of RASSFIA was observed in various cancers, such as lung, breast, 
gastric, ovarian and nasopharyngeal cancers by de novo methylation at the CpG 
island in the promoter region (Burbee D. G, Forgacs E. et al. 2001). RASSFIA is 
a novel tumor suppressor gene that identified at 3p21.3. It has two 5' exons and 
encodes a 39 kDa peptide (Byun D. S., Lee M. G et al. 2001). It contains a 
predicted diacylglycerol (DAG) binding domain that is also found in the related 
protein NOREl but not in RASSFl (Byun D. S., Lee M. G et al. 2001). In 
previous gastric cancer studies, it was found that RASSFIA transcript was 
expressed in 60% (9 of 15) of gastric carcinoma cell lines (Byun D. S., Lee M. G. 
et al. 2001). 
DNA-repair enzyme human 0^-methylguanine-DNA methyltransferase 
(MGMT) gene inhibits the killing of tumor cells by removing mutagenic and 
cytotoxic adducts from the O*^  position of guanine which induced by alkylating 
agents (Esteller M., Garcia-Foncillas J. et al 2000; Oue N.，Shigeishi H. et al. 
21 
2001). MGMT is located at 10q26 which is frequently hypermethylated in certain 
human cancer which result in loss of expression (Oue N., Shigeishi H. et al. 
2001). Promoter hypermethylation of MGMT in gastric carcinoma have been 
studied by a Japanese group. They found that methylation of MGMT was 
detected in 31% (8 out of 26) in the gastric carcinomas. 
Suppressor of cytokine signaling-1 (SOCS-l) is a cytokine-inducible 
negative regulator of cytokine signaling. SOCS-l inhibits the phosphorylation of 
STAT3 protein through direct interaction with active JAK by binding to their 
activation loop. Blockage of JAK activation results in downregulation of 
JAK/STAT pathway (Oshimo Y., Kuraoka K. et al. 2004). Recently, studies 
revealed that inactivation of SOCS-l by promoter hypermethylation activated 
JAK/STAT pathway and their target genes (Oshimo Y., Kuraoka K. et al 2004). 
Furthermore, methylation of SOCS-l has been shown to inactivate SOCS-l gene 
in hepatocellular carcinoma, multiple myeloma, acute myeloid lymphoma and 
hepatoblastoma (Oshimo Y., Kuraoka K. et al 2004). 
The tumor suppressor in lung cancer-1 (TSLCl) is a novel tumor suppressor 
gene which located on chromosome llq23.2 and is frequently inactivated by 
promoter hypermethylation and loss of heterozygosity (LOH) in non-small cell 
lung cancer. Inactivation of TSLCl by LOH has been observed and l lq has been 
shown to be frequently deleted in gastric cancer. As l lq was frequently deleted 
in gastric cancer, therefore it was speculated that promoter hypermethylation of 
TSLC-1 might play an important role in the pathogenesis of gastric cancer 
(Teiichiro Honda, 2002, 857). 
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DOC-2 encodes a unique phosphoprotein involved in modulating 
multiple signaling pathways and protein trafficking. DOC-2 was originally 
isolated from ovarian cancer as a potential tumor suppressor gene, since then, 
downregulation of DOC-2 have been observed in several cancers including 
prostate, mammary, colon and choriocarcinoma (Zhou J., Hernandez G. et al. 
2005). The promoter region of DOC-2 was divided into two regions, m2a and 
m2b (Dote H., Toyooka S. et al. 2005). In gastric cancer, studies have revealed 
aberrant methylation in m2a region in 67% (8 out of 12) of gastric cancer cell 
lines and 46% (16 out of 35) of gastric cancer tissues, while in m2b region in 
67% (8 out of 12) of cell lines and 43% (15 out of 35) of cancer tissues (Dote H., 
Toyooka S. et al. 2005). Thus, DOC-2 methylation is frequently observed in 
gastric cancer which caused gene downregulation. However, methylation may 
not be the only mechanism that regulated DOC-2 expression. As recent studies 
demonstrated that transcriptional regulation of DOC-2 in human transitional cell 
carcinoma was determined by histone acetylation and a specific transcriptional 
factor (Zhou J., Hernandez G. et al. 2005). 
COX-2 often over-expressed in GCA, but some studies suggested that the 
absence of COX-2 expression in gastric cancer may be associated with 
methylation and histone deacetylation (Kikuchi T.，Itoh F. et al. 2002). COX-2 
expression and methylation status have been investigated in AGS cells in 
previous study (Yu J., Leung W. K. et al. 2003). Low level of COX-2 and 
hypermethylation was detected in the AGS cell line and 43.1% (25 out of 58) of 
hypermethylation was detected in primary gastric cancer (Yu J., Leung W. K. et 
al. 2003). 
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Evidences also suggested that there is interaction between DNA methylation 
and histone modifications (Figure 3). For example, Methyl-CpG binding protein 
(MeCP2) has been found to be associated with histone deacetylases 3 (HDAC3) 
which histone modification can be induced by DNA methylation changes (Jones 
P. L., Veenstra G. J. et al 1998). Thus, understanding the relationship between 
DNA methylation and histone modification may provide further insights in 
carcinogenesis. 
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Table 1 The most relevant hypermethylated genes in human cancer reported. 
Modified from (Esteller M. 2002). 
Gene Function Location Tumor profile Consequences 
A P C Inhibitor of p-catenin 5q21 Aerodigestive tract Activation P-catenin route 
AR Androgen receptor Xql 1 Prostate Hormone insensitivity 
B R C A l DNA repair, transcription I7q21 Breast, ovary Double strand-breaks 
C D H l 3 H-cadheiin, cell adhesion I6q24 Breast, lung Dissemination'. ' 
C O X - 2 Cyclooxigenase-2 lq25 Colon, stomach Ant inf lamatory resistance? 
D A P K Pro-apoptotic 9q34 1 Lymphoma, lung, colon Resistance to apoptosis 
EC A D E-cadherin, cell adhesion 16q22 1 Breast, stomach, leukemia Dissemination 
ER Estrogen receptor 6q25 1 Breast Hormone insensitivity 
G S T P I Conjugat ion to Glutathione 1 l q l 3 Prostate, breast, kidney Adduct accumulat ion? 
HIC-1 Transcription factor 17pl3 3 Multiple types Unknown 
l iMLHl DNA mismatch repair 3p21 3 Colon, endometrium, stomach Frameshift mutations 
LlCBI/STKl 1 Serine/Threonine kinase 19pl3 3 Colon, breast, lung Unknown 
M G M T DNA repair of 06-alkyl-guanine 10q26 Multiple types Mutations, chemosensit ivi ty 
p U A R F M D M D 2 inhibitor 9p21 Colon, stomach，kidney degradation of p53 
p l 5 I N K 4 b Cyclin-dependent kinase inhibitor 9p21 Leukemia Entrance in cell cycle 
p l61NK4a Cyclin-dependent kinase inhibitor 9p21 Multiple types Entrance in cell cycle 
p73 p53 homologue lp36 Lymphoma Unknown 
PR Progesterone receptor 1 lq22 Breast Hormone insensitivity 
RARP2 Retinoic acid receptor f,2 3p24 Colon, lung, head and neck Vitamin insensitivity? 
R A S S F l Ras effector homologue 3p21.3 Multiple types Unknown 
Rb Cell cycle inhibitor 13ql4 Retinoblastoma Entrance in cell cycle 
RIZl Histone/protein methyltransferase lp36 Breast, liver Abenan t gene expression ' 
SOCS-1 Inhibitor of JAK/'STAT pathway I 6 p l 3 . 1 3 Liver JAK2 activation 
SRBC BRCAl -b ind ing protein l p l 5 Breast, lung Unknown 
SYK Tyrosine kinase 9q22 Breast Unknown 
THBS-1 Thrombospondin-1, anto-angiogenic 15ql5 Glioma Neovascularization 
丁MSI Pro-apoptotic I 6 p l l Breast Resistance to apoptosis 
T P E F / H P P l Transmembrane protein 2q33 Colon, bladder Unknown 
V H L Ubiquitin ligase component 3p25 Kidney, hemangioblastoma Loss of hypoxic response? 
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Figure 3 Links between DNA methylation, histone modification and chromatin 
remodelling. In mammalian cells, both DNA methylation and histone 
modification are involved in chromatin silencing. Three possible models of how 
they might influence each other are shown (Li E. 2002). (a) A model of DNA 
methylation directing histone methylation. DNA methylation patterns are 
established through de novo methylation by DNA methyltransferase DNMT3a 
and DNMT3b, and are maintained by DNMTl. Methyl-CpG-binding proteins 
(MBD) and histone deacetylase (HDAC) complexes, such as the 
MECP2-Sin3a—HDAC complex, are believed to then be recruited to the 
methylated region to induce histone deacetylation and silencing (Jones P. L.， 
Veenstra G. J. et al 1998; Nan X.，Ng H. H. et al. 1998). The chromatin then 
attracts histone methyltransferases (HMTs) which methylate the lysine 9 residue 
on histone H3 (H3-K9) and stabilize the inactive state of the chromatin (Peters A. 
H., O'Carroll D. et al 2001; Tachibana M., Sugimoto K. et al 2002). (b) A 
model of histone methylation directing DNA methylation. Methyl H3-K9 acts as 
a signal for inactive chromatin by recruiting HPl to methylated histories，which 
might in turn recruit DNA methyltransferases directly or indirectly (via unknown 
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factor X) to the silent chromatin to maintain DNA methylation and stabilize the 
inactive chromatin (Tamaru H. and Selker E. U. 2001; Jackson J. P., Lindroth A. 
M. et al 2002). (c) A model of chromatin remodelling driving DNA methylation. 
The ATP-dependent chromatin-remodelling and DNA-helicase activities of 
proteins might facilitate DNA methylation and histone modification by 
unwinding nucleosomal DNA to increase its accessibility to DNMTs，HDACs 
and HMTs. The disrupted function of these proteins impairs both DNA 
methylation and histone methylation, as has been shown in plants (Jeddeloh J. A., 
Stokes T. L. et al 1999; Gendrel A. V., Lippman Z. et al. 2002). The 
chromatin-remodelling protein (CRP) that is involved in de novo methylation has 
yet to be identified. 
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2.2.2 Histone modification 
Genomic DNA is packaged into precise regulatory complexes known as 
chromatin. Chromatin is organized into two domains, euchromatin and 
heterochromatin, based on the chromosomal architecture, transcriptional activity 
and replication timing (Li E. 2002). It contains various proteins that are required 
for chromatin assembly and packaging, DNA replication, DNA and histone 
modification and transcription activity (Kass S. U. and Wolffe A. P. 1998; Mai A.， 
Massa S. et al 2005). The structural subunit of the chromatin is nucleosome 
which provides the architectural framework for transcription (Wolffe A. R and 
Kurumizaka H. 1998). Nucleosomes composed of approximately 146 base pairs 
of double-stranded DNA wrapped around an octamer core of pairs of histories 
H2A, H2B, H3 and H4 in tight 1.75 superhelical turns (Figure 4) (Luger K., 
Mader A. W. et al 1997; Mei S.，Ho A. D. et al. 2004). The mechanisms involve 
in regulating the chromatin include re-organization of nucleosome position by 
ATP-dependent remodeling complexes that alter post-translational modification 
of histories (Narlikar G J., Fan H. Y. et al. 2002; Lusser A. and Kadonaga J. T. 
2003). 
Histones are the most abundant proteins associated with chromosomes that 
consist of a globular domain and an N-terminal tail protrudes from the 
nucleosome (Thiagalingam S., Cheng K. H. et al. 2003). Histones have large 
numbers of sites where posttranslational modifications can occur and the pattern 
of modifications has been termed as histone code (Strahl B. D. and Allis C. D. 
2000; Rice J. C. and Allis C. D. 2001). It has been proposed that histone 
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modifications function as an information code which can be recognized by non-
histone proteins complexes that regulate gene expression (Jenuwein T. and Allis 
C. D. 2001; Zhang Y. and Reinberg D. 2001; Richards E. J. and Elgin S. C. 2002). 
In general, histone modifications are reversible (Jenuwein T. and Allis C. D. 
2001; Zhang Y. and Reinberg D. 2001; Fischer D. D., Cai R. et al 2002; Lachner 
M. and Jenuwein T. 2002; Richards E. J. and Elgin S. C. 2002; Trojer P., 
Brandtner E. M. et al 2003). The amino-terminal tails serve as the targets for 
posttranslational modifications by acetylation of lysines, methylation of lysines 
and arginines, phosphorylation of serines, and ubiquitination of lysines (Figure 5) 
(Marks R A., Richon V. M. et al 2004). Histories are synthesized in cytosol and 
then assembled into nucleosomes. Some of the modifications of histones occur 
just after their synthesis, but before their assembly. These histones modifications 
are added and removed by the action of enzymes that reside in the nucleus; for 
example, acetyl groups are added to the histone by histone acetyltransferases 
(HATs) or taken off by histone deacetylases (HDACs). These posttranslational 
modifications determine not only the structure but also the pattern of chromatin 
condensation and the histone code involved in gene regulation (Jenuwein T. and 
Allis C. D. 2001; Zhang Y. and Reinberg D. 2001; Thiagalingam S.，Cheng K. H. 
et al. 2003). 
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Figure 4 Schematic of the structure of histories in nucleosomes. The core 
proteins of nucleosomes are designated H2A (histone 2A), H2B (histone 2B), H3 
(histone 3) and H4 (histone 4). Each histone is present in two copies, so the DNA 
(black) wraps around an octamer of histories — the core nucleosome (Marks P., 
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Figure 5 Schematic structure of modifications histories at the amino-terminal 
tails. Lysines (K) in the amino-terminal tails of histories H2A, H2B, H3 and H4 
are potential acetylation/deacetylation sites for histone acetyltransferases (HATs) 
and histone deacetylases (HDACs). Acetylation neutralizes the charge on lysines. 
The modifications include methylation (M), acetylation (Ac), phosphorylation 
(P), ubiquitination (U), and biotinylation (B). Methylation sites that are uncertain 
are denoted as (m) (Espino P. S., Drobic B. et al 2005). 
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I. Histone acetylation and deacetylation 
Among the N-terminal histone tail modification, acetylation is the most 
intensely investigated and has been found associated with actively transcribed 
regions of chromatin (Espino P. S.，Drobic B. et al. 2005). The N-terminl of the 
histories contain several positively charged lysine groups that undergo reversible 
acetylation and deacetylation. Histone acetylation is the modification of 
chromatin structure by attachment of acetyl groups to core histories. While 
histone deacetylation is the removal of the attached acetyl groups. Histone 
acetyltransferases (HATs) and histone deacetylases (HDACs) are two opposing 
enzymes responsible for the histone acetylation and deacetylation respectively. 
In unacetylated histories, the N-terminal lysines are positively charged and 
interact strongly with DNA phosphates, increasing the affinity of DNA for the 
nucleosome surface. This strong interaction may prevent access of transcription 
factors to promoter regions. However, in the acetylated form, the positive charge 
of the lysine-amino groups are neutralized and theirs interaction with DNA 
phosphate group are eliminated. Therefore, it reduces the affinity of histones for 
DNA and facilitates the binding of transcription factors to promoter regions. 
Thus, histone deacetylation has an important role in chromatin-mediated gene 
repression. 
II. Histone methylation 
Posttranslational addition of methyl groups to the N-terminal tails of histone 
proteins was discovered more than three decades ago (Rice J. C. and Allis C. D. 
2001). The characterization of histone methyltransferases (HMTases) provides 
further insights in the understanding of functional implications of histone 
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methylation. HMTases direct the site-specific methylation of lysine residues in 
the amino-terminal of histone H3 (Schotta G, Lachner M. et al. 2004). Recent 
findings suggested that site-specific methylation is associated with various 
biological processes ranging from transcriptional regulation to epigenetic 
silencing via heterochromatin assembly (Rice J. C. and Allis C. D. 2001). 
There are several methylatable lysine positions in the N-termini of H3 
include lysine 4, 9, 27，36 and 79 (H3-K4, H3-K9, H3-K27, H3-K36 and 
H3-K79) and H4 lysine 20 (H4-K20) (Feng Q., Wang H. et al. 2002; Lacoste N., 
Utley R. T. et al. 2002; Ng H. H.，Feng Q. et al. 2002; Lachner M., O'Sullivan R. 
J. et al 2003). Methylation of H3-K4, H3-K36 and H3-79 are mainly associated 
with transcriptional stimulation whereas methylation of H3-K9, H3-K27 and 
H4-K20 are correlated with transcriptional silent chromatin (Lachner M.， 
O'Sullivan R. J. et al 2003). Lysine methylation of histone tails can exist in three 
states: mono-, di-, or tri-methylated states (Santos-Rosa H.，Schneider R. et al. 
2002; Peters A. H., Kubicek S. et al 2003). Furthermore, histone lysine 
methylation is associated with pericentric heterochromatin formation, X 
chromosome inactivation, Polycomb group (Pc-G)-dependent gene silencing and 
euchromatic gene repression (Lachner M., O'Sullivan R. J. et al 2003). 
All these new findings suggested that histone methylation may provide a 
stable genomic imprint that may serve to regulate gene expression as well as 
other epigenetic phenomena. 
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III. Histone phosphorylation 
During mitosis and meiosis, phosphorylation occurs at the serine 10 (SerlO) 
residue of the N-terminal tail of histone H3. Phosphorylation of histone H3 at 
SerlO is correlated to chromosome condensation and segregation which play an 
important role on gene transcriptional regulation (Gurley L. R., Walters R. A. et 
al. 1978). Mitogen- and stress-activated protein kinase-1 (MSKl) and (MSK2) 
are the kinases responsible for phosphorylating H3 SerlO (Chadee D. N., 
Hendzel M. J. et al 1999; Soloaga A., Thomson S. et al 2003). Since the 
discovery, studies have demonstrated that mitosis-specific phosphorylation of 
histone H3 also occurs at Ser28, Threonine 11 (Thrll) and Threonine 3 (Thr3) 
(Preuss U., Landsberg G. et al. 2003). 
Recent works have demonstrated a link between acetylation and 
phosphorylation, but the mechanism is unknown. For example, the location of 
the SerlO residue is in close proximity to other modifiable amino acids in histone 
H3 tail which may allow interaction between phosphorylation of SerlO and 
methylation and/or acetylation of lysine 9 and lysine 14 to occur (Nowak S. J. 
and Corces V. G. 2004). Agaliti et al demonstrated that acetylation and 
phosphorylation of histone act as directed binding sites which are recognized by 
transcriptional machinery, rather than acting as modifications that alter the local 
chromatin environment (Agalioti T.，Chen G et al 2002). 
IV. Histone ubiquitylation 
Unlike the acetylation and deacetylation whose functions are opposing, both 
ubiquitylation and de-ubiquitylation responsible for gene activation (Wyce A., 
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Henry K. W. et al 2004). Ubiquitin is a highly conserved protein that consists of 
76 amino acids and related to proteasome-dependent degradation (Pickart C. M. 
2001). There are few enzymes required for protein ubiquitylation: El 
ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and E3 
ubiquitin-ligase enzyme. The active site of El enzyme covalently binds to the 
Gly 76 residues and activates it (Wyce A., Henry K. W. et al. 2004). Then, 
ubiquitin is transferred to E2 enzyme and recognized by E3 enzyme that 
determines substrate specificity. E3 enzyme recognizes its substrates (or 
ubiquitin) based on the specific ubiquitylation signal and catalyzes the formation 
of an isopeptide bond between lysine residue and the C terminus of ubiquitin 
(Pickart C. M. 2001). 
Harrison Busch and co-workers discovered the first eukaryotic protein, H2A 
that is modified by ubiquitin. H2A was originally isolated from HeLa cells in 
1975 as a histone-like, non-histone chromosomal protein called A24 (Osley M. A. 
2004). Recently, histone H2B was found to be ubiquitylated on lysl23 in the 
budding yeast Saccharomyces cerevisiae, mediated by Rad6 (E2 enzyme) and 
Brel (E3 enzyme) (Hwang W. W., Venkatasubrahmanyam S. et al. 2003; Wood 
A., Krogan N. J. et al. 2003). 
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2.3 HAT，HDAC and HDAC inhibitors 
As described in the above section of histone modification, acetylation of 
histone is controlled by the competitive activities of histone acetyltransferase 
(HAT) and histone deacetylase (HDAC) superfamilies of enzymes (Figure 6). 
Generally, transcriptionally active genes are associated with highly acetylated 
histories whereas transcriptional repression is associated with low levels of 
histone acetylation. Within the nucleosome, positively charged hypo acetylated 
histories are tightly bound to the phosphate backbone of DNA and maintain 
chromatin in a transcriptionally silent state. Histone acetylation neutralizes the 
positive charge on histones, disrupts higher-order structures in chromatin, 
thereby enhancing the accessibility of transcriptional factors, transcriptional 
regulatory complexes, and RNA polymerases to promoter regions of DNA. 
While histone deacetylation restores positive charge on lysine residues of core 
histones and allows chromatin to condense into a tightly supercoiled, 
transcriptionally silent state. 
Thus, the reversible histone acetylation and deacetylation play critical roles 
in the modification of chromatin structure, chromatin function and regulation of 
gene expression (Grunstein M. 1997). Altered expression or mutation of genes 
that encode HATs, HDACs or their binding and recruiting partners can lead to 
aberrant expression of genes that regulate cellular differentiation, cell cycle, and 
apoptosis (Mai A., Massa S. et al. 2005). An imbalance of the equilibrium of 
HATs and HDACs activities results in aberrant transcription or repression of 
genes and has been implicated in carcinogenesis and cancer progression (Mei S., 
Ho A. D. et al 2004). 
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Figure 6 Histone acetylation and deacetylation. (A) The core histones have 
histone-fold domains, which interact with other histones and with DNA in the 
nucleosome, and N-terminal tails, which extend outside of the nucleosome. The 
N-terminal tails of the core histones (e.g., H3) are modified by the addition of 
acetyl groups (Ac) to the side chains of specific lysine residues. (B) 
Transcriptional activators and repressors are associated with coactivators and 
corepressors, which have histone acetyltransferase and histone deacetylase 
activities, respectively. Histone acetylation is characteristic of actively 
transcribed chromatin and may weaken the binding of histones to DNA or alter 
their interactions with other proteins (Cooper G. M. 2000). 
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Moreover, HATs and HDACs may also involved in acetylation and 
deacetylation of non-histone proteins that control cell-cycle progression, 
differentiation, and/or apoptosis. There may be a link between epigenetic 
regulation of gene expression and the post-translational modifications of 
cell-cycle proteins (Mai A., Massa S. et al 2005). 
2.3.1 HAT 
In the 1960s, Allfrey and his colleagues were the first to observe histone 
acetylation and hypothesized that acetylation of histone code was related to the 
regulation of gene transcription (Allfrey V. G 1966). In 1995, David Allis and his 
group discovered the first histone acetyltransferase (HAT) in Tetrahymena 
thermophila and it showed to be homologous to the transcription co-factor GCN5 
characterized in yeast (Brownell J. E. and Allis C D . 1995; Brownell J. E., Zhou 
J. et al 1996; Gregory P. D., Wagner K. et al 2001). There are now 
approximately twenty HAT proteins have been identified from yeast to human. 
Different HAT families have specific and distinct histone substrate specificities 
which fall into several families based on the highly conserved structural motifs 
(Marmorstein R. 2004). GCN5-related N-acetyl transferase (GNAT) is the first 
superfamily that has been identified which includes GCN5 and P/CAF. The 
CBP/p300 family includes p300 and cyclic adenosine monophosphate response 
element (CREB)-binding proteins (CBP) (Giles R. H., Peters D. J. et al 1998; 
Gayther S. A., Batley S. J. et al. 2000). Other families include TATA box binding 
protein-associated factor (TAFII250) family, MYST (named according to 
monocytic leukemia zinc-finger protein (MOZ), YBF2/SAS3, SAS2 and HIV-1 
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TAT-interactive protein 60 (TIP60)) family and steroid receptor co-activator 
(SRC) family (Marmorstein R. 2004). 
HATs do not bind directly to DNA but recruited to DNA by transcription 
protein complexes (Cress W. D. and Seto E. 2000; Gray S. G. and Ekstrom T. J. 
2001). HATs are present in large, multiprotein complex that may include a 
number of additional HATs, various transcription co-activators and co-repressors 
(Mei S., Ho A. D. et al 2004; Somech R., Izraeli S. et al 2004). It catalyzes the 
acetylation of histone proteins by loosening the chromatin structure and 
facilitating transcription through increasing the accessibility of promoter DNA to 
transcription factors (e.g. p53, PLZF, CoREST, E2F, GATAl, TFIIE and TFIIF), 
regulatory complexes and the RNA polymerase (Wolffe A. P. and Guschin D. 
2000; Gray S. G and Ekstrom T. J. 2001; You A., Tong J. K. et al. 2001; Mei S.， 
Ho A. D. et al. 2004). 
2.3.2 HDAC 
In 1990, when Itazaki's and his group were screening for compounds that 
could return spindle-like transformed NIH3T3 cells to normal fibroblast-like 
morphology, they identified an epoxyketone-containing cyclic tetrapeptide 
trapoxin (Itazaki H., Nagashima K. et al. 1990). At that time, they were uncertain 
about the proteins that trapoxin acted on (Thiagalingam S., Cheng K. H. et al. 
2003). Later, it was discovered that after the treatment of trapoxin, trapoxin 
inhibited the histone deacetylation and hyperacetylated histones were increased 
in the cells (Kijima M., Yoshida M. et al 1993). The first histone deacetylase 
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(HDAC) was subsequently identified in 1996 (Taunton J., Hassig C. A. et al. 
1996). Up to now, there are eighteen HDACs have been identified in human. 
According to the sequence homology with the Saccharomyces cerevisiae (yeast) 
proteins (Rpd3，Hdal and Sir2), HDACs are classified into three major classes 
(Table 2) (Marks R A., Richon V. M. et al 2004; Mei S.，Ho A. D. et al 2004). 
fa) Class I 
Class I human HDACs include HDACl, HDAC2, HDACS, HDACS and 
HDAC 11 and have homology to a yeast HDAC Rpd3 (Gray S. G. and Ekstrom T. 
J. 2001; Marks P., Rifkind R. A. et al. 2001; Marks P. A., Richon V. M. et al 
2004). The members of this class are around 350-500 amino acids long and 
mostly located in the nucleus. They are ubiquitously expressed in many human 
cell lines and tissues. The molecular masses of the family are approximately 
22-55 kDa (Marks P. A., Richon V. M. et al. 2004). HDAC 1 and HDAC 2 were 
the first two human HDAC to be cloned. They have a C-terminal Retinoblastoma 
(RB) binding motif adjacent to a basic region and are associated with 
Sin3-containing silencing multiprotein complexes and NuRD (Khochbin S.， 
Verdel A. et al 2001; Hubbert C., Guardiola A. et al. 2002; Thiagalingam S., 
Cheng K. H. et al 2003). HDAC 11 was recently identified and has properties of 
both class I and II HDACs (Gao L., Cueto M. A. et al 2002). Each member map 
to a different chromosomal site (Thiagalingam S., Cheng K. H. et al 2003). All 
the members have shown to be sensitive to histone deacetylase-specific inhibitors, 
such as Trichostatin A (TSA) and Suberoylanilide Hydroxamin Acid (SAHA) 
(Marks P., Rifkind R. A. et al. 2001). Moreover, class I HDACs seem to interact 
with a different set of proteins in vivo compare to class II HDACs (Mai A., 
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Massa S. et al 2005). Class I HDACs interact with Sin3 and Mi-2/NuRD 
complexes, as well as transcriptional co-repressors SMRT and N-CoR 
(Thiagalingam S.，Cheng K. H. et al 2003). In addition, members of the class I 
HDACs are also associated with Retinoblastoma (Rb) (Lai A., Lee J. M. et al 
1999)，DNA methyltransferase 1 (Robertson K. D., Ait-Si-Ali S. et al 2000), 
TGIF/Smads (Wotton D.，Lo R. S. et al. 1999), glucocorticoid receptor (Ito K., 
Barnes P. J. et al 2000) and Spl (Choi H. S.，Lee J. H. et al 2002). 
(b) Class II 
Class II HDACs include HDAC4, HDAC5, HDAC6, HDAC7，HDAC 9, 
HDAC 10 and HDAC 11 and are homologous to the yeast HDAC Hdal (Gray S. 
G. and Ekstrom T. J. 2001; Marks R，Rifkind R. A. et al. 2001; Marks P. A., 
Richon V. M. et al. 2004). Class II can be further divided into two subclasses, Ila 
and lib, based on the sequence homology among the deacetylase domains (Mai 
A., Massa S. et al. 2005). The molecular masses of class II deacetylases are 
120-135 kDa (Marks P. A., Richon V. M. et al 2004). Class II family are twice as 
large as the class I family with approximately 1000 amino acids. Most of the 
members have a COOH terminus catalytic domain, except for HDAC 6 which 
contains two catalytic domains in the NH2 terminus (Hubbert C., Guardiola A. et 
al. 2002; Zhang Y., Li N. et al 2003). HDAC 10 has an NH2 terminus catalytic 
domain and a COOH terminus that shared homology with the catalytic domain 
(Thiagalingam S., Cheng K. H. et al. 2003). Therefore based on the homology of 
the domain, only HDAC 6 and HDAC 10 belong to subclass lib. Class II HDACs 
are tissue-specific in humans and mice whereas class I are ubiquitously 
expressed (Bertos N. R., Wang A. H. et al. 2001). Class II HDACs are associated 
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with one or more DNA binding TFs (such as MEF2, BCL2, PLZF and TR2), 
with transcriptional co-repressors (e.g. N-CoR, SMRT，B-CoR and CtBP) and 
with methyllysine-binding protein HPl (Mai A., Massa S. et al 2005). Both class 
II HDACs and HDAC 3 are associated with co-repressors N-CoR and SMRT but 
not Sin3 and NuRD (Grozinger C. M., Hassig C. A. et al. 1999). These 
transcriptional factors play an important role to recruit HDAC-containing 
multiprotein complexes to specific promoter regions (Torchia J., Glass C. et al 
1998; Grozinger C. M., Hassig C. A. et al. 1999). Class II HDACs also are 
sensitive to histone deacetylase inhibitors such as Trichostatin A (TSA), 
Suberoylanilide Hydroxamin Acid (SAHA) and related compounds (Grozinger C. 
M., Hassig C. A. et al. 1999). 
(c) Class III 
Class III HDACs were identified based on the similarity to Sir2 gene and 
are NAD-dependent Sir2 deacetyltransferase which do not share homology with 
others HDACs (Kyrylenko S., Kyrylenko O. et al 2003; Mei S., Ho A. D. et al. 
2004). In humans, there are seven sirtuins (SIRTl-7) with around 300-400 amino 
acids, except for SIRTl. The catalytic domains contain two CXXC motifs that 
function as a zinc finger domains (Frye R. A. 1999). Class III HDACs appears 
not to act on histones and are insensitive to HDAC inhibitors (Marks P., Rifkind 
R. A. et al 2001). 
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Table 2 Classification of mammalian histone deacetylases (HDAC). (Mai A., 
Massa S. et al 2005) 
Class Enzyme 〔二二： de二etCjIl^ S^a二^"^『！玄丫 Subcellular localization Tissue expression Inhibitor sensitivity 
HDAC 1 1 Zinc dependent Nuclear Ubiquitous Sensitive 
HDAC 2 1 Zinc dependent Nuclear Ubiquitous Sensitive 
(Rpd3-Uke) HDAC 3 1 Zinc dependent Nucleocytoplasmic shuttling Ubiquitous Sensitive 
HDAC 8 1 Zinc dependent Nuclear Ubiquitous Sensitive 
HDAC 11 I Zinc dependent Nuclear Ubiquitous Sensitive 
HDAC 4 1 Zinc dependent Nucleocytoplasmic shuttling Tissue specific Sensitive 
HDAC 5 1 Zinc dependent Nucleocytoplasmic shuttling Tissue specific Sensitive 
HDAC 6 2 Zinc dependent Nucleocytoplasmic shuttling Tissue specific Sensitive 
n 
(Hdal-like) 
HDAC 7 1 Zinc dependent Nucleocytoplasmic shuttling Tissue specific Sensitive 
HDAC 9 1 Zinc dependent Nucleocytoplasmic shuttling Tissue specific Sensitive 
HDAC 10 1 Zinc dependent Nucleocytoplasmic shuttling Tissue specific Sensitive 
SIRT 1 1 NAD dependent Nucleus Unknown Insensitive 
S I R T 2 1 NAD dependent Cytosol Unknown Insensitive 
SIRT 3 1 NAD dependent Mitochondria Unknown Unknown 
III (Sir2-like) SIRT 4 1 NAD dependent Unknown Unknown Unknown 
SIRT 5 丨 NAD dependent Unknown Unknown Unknown 
SIRT 6 1 NAD dependent Unknown Unknown Unknown 
SIRT 7 1 NAD dependent Unknown Unknown Unknown 
HDAC inhibited by Trichostatin A (TSA), Suberoylanilide Hydroxamin Acid 
(SAHA), trapoxin and/or related compounds. "S", sensitive to inhibition; "NS", 
insensitive to inhibition; “NU”，not fully understood. 
4 3 
(d) Mammalian HDAC and their mechanism of deacetylation 
HDACs alter the structure of chromatin by removing the acetyl groups from 
the amino terminal of histone tails that leads to decreasing in the level of histone 
acetylation. The decrease of histone deacetylation facilitates gene-specific 
activation of transcription. Furthermore, HDACs are responsible for removing 
acetyl groups from various proteins including MyoD, p53, Hsp90, GATA-1 and 
tubulin (Juan L. J., Shia W. J. et al. 2000; Hubbert C., Guardiola A. et al 2002; 
de Ruijter A. J., van Gennip A. H. et al 2003; Marks R A., Miller T. et al. 2003) 
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2.3.3 HDAC inhibitors 
In 1970s, scientists discovered that sodium butyrate inhibited histone 
deacetylase in cultured cells (Candido E. R, Reeves R. et al 1978). As a result of 
this discovery, numerous of HDAC inhibitors have been identified (Table 3) that 
inhibit deacetylation of both histone and non-histone proteins. HDAC inhibitor 
causes the accumulation of acetylated histones in nucleosomes that result in the 
re-expression of specific genes (such as the cyclin-dependent kinase inhibitor 
which are responsible for apoptosis, cell arrest and differentiation but 
repression of others (Vigushin D. M. and Coombes R. C. 2002). HDAC inhibitor 
can be divided into two major classes, natural and synthetic. The classes of the 
compounds can be further sub-divided based on the structure, include 
hydroxamates (such as SAHA, pyroxamide, TSA, oxamflatin and CHAPs), 
cyclic peptides (such as trapoxin, apicidin and depsipeptide), aliphatic acids 
(such as valproic acid) and benzamides (such as MS-275) (Miller T. A., Witter D. 
J. et al 2003). ; 
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Table 3 Histone deacetyase inhibitors. 
Name Activity 
HDAC Cell culture Animal tumor cl inical trials 
models 
Apicidin Y Y Y -
Butyrate Y Y Y Y 
Depsipeptide (FR901228, FK-288) Y Y Y Y 
Depudecin Y Y Y -
m-Carboxy dinnamic acid bishychroxamic acid (CBHA) Y Y Y -
MS-275 Y Y Y -
Cl-994 (N-acetyl dinaline) + Y Y Y 
Oxamflatin Y Y Y -
Pyroxamide Y Y Y Y 
Scriptaid Y Y - -
Suberoylanilide hydroxamic acid (SAHA) Y Y Y Y 
TPX-HA analogue (CHAP) Y Y Y -
Trapoxin Y Y - -
Trichostatin A (TSA) Y Y Y -
Valproic acid Y Y Y Y 
"Y" indicates that the compound has been shown to have activity inhibiting 
partially purified H D A C , growth of transformed cells in cultures and in vivo 
tumor growth in animal studies. Clinical trials indicate that the agent is in Phase 
or Phase II clinical trial, indicates no data reported; indicates that CI-994 is 
reported to inhibit histone deacetylation but does not seem to directly inhibit 
H D A C . 
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I. Class I/II natural inhibitors 
Trichostatin A (ISA) was the first natural hydroxamate compound 
discovered to inhibit HDACs directly (Yoshida M., Kijima M. et al. 1990). TSA 
and its derivative trichostatin C were isolated from metabolites of strains of 
Streptomyces hygroscopicus as a new antifungal antibiotic against Trichophyton 
and some fungi (Tsuji N., Kobayashi M. et al. 1976). Since then, trichostatins 
were found to have the ability for anti-proliferation and enhance differentiation at 
low concentrations. TSA was active in a number of normal and tumor cell lines, 
and have the ability to cause G1 and G2 phases cell cycle arrest (Yoshida M. and 
Beppu T. 1988). Some studies also demonstrated that after the treatment of TSA, 
the nuclear histories were highly acetylated due to decreased deacetylation rather 
than increased acetylation (Yoshida M., Kijima M. et al. 1990). 
Sodium n-butyrate (NaBu) is a non-specific inhibitor of HDACs that lack 
potency (Kruh J. 1982). NaBu was shown to reduce the proliferation of many 
tumor cell lines, enhance differentiation and induce apoptosis which eventually 
caused cell death (Ransom R. F. and Walton J. D. 1997; Saw a H., Murakami H. 
et al 2001; Chopin V., Toillon R. A. et al. 2002). In addition, NaBu also affects 
phosphorylation and methylation of histories and other nuclear proteins (Ransom 
R. F. and Walton J. D. 1997). 
Trapoxins A and B were isolated from fungus Helioma amibiens as an 
antitumor agent against v-sis oncogene-transformed NIH3T3 cells (Itazaki H., 
Nagashima K. et al 1990). Trapoxins induce the accumulation of hyperacetyated 
histories by irreversibly inhibited the deacetylation of acetylated histone (Kijima 
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M., Yoshida M. et al. 1993). 
In addition, there are others natural products have been isolated such as 
apicidin, depsipeptide (FR-901228) and depudecin. Apicidin is a cyclic 
tetrapeptide metabolite isolated from the fungal species Fusarium 
(Darkin-Rattray S. J., Gumett A. M. et al. 1996). Depsipeptide (FR-901228), 
now called FK-228, was a cyclic peptide that isolated from Chromobacterium 
violaceum and is one of the first potent compounds to enter clinical trials (Ueda 
H., Nakajima H. et al. 1994; Vigushin D. M. 2002). Depudecin is a metabolite of 
the fungus Alternaria brassicicola that has an unusual chemical structure 
(Shimada J., Kwon H. J. et al. 1995). 
II. Class I/II synthetic inhibitors 
Most of the synthetic compounds identified are hydroxamic acids, such as 
oxamflatin and suberoylanilide hydroxamic acid (SAHA). SAHA is a nanomolar 
.1 
HDAC inhibitor which contains relatively simple structural complexity (Richon ： 
V. M.，Webb Y. et al. 1996; Richon V. M., Emiliani S. et al 1998). SAHA is now 
in phase II clinical trials and is reported to be active in cancer patients with either 
solid tumors or Hodgkin's disease at doses that have no clinical toxicity (Marks 
R, Rifkind R. A. et al 2001). X-ray crystallographic studies have shown that 
SAHA interacts with the residues at the rim, walls and bottom of the catalytic site 
inside the enzyme pocket of a histone deacetylase (HDAC)-like protein. The 
active catalytic site of the HDAC-like protein is based on the HDAC homologue 
from the hyperthermophilic bacterium, Aquifex aeolicus that shares 35.2% 
identity with human HDACl over 375 residues (Finnin M. S.，Donigian J. R. et 
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al 1999). The binding end of the SAHA binds to the zinc atom at the bottom of 
the pocket. HDAC inhibitor interacts with the catalytic site of the pocket, thereby 
blocking the substrate access to the zinc atom at the base (Marks R, Rifkind R. A. 
et al 2001). In addition, other related hydroxamate inhibitors such as TSA, 
similarly insert into the catalytic pocket and binds to the zinc ion of HDACs to 
prevent the binding of the substrate and deacetylation (Finnin M. S.，Donigian J. 
R. et al 1999). 
Others synthetic compounds include Cyclic Hydroxamic Acid-containing 
Peptides (CHAPs), CI-994 and MS-275. CHAPs are hybrids of trapoxins and 
TSA, and are the members of benzamide class. Although CHAPs are very potent, 
they have been abandoned in clinical trials due to the high toxicity (Vigushin D. 
M. and Coombes R. C. 2002). MS-275 is the most potent synthetic benzamide 
derivatives and has entered the phase I clinical trials (Saito A., Yamashita T. et al. 
1999). CI-994 is MS-275's analog and also enter the phase I clinical trials as a 
potential anticancer drug (Prakash S.，Foster B. J. et al. 2001) : 
III. Sirtuins inhibitors 
Only a few molecules have been identified as sirtuins for class II HDACs. 
Sirtinol was discovered by a high throughput, phenotypic screening in cells 
(Grozinger C. M., Chao E. D. et al 2001). Splitomicin is a compound that 
creates a conditional phenocopy of a sir2 deletion mutant in Saccharomyces 
cerevisiae and was discovered by screening libraries (Bedalov A.，Gatbonton T. 
et al. 2001). Vitamin nicotinamide can inhibit the sirtuins without competing 
with NAD+ (Bitterman K. J., Anderson R. M. et al. 2002). 
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IV. Activity of HDAC inhibitors in vitro 
HDAC inhibitors have the potential to activate differentiation programs, 
inhibit cell proliferation by G1 and/or G2 phase cell cycle arrest and to induce 
apoptosis in culture transformed cells. It is hypothesized that histone acetylation 
is associated with activation of gene transcription. The cellular effect of 
individual HDAC inhibitors depend on the concentration, the duration of 
exposure and is cell-line specific (Mei S., Ho A. D. et al. 2004). In recent studies, 
HDAC inhibitors have shown to reverse morphological changes, to induce 
differentiation and to inhibit proliferation in most transformed cell types, 
including epithelial (neuroblastoma, glioma, melanoma, breast, ovary, colon, 
bladder, gastric, pancreas, lung and prostate) and hematological tumors 
(leukemia, lymphoma and multiple myeloma) (Kelly W. K., O'Connor O. A. et al. 
2002). 
a. Effect in the gene expression 
HDAC inhibitors induce the histone hyperacetylation is responsible for the 
anti-proliferative activity through induction of specific genes that play important 
roles in the cell cycle and cell morphology (Han J. W., Ahn S. H. et al 2000). 
The results of HDAC inhibitors on gene expression seem to be selective and 
affect approximately 2-5% of cellular genes (Van Lint C., Emiliani S. et al 1996; 
Glaser K. B., Staver M. J. et al 2003). However, the underlying mechanism that 
regulates gene expression is not known. Using differential display to compare the 
differences in gene expression on lymphoid cell lines found that only 2% of 
genes out of 340 were affected after TSA treatment (Van Lint C., Emiliani S. et 
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al. 1996). In recent studies, high-throughput microarray analysis of gene 
expression profiles displayed -7% (out of 8000 genes) of gene alternations in 
two colon carcinoma cell lines and >9% (out of 12000 gene) in two leukemia cell 
lines upon treatment of TSA (Mariadason J. M., Comer G. A. et al. 2000; 
Chambers A. E., Banerjee S. et al 2003). The difference (2% compared to >9%) 
is most likely due to the greater resolution of the microarray analysis against the 
differential display detection (Chambers A. E., Baneijee S. et al 2003). 
One of the genes that are commonly induced by HDAC inhibitors is 
CDKNIA, which encodes the cyclin-dependent kinase (cdk) inhibitor p21 ^ ^^^ 
(Table 4). p21 ^^^^ gene is localized on chromosome 6p21.2 and is a well studied 
tumor suppression gene (el-Deiry W. S., Tokino T. et al 1993). HDAC inhibitors 
cause an increase of mRNA and protein levels of p21 ^^^^ as well as cell cycle 
arrest (Archer S. Y., Meng S. et al 1998; Blagosklonny M. V., Robey R. et al. 
2002). silencing is caused by recruitment of HDACs to the promoter in 
the absence of DNA methylation. Thus, the induction of p21mRNA and : 
protein by HDAC inhibitor is regulated by the degree of acetylation of histones 
associated with the p21 promoter region (Richon V. M., Sandhoff T. W. et al. 
2000; Gui C. Y., Ngo L. et al. 2004). This indicated t h a t p 2 J題 is a direct target 
gene for HDAC inhibitors. 
Recent studies have found that the induction ofp21 by TSA required the 
presense of the Spl transcription factor binding site in the promoter (Han J. W., 
Ahn S. H. et al. 2001; Zhao S., Venkatasubbarao K. et al 2003). Spl (located at 
-102 bp relative to the transcription start site) has been reported to be the target of 
51 
transcriptional repression mediated by HDACl (Doetzlhofer A., Rotheneder H. 
et al 1999). Therefore, this indicates that HDAC inhibitor acts directly on the 
promoter instead of upstream element of the pathway (Marks R, Rifkind R. A. et 
al 2001). Studies with transformed cells that were treated with SAHA caused 
specific modifications in acetylation and methylation of histones associated with 
p21^F� promoter (Gui C. Y., Ngo L. et al 2004). Moreover, these changes did 
not occur in the or epsilon-globin gene-related histones. The HDAC 
inhibitor also caused a marked decrease in HDACl and Myc and an increase in 
RNA polymerase II in proteins bound to the p21腳�promoter (Gui C. Y., Ngo L. 
et al. 2004). Although the HDAC inhibitors act on similar mechanism (e.g. by 
preventing the access of acetyl-lysine residues to the HDAC catalytic pocket), 
different HDAC inhibitors have different effects. Diverse patterns of gene 
expression are observed when different compounds are treated in the same cell 
line (Glaser K. B., Staver M. J. et al 2003) and cell cycle arrest can be produced 
at G2/M (most commonly) or Gl/S (Jaboin J., Wild J. et al 2002). This may be 
due to the non-specificity of the drug such as sodium valproate also blocks 
ion-channel or due to different affinities for the various HDACs (Villar-Garea A. 
and Esteller M. 2004). 
In additional to , other genes being commonly activated by HDAC 
inhibitors include CDKN2A, CDKNIB, CDKNIC, genes for 27似gelsolin, 
cyclin E and thioredoxin binding protein 2 (TBP2)(Han J. W., Ahn S. H. et al. 
2000; Kelly W. K., O'Connor O. A. et al. 2002). SAHA has been reported to 
induce the expression of vitamin D-up-regulated protein 1 /thioredoxin-binding 
protein-2 (TBP-2) and downregulate the expression thioredoxin. In transient 
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transfection assays, HDAC inhibitors induce TBP-2 promoter constructs, and this 
induction requires an NF-Y binding site (Butler L. M., Zhou X. et al. 2002). 
I ,I 
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Table 4 Genes commonly transcriptionally regulated by H D A C inhibitors 
(Adapted from (Marks P. A.，Richon V. M . et al. 2004). 
Gene HDAC inhibitor 
Induced senes 
p21WAFl TSA, NaB, PB, SAHA, FK-228, MS-275,oxamflatin 
Gelsolin TSA, NaB, PB, SAHA, FK-228, MS-275,oxamflatin 
Metallothionein IL TSA, SAHA, MS-275 
Histone H2B TSA, SAHA, MS-275 
Cyclin E TSA, trapoxin, FK-228, oxamflatin 
TBP2 SAHA 
Repressed senes 
Cyclin D1 TSA, SAHA, FK-228 
ErbB2 TSA, SAHA, LAQ-824, FK-228 
Thymidylate synthase TSA, SAHA, MS-275 
Importin p TSA, SAHA, MS-275 
Cyclin A TSA, NaB, oxamflatin, FK-228 
VEGF TSA, NaB, PB 
Abbreviations: N a B , sodium bytyrate; PB, phenylbutyrate; S A H A , 
suberoylanilide hydroxamic acid; TSA, trichostatin A 
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b. Non-transcriptional effects 
Histone deacetylase inhibitors trigger a G2-phase checkpoint response in 
normal cells but are cytotoxic in tumor cells in which the G2-phase checkpoint is 
defective and result in disruption of two cell cycle checkpoints. Although HDAC 
inhibitors acetylate histories both in normal and tumor cells to a similar extent, 
disruption of both checkpoints are depends on the selective cytotoxicity of 
HDAC inhibitors (Warrener R., Beamish H. et al 2003). The disruption of both 
checkpoints results in the premature exit of cells from mitosis followed by , 
( 
apoptosis (Kouzarides T. 2000; Warrener R., Beamish H. et al. 2003). An 
increase of the accumulation of acetylated histories during S and G2 phase of the 
cell cycle can activate a G2 checkpoint which result in G2 cell cycle arrest 
(Marks P. A., Richon V. M. et al. 2004). 
i 
HDAC inhibitors induce apoptosis in various tumor cells but the molecular 
mechanisms underpinning their anticancer effects are poorly understood. 
Evidences have indicated that HDAC inhibitors can activate both death receptor 
pathway and intrinsic mitochondrial pathway (Peart M. J., Tainton K. M. et al. 
2003). The death receptor pathway involves ligation of receptors {i.e. Fas, tumor 
necrosis factor receptor, and TRAILR) to the ligands, resulting in binding of 
adaptor proteins and recruitment and activation of membrane caspases {i.e. 
caspase-8 and caspase-10). These enzymes subsequently activate effector 
caspases {i.e. caspase-3), resulting in the cleavage of a number of nuclear and 
cytoplasmic substrates to induce the morphological changes characteristic of 
apoptosis (Peart M. J., Tainton K. M. et al 2003). The intrinsic pathway, also 
known as stress pathway, is primarily activated by stress stimuli such as 
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chemotherapeutic drugs, ionizing radiation and growth factor withdrawal (Cory S. 
and Adams J. M. 2002). For instance, both butyrate and TSA convert the 
caspase-3 of intrinsic pathway to catalytically active protease which resulted in 
apoptotic cell death (Mei S., Ho A. D. et al. 2004). Studies have demonstrated 
that SAHA and oxamflatin enable to activate the intrinsic pathway through 
cleavage and activation of caspase-2 and Bid in leukemia and colon carcinoma 
cells (Peart M. J., Tainton K. M. et al. 2003). Suberic bishydroxamic acid (SBHA) 
also has been reported to induce apoptosis through a caspase-dependent and a .„ 
I 
mitochondrial pathway in melanoma cell lines (Zhang X. D., Gillespie S. K. et al 
2003). 
Tumors induce angiogenesis by secreting various growth factors such as 
vascular endothelial growth factor (VEGF) which can induce capillary growth 
into the tumor, supplying required nutrients and allowing for tumor expansion. 
Thus angiogenesis is considered to be critical for tumor growth and progression j 
(metastasis). HDAC inhibitors include TSA, PB and FK-228 can inhibit :: 
angiogenesis by suppression of VEGF production from tumor cell and inhibit the 
endothelial cells migration and proliferation (Goh M.，Chen F. et al 2001; Kim 
M. S., Kwon H. J. et al. 2001; Deroanne C. R, Bonjean K. et al 2002; Kwon H. 
J., Kim M. S. et al 2002). HDACs are involved in oxygen-dependent gene 
expression and hypoxia-induced angiogenesis (Kim S. H., Ahn S. et al. 2004; 
Michaelis M., Michaelis U. R. et al. 2004). Under hypoxia conditions, TSA and 
FK-228 enable to inhibit VEGF expression and induce the expression of 
angiogenic-inhibiting factors (i.e. p53). 
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c. Activity of HDAC inhibitors with other agents 
A growing number of studies have demonstrated that HDAC inhibitors can 
be synergistic or additive with a number of compounds which include anticancer 
agents such as radiation, anthracyclines, flavopiridol, anti-angiogeneic agents 
and nuclear receptor ligands (Johnstone R. W. and Licht J. D. 2003). HDAC 
inhibitors act synergistic ally with demethylating agent, 5 -aza-2 ‘ -deoxycytidine 
(5-aza-CdR), on the re-activation of tumor suppressor genes (Kishikawa S., Ugai 
H. et al 2002). 5-aza-CdR in combination with HDAC inhibitors such as PB, , 
I 
TSA, SAHA and FK-228 is very effective and synergistic with regards to cell 
differentiation and/or cell growth arrest , apoptosis and cytotoxicity, and 
produced a greater reactivation silenced gene as compared to each agent alone 
(Cameron E. E., Bachman K. E. et al 1999; Zhu W. G, Lakshmanan R. R. et al. 
\ 
2001; Boivin A. J.，Momparler L. F. et al 2002; Klisovic M. I., Maghraby E. A. 
et al 2003; Primeau M., Gagnon J. et al 2003). 
HDAC inhibitors may act synergistically or additively with DNA-damaging 
agents by altering the conformation of chromatin which resulted in a open 
structure that allow the access to DNA and increase the DNA damage (Vrana J. 
A., Decker R. H. et al 1999; Marks P. A., Richon V. M. et al. 2004). HDAC may 
alter gene expression (e.g. genes encodes Bcr-Abl, thymidylate synthase and 
ErbB2) by increasing the cell sensitivity to the agents such as imatinib, 
5-fluorouracil and trastuzumab (Marks P. A., Richon V. M. et al 2004). 
d. Effects in xenograft tumor models 
An increasing number of HDAC inhibitors have been identified that inhibit 
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proliferation and induce differentiation and/or apoptosis of tumor cells in animal 
models of solid tumors and hematological malignancies with little or no toxicity 
(Butler L. M.，Agus D. B. et al. 2000; Marks P. A.，Miller T. et al. 2003). HDAC 
inhibitors cause an accumulation of acetylated histones in tumor and normal 
tissues include liver，spleen and peripheral mononuclear (PMN) cells (Butler L. 
M., Agus D. B. et al 2000). Although histone acetylation is a major target for 
HDAC inhibitors, the accumulation of hyperacetylated histones is not sufficient 
to inhibit the cell growth in all cell types (Brinkmann H., Dahler A. L. et al. � 
( 
2001). Moreover, increased accumulation of acetylated histones is a useful 
marker of HDAC biological activity and has been used to monitor dosing in 
patients in clinical trials. 
In mice with transplanted CWR222 human prostate tumors, SAHA caused 
significant suppression of tumor growth with a 97% reduction in the mean final 
tumor volume compared with controls. Accumulation of acetylated histones H3 
and H4 were increased in prostate tumors within 6 hr after SAHA administration 
'•I 
，.,1 
(Butler L. M.’ Agus D. B. et al 2000). Human prostate tumor xenografts from 
mice treated with pyroxamide also showed increased levels of histone acetylation 
and increased expression of the cell cycle regulator (Butler L. M., Webb 
Y. et al 2001). Administration of CBHA induced apoptosis of human 
neuroblastoma cells in nude mice xenograft model (Coffey D. C., Kutko M. C. et 
al 2001). 
TSA showed potent dose-dependent antitumor activity against breast cancer 
in vitro and in vivo (Vigushin D. M., Ali S. et al 2001), but no anti-tumour 
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activity in human melanoma xenograft in nude mouse model (Qiu L.，Kelso M. J. 
et al 1999). However, Kim and his group discovered that TSA specifically 
inhibited hypoxia-induced angiogenesis in the Lewis lung carcinoma model 
(Kim M. S., Kwon H. J. et al 2001). 
Furthermore, orally administered MS-275 strongly inhibited the growth in 
seven out of eight tumor lines implanted into nude mice, although most of these 
did not respond to conventional chemotherapy 5-fluorouracil (Saito A., , 
I 
Yamashita T. et al. 1999). 
V. Clinical trials of HDAC inhibitors 
A number of HDAC inhibitors such as SAHA, phenylbutyrate and 
i 
phenylacetate, have shown impressive antitumor activity in vivo with remarkably 
little toxicity in preclinical studies and have entered into phase I/II clinical trials 
(Table 5). However, only phenylacetate has been approved for use in patients. 
•...I 
Phenylacetate (PA) is approved to use in children with urea cycle disorders 
and in patients with portal encephalopathy and chemotherapy-induced 
hyperammonemia (Marks R A.，Richon V. M. et al 2004). PA is a metabolite of 
phenylbutyrate following beta-oxidation in the liver and kidney. In early phase I 
trial, PA result in drug accumulation and dose-limiting neurological toxicity 
(Thibault A., Samid D. et al. 1995) and phase II revealed only little activity on 
recurrent malignant gliomas (Chang S. M., Kuhn J. G. et al. 1999). Phase I 
studies of intravenous and oral administered phenylbutyrate (PB) showed that 
patients with myelodysplastic syndrome or acute myeloid leukemia were well 
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tolerated clinically (Gore S. D. and Carducci M. A. 2000; Gore S. D., Weng L. J. 
et al. 2001; Gore S. D.’ Weng L. J. et al. 2002). However, plasma concentrations 
achieved at the maximum tolerated dose were less than those targeted in vitro 
studies, a prolonged infusion of PB is recommended (Gore S. D., Weng L. J. et al 
2002). 
Intravenous of SAHA showed to inhibit histone deacetylase in normal and 
malignant cells and antitumoral activities in solid and hematological tumors with •�. 
I 
prolonged response to therapy. In phase I studies, administration of SAHA by 2 
hr intravenous infusion in patients with advanced cancer was well tolerated 
(Kelly W. K., Richon V. M. et al. 2003). Preliminary results of phase II studies 
with oral administration in patients with refractory cutaneous T cell lymphoma 
(CTCL) revealed that 5 out of 13 patients have partial objective response to the 
treatment (Marks P. A., Richon V. M. et al. 2004). 
I ；! 
Although CI-994 is a weak inhibitor of histone deacetylase, cytostatic ； 
effects were observed in clinical trial. Phase I study of chronic oral 
administration of CI-994 determine the maximum tolerated dose, 
pharmacokinetic profile and anti-tumor activity. The recommended Phase 2 
starting dose is 8 mg/m2/day for 8 weeks repeated after a 2-week drug-free 
interval. Phase II trial showed that CI-994 have promising antitumoral effects in 
non-small cell lung cancers and in renal or colorectal cancers (Prakash S., Foster 
B. J. et al 2001). 
Depsipeptide (FR-901228 or FK-228) were administrated through a central 
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venous by a 4 hr infusion on day 1 and 5 of a 21-day cycle or on days 1，8, 15 of 
a 28-day cycle in patients with refractory or advanced cancer (Marshall J. L., 
Rizvi N. et al 2002; Sandor V., Bakke S. et al. 2002). The maximum tolerated 
dose and toxic effect were defined. The case study conducted at the National 
Cancer Institute, three patients with cutaneous T-cell lymphoma (CTCL) had a 
partial response, and one patient had a complete response (Piekarz R. L., Robey 
R. et al. 2001). Therefore, a phase II study with cutaneous T-cell lymphoma has 
been initiated. > 
I. 
Oral administration of MS-275 impressively suppressed the growth of 
tumors such as neuroblastoma and undifferentiated sarcoma. Preliminary data 
suggested that administrated oral daily on 28-day cycle was poorly tolerated. 
i 
Thus, oral treatment is currently under investigations to optimize the oral 
schedule (Marks P. A., Richon V. M. et al 2004). 
‘.I 
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Table 5 Clinical Trials o f H D A C inhibitors (Marks P. A.，Richon V. M . et al 
2004). 
Agent name Administrat ion T u m o r profi le Author 
Phase I Trial 
Thibault et al. (1994) , 
Phenylaceta te (PA) intravenous Solid tumors Thibault et al. 0 9 9 5 ) , 
Carducci et al. (1997) 
Phenylbutyrate (PB) oral Solid tumors Gilbert et al. (2001) 
intravenous Myeloid malignancies Gore et al. (1997) 
Phenylbutyrate (PB) + 5-azacytidine (AC) Solid tumors Gilbert et al. (2001) 
Retinoic acid + phenylbutyrate Acute promyelocytic leukemia 工二e:!； al ^(2002)^^' 
Suberoylani l ide hydroxamic acid (SAHA) intravenous Solid tumors and hematologic tumors kelly et al. (1998) ‘ 
oral Solid tumors and hematologic tumors kelly et al. (2003) 
Depsipept ide (FR901228, FK-288) intravenous Solid tumors Sandor et al. (2002) 
CI-994 (N-acetyl dinaline) Solid tumors Prakash et al. (2001) 
CI-994 + capecitabine Refractory solid tumors Kimmel et al. (2001) 
CI-994 + carboplatin/paclitaxel Refractory solid tumors Olivares et al. (2001) ‘ 
. … _ , J , , Ryan e t a l . (2003), 
MS-275 oral Solid tumors and lymphoma Wisinski (2003) 
I 
Phase II Trial 
Phenylacetate (PA) intravenous Recurrent malignant glioblastoma Chang e t a l . (1999) ； | 
Pivaloyloxymethylbutyrate intravenous Non-small cell lung cancer keer e t a l . (2001) ；丨 
CI-994 (N-acetyl dinaline) Renal Cell Carcinoma Wozniak et al. (1999) .丨 
Depsipeptide (FR901228, FK-288) intravenous f^；；；^二^网丁 Piekarz et al. (2003) 
Suberoylanil ide hydroxamic acid (SAHA) oral ^/^！^�；；^卩？！：“�Duvic et al. (2003) 
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Chapter 3 Aims of the study 
1. Assess the potential anti-cancer effect of HDAC inhibitors in a gastric 
cancer cell line model. 
The two commonly used HDAC inhibitors, Trichostatin A (TSA) and 
Suberoylanilide Hydroxamic Acid (SAHA) are studied. TSA is frequently used 
V 
I, 
in cell line experiment, but not applicable in clinical trial. However, SAHA can 
be used in clinical setting. Thus, both TSA and SAHA will be employed in the 
current studies. Experiments include observations of cell morphology, cell 
proliferation, assessment of apoptosis and cell cycle analysis will be conducted to 
assess the potential anti-cancer effects of TSA and SAHA. The results may ‘ 
provide further evidence to support the anti-cancer effect of HDAC inhibitors for 
gastric cancer. j 
I 
I ‘ 
2. To explore the alterations of genes expression upon treatment of HDAC 丨 
inhibitors. 
The underlying mechanisms lead to potential anti-cancer effect of HDAC 
inhibitors are unclear. Micro array expression analysis will be employed to assess 
the global gene expression profiles after treatments of AGS cell line with TSA 
and SAHA. A selected group of up-regulated genes will be further confirmed by 
RT-PCR. The results will provide insights in the effects of HDAC inhibitors and 
enhance our understanding of gastric carcinogenesis. 
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Chapter 4 Materials and Methods 
4.1 Cell culture 
Human gastric adenocarcinoma cell line AGS was purchased from American 
Type Culture Collection (ATCC) (CRL-1739; Rockville, Maryland, USA). The cell lines :: 
were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin, all were purchased from Gibco (Carlsbad, 
California, USA). After retrieval of cell pellets from the liquid nitrogen tank, cells 
pellets were dispersed with 10ml culture medium in 75 cm culture flasks (Greiner 
Bio-One, Frinkenhausen). Cells were then incubated in a 37°C incubator, supplied with 
humidified atmosphere containing 5 % CO2 and 95% air. Cells were sub-cultured or 





4.2 Drug treatment 
4.2.1 Suberoylanilide Hydroxamic Acid treatment 
Histone deacetylase (HDAC) inhibitors, Suberoylanilide Hydroxamic Acid (SAHA; 
BioVision, Mountain View, CA, USA) were used in this experiment. A stock solution of 
SAHA was dissolved in DMSO and aliquoted to 10 mM and stored at 4°C. AGS cell 
lines at 80% confluency were harvested by trypsinization and 2x10^ cells were seeded 
on 100-mm culture plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Drug 
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treatment was started after 3 hours when the cells had seeded on the bottom of the plates. 
The AGS cells were treated with various concentrations of SAHA for 24 or 48 hours. 
The drug concentrations used were 0 [iM (as negative control), 1 |liM, 2 FIM, 4 |liM, 8 )liM 
and 15 |jM. 
4.2.2 Trichostatin A treatment 
"111 
Trichostatin A (TSA; Sigma-Aldrich Co., St. Louis, MO, USA) is a histone : 
deacetylase inhibitor. A stock solution of TSA was dissolved in dimethyl sulfoxide 
(DMSO) and aliquoted to Img/ml and stored at -20�C. AGS cell lines at 80% 
confluency were harvested by trypsinization and 2 x 10^  cells were seeded on 100-mm 
culture plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA). Drug treatment 
was started after 3 hours when the cells had seeded on the bottom of the plates. Various 
i 
concentrations of TSA were added to the culture for 24 or 48 hours. The drug 
I 
concentrations used were 0 ng/ml (as negative control), 25 ng/ml, 50 ng/ml, 100 ng/ml, 
200 ng/ml and 400 ng/ml. 
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4.3 Cell proliferation assay 
Cell proliferation was measured by 3-(4,5-dimthylthiazol-2yl)-2,5- diphenyl-
tetrazolium bromide (MTT) (Promega, Madison, WI, USA), which access the number of 
viable cells in proliferation and determine the IC50.50 jul of culture medium containing 
various concentrations of TSA or SAHA were added to 96-well plate and equilibrated at 




the pre-equilibrated 96-well plates at a density of 1 x 10 cells in 50 |il to give a total 
volume of 100 jil/ml. After 48hr of incubation, 15 |li1 of Dye solution was added to each 
1 
well. The plate was then incubated in a humidified atmosphere of 5 % CO2 at 37°C for 4 j 
hours. After incubation, 100 |il of Solubilization/Stop solution was added to each well. 
i 
One hour after the addition of the Solubilization/Stop solution, the contents of the wells 
were mixed to get a uniformly colored solution. Absorbance at 570 nm was measured 




4.4 Apoptotic assay 
For detection and/or quantification of apoptosis Annexin V-FITC binding method 
were used. Annexin V staining can identify apoptosis at earlier stage than other assays 
that based on nuclear changes such as DNA fragmentation. Annexin V binding was 
determined using Annexin V-FITC apoptosis detection kit (BD Biosciences, San Jose, 
CA, USA) and analyzed by flow cytometry as described below (Refer to section 4.5). 
� 
4.5 Flow cytometry 
4.5.1 Cell preparation 
AGS cells from low passages (-passage 10) were treated with various 
concentrations of TSA (0 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml and 400 \ 
i 
ng/ml) or SAHA (0 |LIM, 1 |iM, 2 \iM, 4 [iM, 8 |LIM and 15 |LIM). Cells were incubated at j 
I 
37°C in a humidified atmosphere of 5 % CO2 and 95% air for 24 hours. Cells were ' 
harvested by complete trypsinization to ensure single tumor cell suspension. 1 
Approximately 1 x 10^  cells were collected and washed twice with cold PBS. Harvested 
cells were then passed through the single cell filter and resuspend in 70% ethanol (for 
Propidium Iodide) or PBS (for Annexin V-FITC). Cells were then stained with PI and/or 
Annexin V-FITC. 
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4.5.2 Propidium Iodide staining 
Propidium Iodide (PI) is a standard flow cytometric viability probe which used to 
distinguish viable and dead cells. PI staining solution (8.5 ml of 0.1% BSA staining 
buffer, 1 ml of 0.1% RNase and 500 |li1 of 1 mg/ml PI stock solution) was prepared 
freshly before the staining assay. The samples were vortex gently and centrifuged at 
3,000 rpm for 10 minutes. The ethanol was discarded but less than 200 |a,l of ethanol was 
left behind in the samples. The samples were gently vortex to resuspended cells in : 
residual ethanol. 500 |il to 1 ml of PI staining solution was added to the samples and 
briefly vortex the samples. The samples were incubated in the dark at room temperature 





4.5.3 Annexin V-FITC staining 
Annexin V-FITC is a sensitive probe specific for identifying apoptotic cells at 
earlier stage with exposed phospholipids phosphatidylserine (Martin S. J., 
Reutelingsperger C. P. et al 1995; Vermes I., Haanen C. et al 1995). Purified 
recombinant Annexin V was conjugated to FITC under optimum conditions. Annexin 
V-FITC staining was performed by Annexin V-FITC apoptosis detection kit (BD 
Biosciences, San Jose, CA, USA) according to manufacturer's protocol. Cells were 
washed twice with cold PBS and resuspended in 1 x binding buffer at a concentration of 
1 X 10^  cells/ml. 100 )LI1 of the solution (1 x 10^  cells) was transferred to a 5 ml culture 
tube and 5 |jI of FITC-labeled Annexin V and 5 |j.l Propidium Iodide were added to the 
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solution. The solution mixture was gently vortex and incubated for 15 minutes at room 
temperature in the dark. 400 |li1 of 1 x binding buffer was added to the solution mixture. 
The samples were analyzed by flow cytometer immediately. 
4.5.4 Flow cytometry analysis 
After staining procedure, the samples were analyzed by COULTER® E P I C S � ；： 
XL-MCL flow cytometer (Beckman Coulter, Fullerton, CA, USA) CellQuest sodtware : 
(BD Biosciences, San Jose, CA, USA). CellQuest was also used to analyze Annexin V 








4.6 Total RNA extraction 
For RNA extraction, cells were washed with 5-10 ml of cold PBS. Total RNA was 
extracted from SAHA or TSA treated cells using RNeasy kit (Qiagen, Germantown, 
MD). 350 [il of RLT (1% of (3-Mercaptoethanol was freshly added) was added to the 
culture plates and collected the cells by a cell scraper. The cell lysate was then passed 
through a 21-gauge needle (Becton Dickinson Lab ware, Franklin Lakes, NJ, USA) fitted 
on an RNase-free 5 ml syringe (Becton Dickinson Labware, Franklin Lakes, NJ, USA). ' 
350 \i\ of 70% ethanol was added to the homogenized lysate. The samples were mixed 
and transferred to an RNeasy mini column placed in a 2 ml collection tubes (supplied by 
manufacturer) and centrifuged for 30 seconds at 10,000 rpm. The flow through was 
discarded and 700 of RWl buffer was added to the column. The columns were i 
washed by centrifugation at 10,000 rpm for 30 seconds. The columns were transferred to 
i 
a new collection tube and added 500 |li1 of RPE Buffer (added 4 x 100% ethanol to I 
obtain a working solution) to wash the column twice. The columns were centrifuged for 丨  
I 
30 seconds at 10,000 rpm and discard the flow through afterwards. In order to avoid 
.I 
RPE buffer carryover, the columns were centrifuged for 2 minutes at 10,000 rpm. The 
total RNA was eluted by adding 30 )li1 of RNase-free water directly onto the RNeasy 
silica-gel membrane and centrifuged for 1 minute at 10,000 rpm. Total cellular RNA 
concentrations were measured by spectrophotometer to read the absorbance at 
wavelength 280 nm (Biorad, Hercules, CA, USA). The RNA samples were stored at 
-80°C until subsequent analysis. 
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4.7 DNA extraction 
For the extraction of DNA, cells were washed with 5-10ml phosphate-buffered 
saline (PBS), followed with the treatment of 0.25% tryspin-EDTA (Gibco, Carlsbad, 
California, USA) for 5 minutes at 37°C incubator to detach the cells from the bottom of 
the flasks. Cells were collected by centrifugation at 800 rpm for 3 minutes. The 
supernatant was discarded and the cell pellets were stored at -80°C. DNA from the cell 
pellet samples were retrieved by High Pure PCR Template Preparation Kit (Roche, 
'r 
Mannheim, Germany) according to manufacturer protocol. The cell pellet was 
resuspended in 200 |LI1 of PBS. 40 [d of 1 mg/ml proteinase K was added into the 丨 
I 
samples and incubated at 56°C for few hours. After complete digestion of the samples, | 
200 [l\ of binding buffer was added and incubated at 72°C for 10 minutes. The reaction i 
mixture was then mixed with 100 |LI1 of isopropanol and transferred to the High Pure 
filter column (combined with collection tube) and centrifuged at 8,000 rpm for 1 minute. 
The flow through and the collection tube were discarded and 500 jul of washing buffer 
was added to the column followed by centrifugation at 8, 000 rpm for 1 minute. The 
washing procedure was repeated for the second time. The column was centrifuged at 
12,000 rpm for 10 seconds to remove the residual wash buffer. The elution buffer was 
pre-warmed at 70°C for few minutes before the elution procedure. Lastly, the column 
was placed into a new 1.5 ml eppendrof tube and DNA was eluted with 200 ju.1 of 
pre-warmed elution buffer. The concentration of DNA was measured by a 
UV-spectrometer (Biorad, Hercules, CA, USA) at 260nm wavelength. 
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4.8 Protein extraction 
Drug treated and untreated AGS cell lines were harvested 24 hours after the drug 
treatment. Sub-confluent dishes of cells were washed in phosphate-buffered saline (PBS) 
and collected by cell scrapter. Whole cell lysates from treated and untreated AGS were 
incubated in RIPA lysis buffer containing 1% Triton X-100, 1% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 150mM NaCl, 500mM Tris-HCl, ImM EDTA and Ix 
Protease Inhibitor Cocktail (Roche, Indianapolis, IN) for 20 min on ice. The cell lysates 
：‘' 
were centrifuged at 12,000 rpm in a microcentrifuge for 20 min at 4°C. The supernatant 
was collected and aliquot in 0.5 eppendrof tubes and store at -80°C for further analysis. 
i i 
J 
4.9 Western blotting ’ 
Protein concentration was measured using the Bradford Dc protein assay kit 
(Biorad, Hercules, CA, USA) and bovine serum albumin (BSA; Promega, Madison, WI, 
！ 
USA) was used as a standard. The concentrations of protein samples were measured by 
96-well plate reader spectrophotometer to read the absorbance at 595 nm wavelength 
(Rainbow Spectra, Tecan, Switzerland). 50ug of cell protein extracts were denatured in 
6x sample buffer containing 350mM Tris-HCL pH 6.8, 10% (w/v) SDS, 30% (v/v) 
glycerol, 0.6M DTT, 0.012% (w/v) bromophenol blue (all, except SDS, were purchased 
from Sigma, St Louis, MO). The protein samples were heated to 95°C for 5 minutes. 
Samples were then electrophoresed through a 12% SDS-polyacrylamide gel (SDS/PAGE) 
at llOV for 1 hr at room temperature. Rainbow marker SeeBlue Plus 2 from Invitrogen 
(Carlsbad, California, USA) was used as a size marker. 
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The proteins on the separating gel were transferred onto PVDF membranes by 
electroblotting. Membranes were then incubated overnight at 4°C with blocking solution 
[5% (w/v) low-fat milk in TBS-T (lOmM Tris pH 7.5, lOOmM NaCl and 0.1% Tween 
20)]. Antibodies against Histone acetylated H3 (1:50 000) or Histone acetylated H4 
(1:1000), all were purchased from Upstate Biotectnology, was probed for 1 hr at room 
temperature on a shaker. Monoclonal anti-actin antibody (Sigma, St. Louis, MO, USA) 
was used as a control. Following incubation with the primary antibody, blots were 
,丨:i 
washed in TBS-T x 3 times for 5 min each. Secondary antibody linked to horseradish ； 
I 
peroxidase conjugated anti-rabbit HRP (Upstate Biotectnology, Waltham, MA, USA) or !l 
anti-mouse HRP was incubated with the blots for 1 hr at room temperature on a shaker. j 
Blots were then washed as previous described and developed with an ECL detection kit 
(Amersham Bioscience, Chandler, USA). Immunodectection was recorded by 




4.10 Microarray analysis 
4.10.1 Sample preparation for microarray 
Total cellular RNA was isloated from AGS treated with TSA or SAHA for 24 h 
using RNeasy kit (Qiagen, Germantown, MD) according to the manufacturer's 
instructions and stored at -80°C. Total cellular RNA concentration was assessed by 
、丨I, 
spectrophotometer (Biorad, Hercules, CA, USA) and quality was assessed by gel � 
丨 
electrophoresis. They should have a minimum purity and integrity standards for total 
RNA quality i.e. OD 260/280 > 1.8, DNA contamination < 5%. CodeLink^'^ UniSet 
Human 20K Gene Expression Array (Amersham Bioscience, Chandler, USA) contains a 
collection of approximately 20,289 probes and 19,881 number of genes was used to ^ 
perform the bioarray hybridization. 2ug of total cellular RNA was used to synthesize the 
first-strand cDNA according to the manufacturer's protocol. Six bacterial mRNA 
controls were prepared freshly before the first-stand cDNA reaction and act as fiducial I 
markers for the cDNA synthesis and in vitro transcription reactions. After the 
I 
second-strand cDNA synthesis, the double-stranded cDNA was purified using GFX-PCR 
purification kit (Amersham Bioscience, Chandler, USA) and concentrated. cDNA serves 
as the template for an in vitro transcription reaction to produce the target cRNA. The in 
vitro transcription reaction was incubated in a thermal cycler at 37°C for 15 h and the 
target cRNA was labeled by the biotin-ll-UTP (Perkin Elmer, Boston, MA). Though 
this amplification method, 1000-5000 fold of the input poly(A)+ RNA could be produced. 
Biotin-ll-UTP labeled cRNA was recovered using an RNeasy Mini kit (Qiagen 
Germantown, MD). Quantitation of cRNA was performed by UV spectrophotometry 
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(BioPhotometer, Eppendor, Hamburg, Germany) at 260nm and the concentration and 
purity were assessed. The cRNA OD 260/280 ratio of the samples all were within 
1.8-2.1 which indicated the samples were pure. 
4.10.2 Hybridization 
20 ug of cRNA was fragmented and mixed with the hybridization buffer. The 
� 
hybridization reaction mixture was then slowly injected into the array chamber. ！ 
I, 
:r 
Hybridization was performed in a 37°C shaking incubator for 18 hours at 300 rpm. 
！ 
Post-hybridization, the bioarray was subjected to a stringent wash to remove the 
unbound and non-specific hybridization. The bioarray was stained with Cy5-streptavidin 
dye (Amersham Bioscience, Chandler, USA) conjugate in the dark. Unbound conjugate ^ 
was removed by several non-stringent washes at room temperature (IxTNT, 5 min x 4; 
0.05% Tween 20, 30 seconds) and dried by low speed centrifugation. ； 
I 
I 
4.10.3 Scanning and data processing 
Bioarray slides were scanned by 4000B GenePix™ scanner (Axon Instruments, 
Foster City, CA) calibrated prior to each use. Laser scanning parameters were 635 nm, 
PMT voltage at 600, and 10 u resolution of 10 |im and the scan area adjusted for the 
entire array. The bioarray was quantitated by Codelink Scanning and Expression 
Analysis software (version 2.3; Amersham Bioscience, Chandler, USA). The program 
generated raw outputs for each spot by segmentation and detection of the spot intensity 
versus surrounding background. The data were determined by using the raw intensity per 
75 
pixel within each probe zone subtracted by the local background. Each spot was 
evaluated by comparison to local array signal to noise ratios. The data was generated as 
both raw intensity values and normalized for the large dynamic range by dividing each 
probes by the overall median array intensity value. The spot with manufacturing error or 
poor spot profiles were removed from computation. Each batch of bioarray have 
approximately 1% manufacturing errors that designated by the CodeLink manufacturing 
spot report. 
4.10.4 Data analysis 丨 
I 
Different threshold values were used to identify the number of genes that have 
altered expression and the results were compared. A more stringent threshold value of 
2.5 was used as the cutoff value for the differential expression of the genes. Duplicate 
！ 
experiments were performed on each HDAC inhibitors, SAHA and TSA. Two 
I 
independent experiments results from each SAHA and TSA treatment were compared 丨 
and overlapped genes were selected. In order to selected core gene set that were 
regulated by HDAC inhibitors, a more stringency approach was used. Overlapped genes 
from both of the drug treatment were compared and further selected for analysis. The 
selected genes was then categorized into different groups according to their cellular 
function obtained from the Gene Ontology (GO) terms such as signal transduction, 
apoptosis and regulation of transcription. 
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4.11 Primer design 
For real time RT-PCR, the mRNA sequence of the target genes are obtained from 
National Center for Biotechnology Information (Entrez, Nucleotide). The primers were 
designed using web software PrimerS 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) provide by Whitehead 
Institute/MIT Center for Genome Research. 
� l-'i 
4.12 RT-PCR 
4.12.1 Reverse transcription 
i 
The reverse transcription of total RNA to complementary DNA (cDNA) was 
performed using SuperScritptTM III reverse transcriptase for RT-PCR kit (In vitro gen, | 
Carlsbad, CA, USA). For each reaction, 2 ug of total RNA was mixed with 1 \i\ of 0.3 
I 
|Lig/|il random primers (50-250 ng) and 1 |LI1 of 10 mM dNTP Mix (10 mM each dATP, | 
dGTP, dCTP and dTTP at neutral pH). Sterile and distilled water was added to bring a 
final volume of 13 |LI1. The mixture was incubated at 65°C for 5 minutes and chilled on 
ice for at least 1 minute. Other reaction components including 4 |LI1 of 5 x First-Strand 
buffer (250 mM Tris-HCL (pH 8.3), 375 mM KCL, 15 mM MgC12), 1 |xl of 0.1 M DTT 
and 1 )Lil of superscript丁M III RT (200 units/|Lil) were added to the mixture and 
incubated at 25°C for 5 minutes and 50°C for 1 hour to synthesize the first strand cDNA. 
The reverse transcription reaction was inactive by heating at 70°C for 15 minutes. The 
first strand cDNA was stored at -20°C until subsequent PCR reaction. 
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4.12.2 Quantitative RT-PCR 
In order to verify the results of the microarray analysis, quantitative real time 
polymerase chain reaction (RT-PCR) was performed on (1) 28 pairs of primers which 
included CDKNIA, CDKNIB, CCNA2, CCNEl，BIK’ BAKl, BAX，GMFG, BCL2, BTGl, 
TXNIP, QSCN6’ FOS, IL-8, IGFBP2, ITGA7, SIPAl, CIDEB, CYR61’ MT2A, AKR1C3, 
C4.4A, SERPINIl, SERPINEl, ADM, HEP27, CCK and SILV (Appendix I) and (2) , 
Eleven pairs of primers which included COX-2, DOC-2，MGMT’ MLHl, pi严, ：； 
： 
pl5iNK4B, pi 6腿a，pteN’ RASSFIA, SOCS-1 (Appendix II) in the methylation part of j 
study. P—actin, the house-keeping gene was also included as a control. After reverse 
transcription, first strand cDNA samples were amplified by using RT-PCR with specific 
ii 
primers for the target genes. Each 25 |LI1 of PGR reaction mix was prepared as followed: 
2 ug of cDNA, 12.5 |LI1 of 2X SYBR Green SuperMix (Applied Biosystems, Foster city, 
i 
CA, USA), 0.5 of 10 pmole/|il forward and reverse primers and appropriate amounts I 
I 
of milli-Q water to bring up the volume to 25 jil. The reaction was performed on the ABI 
PRISM® 7000 Sequence Detection System (Applied Biosystems, Foster city, CA, USA). i 
The PCR reactions were performed under the following conditions: 95°C for 12 minutes, 
40 cycles of 95°C for 45 seconds, the specific annealing temperature for each gene (refer 
to Appendix I & II) for 30 seconds and 72°C for 1 minute. The fold induction (intensity 
of PCR products with drug treatment normalized by p-actin expression/intensity of 
untreated PCR products normalized by P—actin expression) was calculated for each gene. 
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4.13 Methlyation study 
4.13.1 Demethylation by 5-aza-2Meoxycytidine 
An amount of 1 x 10^  cells were seeded at 100mm dish at day 0. Demethylating 
agent 5 -aza-2 ‘ deoxycytidine was added to the culture at day 1 and daily treated for 3 





4.13.2 Bisulfite modification 
'：丨 •i ：丨 
Genomic DNA from gastric cancer AGS cells were subjected to bisulfite i 
modifications. Treatment of genomic DNA samples with sodium bisulfite converts all , 
unmethylated cytosines (but not methylcytosines) to uracils, which then further 
converted to thymidine during the subsequent PCR step. Bisulfite modification allows 
the subsequent differentiation of methylated and unmethylated sequences by { 
！ 
methylation-specific polymerase chain reaction (MSP). Bisulfite modification of DNA 
(1 mg) was carried out by MethylEasy ™ (Human Genetic Signatures Proprietary 
Limited, Sydney, Australia) according to the manufacturer's description. 
4.13.3 Methylation-spedfic PCR (MSP) 
The bisulfite-modified DNA samples are amplified by primers specifically designed 
to distinguish between methylated and unmethylated DNA. CpG-island methylation was 
examined in 11 cancer-related genes, including COX-2, DOC-2, MGMT’ MLHl, pi严’ 
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p l f , pi 6丨斷 PTEN，RASSFIA, SOCS-1 and TSLCl. Both methylated and 
unmethylated primer sequences, annealing temperatures and the expected PCR product 
sizes of the gene were summarized in Appendix III. Amplifications of these genes were 
performed in AGS cells and 5-aza-2‘deoxycytidine-treated AGS cells. For most of the 
genes, PCR was performed in 20 iil reaction volumes containing 2 |LI1 of lOX PCR Buffer, 
1.6 [l\ of 2.5mM of dNTP mix, 1.6 |li1 of 25mM MgCb, 0.3 |LI1 of forward and reverse 
primer specific for methylated and unmethylated DNA sequence (synthesized by \ 
invitrogen), 0.2 |LI1 of Taq polymerase (AmpliTaq Gold; Applied Biosystems, Foster City, , 
'丨 
CA), 2 III of modified DNA and 12 |il of milli-Q water. The temperature profiles for the 
amplification were as follows: 10 minutes at 95 °C, 40 cycles of denaturing at 95�C for : 
30 seconds, 45 seconds annealing at specific temperature, 1 min at 72。C. A positive 
] 
control for both methylation (In vitro- modified methylated positive control (Invitrogen; 
Carlsbad, California, USA) and unmethylation (normal human DNA) and a negative | 
control (distilled water) were included in each amplification. PCR products were I 
！ 




Chapter 5 Results 
5.1 Morphological changes in AGS cells 
Human gastric adenocarcinoma AGS cells have an oval appearance in the absence 
of HDAC inhibitors as shown in Figure 7. AGS cells were treated with either ‘ 
'I 
Trichostatin A (TSA) (lOOng/ml and 400ng/ml) or Suberoylanilide Hydroxamic Acid ！ 
(SAHA) (4 |iM and 15 jiM) for 24 hours (hr). After the drug treatment, AGS cells 
showed gradual morphological changes such as cytoplasmic elongation, loss of 
cell-to-cell contact and production of filamentous protrusions with increasing 
) 
concentrations. These morphological changes appeared to be concentration-dependent. 
Furthermore, cell treated with TSA or SAHA triggered morphological features 
j 
suggestive of apoptosis with a smaller size and rounder shape. As both of the HDAC | 
I 
inhibitors, SAHA and TSA produced similar morphological alterations in AGS which 
indicated that the changes may likely related to the inhibition of HDAC activity. 
5.2 Anti-cancer effects of HDAC inhibitors 
5.2.1 Effect of HDAC inhibitors on cell growth 
To investigate the possible anti-cancer effects of Suberoylanilide Hydroxamic Acid 
(SAHA) and Trichostatin A (TSA), we first examined their potency to inhibit the cell 
proliferation of human gastric adenocarcinoma AGS cells by using 
81 
3-(4,5-dimthylthiazol-2yl)-2,5- diphenyl- tetrazolium bromide (MTT) assay. This 
colorimetric assay determines the number of viable cells in proliferation and apoptosis 
assays. It detects the cleavage of the tetrazolium salt MTT to a formazan dye that occurs 
only in metabolically active cells. Three independent experiments were performed on 
each agent. 
a. SAHA inhibits cell proliferation 
D 
We examined the effect of the HDAC inhibitor SAHA on the proliferation of AGS , 
'1, 
cells. The MTT assay revealed that SAHA greatly inhibited the growth of AGS cells to 
•j 
various degrees in a concentration-dependent manner (Figure 8). Cells were cultured ； 
I 
with various concentrations of SAHA for 48 hours. Untreated AGS cells (0 juM SAHA) 
have 100% cell viability. Cell viability has dropped 15% when treated with 1 |iM SAHA. ‘ 
With increasing dosage of SAHA starting from 2 pM, cell growth was dramatically 
decreased. Fifty percent growth inhibition (IC50) was recorded between 4 |LIM to 8 [iM of 
S A H A treatment. Cells were completely died when they were treated with 15 |LIM of j 
SAHA. , 
b. TSA inhibits cell proliferation 
TSA showed a marked anti-proliferative effect against AGS in a dose-dependent 
manner. As shown in Figure 9, cell growth was inhibited to various degrees in the 
presence of TSA treatment. AGS cells were treated with 1 ng/ml, 2 ng/ml, 5 ng/ml, 50 
ng/ml, 100 ng/ml, 200 ng/ml, 400 ng/ml and 800 ng/ml for 48 hours. Cell viability was 
dropped dramatically to 30% when they were treated with 200 ng/ml TSA. Fifty percent 
growth inhibition (IC50) was between 100 ng/ml to 200 ng/ml. From concentrations of 
82 
200 ng/ml to 800 ng/ml, percentage of cell viability had reduced gradually until all cells 
were death. 
Both SAHA and TSA caused a progressive decline in cell growth in a 
concentration-dependent manner which revealed their ability to inhibit the cell 
proliferation in proliferating cultures. 
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Morphological changes of AGS cells induced by HDAC inhibitors 
SAHA (OnM) SAHA (4 jiM) SAHA (15 jiM) 
纖 國 P i 
TSA (0 ng/ml) TSA (100 ng/ml) TSA (400 ng/ml) 
Figure 7 Morphological changes of AGS cells induced by HDAC inhibitors. AGS were treated without or with the 
indicated concentrations of SAHA (4 ^M and 15 |iiM) and TSA (100 ng/ml and 400 ng/ml) for 24 hours. SAHA and TSA 
caused cell elongation and cell detachment. 
84 




^ 70 - �� 承 - - X t 
I 60 - ：； 
• 40 - : 
� 3 � 
20 
10 1 
Q I I I I i I I 1 
0 2 4 6 8 10 12 14 i 
SAHA (^iM) 
{ 
Figure 8 SAHA inhibited the cell proliferation in AGS cells. Cells were cultured 
I 
with the indicated concentrations of SAHA for 48 hours. The mean 土 standard 
deviations of the data of three independent experiments are shown. 
j 
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Figure 9 TSA inhibited the cell proliferation in AGS cells. Cells were cultured 
with the indicated concentrations of TSA for 48 hours. The mean 土 standard deviations ！ 
i 
of the data of three independent experiments are shown. 
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5.2.2 Cell cycle analysis 
In order to analyze the potential distributane of cell cycle of these two histone 
deacetylase inhibitors, their effect on the cell cycle was investigated. For cell cycle 
analysis, AGS cells were treated with various concentrations of SAHA (0, 1, 2, 4, 8 and 
15 mM) and TSA (0，25, 50, 100, 200 and 400 ng/ml) for 24 hr or 48 hr and nuclear DNA 
was stained with Propidium Iodide (PI). The results analyzed by the FACS contained 
two individual peaks, the left peak represented the cell populations that reported in , 
i 
•！ 
GO/Gl phase and the right peaks represented the cell populations that reported in G2/M j 
phase. The cell populations between these two peaks were cells that reported in S phase. 
a. Effect of SAHA on cell cycle 
FACS cell cycle analysis of SAHA-treated AGS cells revealed that starting from 
i 
concentration at 4 |iM of SAHA, cells accumulated in G2/M phase. The percentage of j 
cells in the G2/M phase of the cell cycle accumulated in a concentration-dependent 
fashion, whereas cells in the GO/Gl gradually decreased in both 24 and 48 hr time points 
(Figure 10). 
At 24 hr, without the SAHA treatment, around 42%, 33% and 25% of the cells were 
in the GO/Gl phase, S phase and G2/M phase respectively. With the treatment of 1 fiM 
and 2 |LIM of SAHA, there was mild increased in the number of cells in the GO/Gl phase. 
Cell cycle arrest was observed in G2/M phase when 4 |iM of SAHA was added to the 
culture and the cell populations in G2/M phase had increased to 38%. When the dosage 
87 
of SAHA increased, it gradually increased the accumulation of cells in G2/M phase. The 
cell populations in GO/Gl phase gradually decreased starting from 2 juM of SAHA while 
the S phase population gradually increased. Similar results were observed at the 48 
hours time point. At the concentrations of 4 |LIM of SAHA, cells were accumulated in the 
G2/M phase. A strong arrest was noted at 8 |iM of SAHA as the cell populations of 
G2/M phase increased 2-fold compared to the control. However, as shown in the figures, 
4 |iM of SAHA induced lots of apoptosis in the cell culture at 48 hours. Large amounts ’ 
of aggregates were reported when the dosages were greater than 4 pM of SAHA. The 
I 
amounts of aggregates and apoptotic cells were much greater at 48 hr than that at 24 hr. J 
In summary, SAHA induced cell arrest in G2/M at higher drug concentrations in a 
dose-dependent manner at both 24 hours and 48 hours time points. 
I 
i 
b. Effect of TSA on cell cycle | 
I 
Cell cycle effects were examined by FACS analysis on TSA treated AGS cells at 
both 24 and 48 hours. Similar results were observed in TSA treatment compared to 
SAHA treatment. 
At 24 hr, in the absence of TSA, around 42%, 33% and 25% of the cells were in the 
GO/Gl phase, S phase and G2/M phase respectively. When the dosage of TSA increased, 
it gradually increased the accumulation of cells in G2/M phase. A strong arrest was 
observed in G2/M phase when 100 ng/ml of TSA was added to the culture and the cell 
populations markedly accumulated to 2-fold as compared to control at 24 hr in G2/M 
phase. Similar results were observed at the 48 hr time point. High concentrations of TSA 
88 
treatment (> 100 ng/ml) also induced lots of apoptosis which produced large amounts of 
aggregates in the cell culture, especially at 48 hr time point. The amounts of aggregates 
and apoptotic cells were much greater at 48 hr than that at 24 hr. Therefore the apoptotic 
cells and aggregates might influence the analysis of the cell cycle distribution. In 
summary, TSA induced cells cycle arrest in G2/M in a dose-dependent manner at both 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.3 Induction of apoptosis on AGS cells 
To further investigate the anti-cancer effects of SAHA and TSA, we exposed AGS 
to these agents and determined apoptosis levels after 24 and 48 hours of incubation 
times. The cells were incubated with 1, 2, 4, 8 and 15 |LIM of SAHA or 25, 50, 100, 200 
and 400 ng/ml of TSA for 24 and 48 hours. Annexin V-FITC flow cytometry analysis 
was used to access the levels of apoptotic cell death. 
In the early stage of apoptosis, the membrane phospholipids phosphatidylserine (PS) ! 
is translocated from the inner to the outer leaflet of plasma membrane. Annexin V-FITC 
staining can identify apoptosis at an earlier stage than other assays which based on 
nuclear changes such as DNA fragmentation. Annexvin V is a calcium-dependent 
I I 
phospholipid-binding protein which has a high affinity for PS. Propidium Iodide (PI) is a 
standard flow cytometric viability probe that is used to distinguish viable from 
non-viable cells. The figures from the apoptosis flow cytometery results contained four 
quadrants: (a) up-right: cells that are in the end stage of apoptosis that undergoing 
necrosis or are already dead (stain positive for both Annexin V-FITC and PI), (b) 
bottom-left: viable cells with intact membranes (stain negative for both Annexin V-FITC 
and PI), (c) bottom-right: cells in early stage of apoptosis (stain positive for Annexin 
V-FITC but negative for PI). 
a. SAHA induces apoptotic cell death 
In Figure 12 to 14, the dose-dependence of SAHA to induce apoptosis was 
92 
demonstrated using the FACS-based quantitative apoptosis assays (Propidium Iodide 
staining combined with Annexin V-FITC staining). The percentage of cells in early 
apoptosis and late apoptosis were added together to plot against different concentrations 
of SAHA (Figure 13 and 14). At 24 hours, the percentage of apoptotic cell numbers for 
untreated cells was 23% 土 2o/o. The viable cell numbers gradually decreased and the 
numbers of apoptotic cell increased as the concentrations of SAHA increased. At 1 |iM 
concentration of SAHA, the apoptotic cell numbers increased to 31% 土 9%. At . 
— 1 
concentration 2 |LIM, similar amounts of apoptotic cells were observed compared to 1 )LIM 
of SAHA. Further increased concentrations of SAHA to 4 jiiM of SAHA, the percentage I 
of apoptotic cells increased to 43% 土 6o/O. In the treatment of 8 |LIM and 15 JIIM SAHA, : 
i 
the apoptotic cells increased to 56% 土 23o/o and 64% 土 20o/o respectively. 
Similar amounts of apoptotic cells were observed at 48 hours in untreated cells with 
apoptotic cells numbers 23% 土 3o/o. The viable cell numbers gradually decreased and the 
numbers of apoptotic cell increased as the concentrations of SAHA increased. At 1 |LIM 
concentration of SAHA, the percentage of apoptotic cell numbers was 24% 土 8o/o. At 
concentration 2 |J,M, similar amounts of apoptotic cells were observed compared to 1 |LIM 
of SAHA. Further increased concentrations of SAHA to 4 |iM of SAHA, the percentage 
of apoptotic cells increased to 40% 土 9%. In the treatment of 8 JIIM and 15 |LIM SAHA, 
the apoptotic cells increased to 56% 土 12o/o and 6I0/0 土 15o/o respectively. 
In summary, SAHA induced apoptosis in a concentration-dependent manner. At the 
IC50 dosage (4 |iM), SAHA induced 43% 土 6o/o apoptosis at 24 hours and 40% 土 9o/o at 
93 
48 hours upon treatment. 
b. TSA induces apoptotic cell death 
The dose-dependence of TSA induced apoptosis was investigated using 
FACS-based quantitative apoptosis flow cytometry analysis (Figure 15 to 17). Without 
the addition of TSA, the apoptotic cell numbers were around 17% 土 4o/o at 24 hours 
(Figure 16). The viable cell numbers gradually decreased and the numbers of apoptotic 
, r 
cell increased as the concentrations of TSA increased. At 25 ng/ml of TSA, the 
percentage of apoptotic cells increased to 34% 土 When the concentration of TSA j 
increased to 50ng/ml, the apoptotic cell numbers were 45% 土 3o/o. Further increased the 
dosage of TSA to 100 ng/ml, the treatment induced 58% 土 16o/o apoptotic cells. Similar , 
amounts of apoptotic cells were observed at 200 ng/ml (67% 土 15o/o) and 400 ng/ml 
I 
(68% 土 14o/o) of TSA treatment. 丨 
At 48 hours, the apoptotic cell numbers for untreated cells was 24% ±30/) (Figure 
17). The viable cell numbers gradually decreased and the numbers of apoptotic cell 
increased as the dosage of TSA increased. At 25 ng/ml of TSA, the apoptotic cell 
numbers slightly increased to 28% 土 9o/o. At concentration of 50 ng/ml, it induced 49% 
土 14 % of apoptosis. Further increased the concentrations to 100 ng/ml of TSA, the 
percentages of apoptotic cell increased to 60% 土 17o/o. In the treatment of 200 ng/ml and 
400 ng/ml TSA, the apoptotic cells increased to 67% 土 17o/o and 75% 土 17o/o 
respectively. 
In summary, TSA induced apoptosis in a concentration-dependent manner. At the 
94 
ICso dosage (100 ng/ml), TSA induced approximately 58% 土 16o/o apoptotic cells at 24 














































































































































































































































































































































































































































































































































































































































































































































































































































SAHA induction of apoptosis at 24 hours 
% of Apoptosis- Annexin V Method (24hr) 
100「 ！ 
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0 1 2 4 8 15 
SAHA (mM) 
Figure 13 AGS cells were incubated with different concentrations of SAHA (0, 1, 2, 
4，8 and 15 |iM) for 24 hours. Cells were analyzed by flow cytometer and total amounts 
of apoptotic cells in percentage (late stage and early stage apoptotic cells) were plotted 
against different concentrations of SAHA. The data showed the mean and standard 
deviation from triplicate experiments. 
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SAHA induction of apoptosis at 24 hours 
% of Apoptosis- Annexin V Method (48 hr) 
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Figure 14 AGS cells were incubated with different concentrations of SAHA (0，1，2, 
4，8 and 15 |xM) for 48 hours. Cells were analyzed by flow cytometer and total amounts 
of apoptotic cells in percentage (late stage and early stage apoptotic cells) were plotted 
against different concentrations of SAHA. The data showed the mean and standard 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































SAHA induction of apoptosis at 24 hours 
o/o of Apoptosis- Annexin V Method (24 hr) 
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Figure 16 AGS cells were incubated with different concentrations of TSA (0, 25, 50, 
100，200 and 400 ng/ml) for 24 hours. Cells were analyzed by flow cytometer and total 
amounts of apoptotic cells in percentage (late stage and early stage apoptotic cells) were 
plotted against different concentrations of TSA. The data showed the mean and standard 
deviation from triplicate experiments. 
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Figure 17 AGS cells were incubated with different concentrations of TSA (0, 25, 50, 
100, 200 and 400 ng/ml) for 48 hours. Cells were analyzed by flow cytometer and total 
amounts of apoptotic cells in percentage (late stage and early stage apoptotic cells) were 
plotted against different concentrations of TSA. The data showed the mean and standard 
deviation from triplicate experiments. 
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5.3 Induction of histone expression on AGS cells 
Since histone deacetylase inhibitor is supposed to mediate many of its biological 
effects through inhibition of histone deacetylases, thus we determined histone acetylation 
status in drug treated AGS cells. We examined the levels of histone acetylation after 
treatment with HDAC inhibitors. With the use of AGS human gastric adenocarcinoma 
cells in culture, the effects of SAHA and TSA on the acetylation of histone H3 and 
I 
histone H4 have been determined. AGS cells were treated with various concentrations of 
I 
SAHA (1, 2, 4，Sand 15 |LIM) or TSA (25, 250, 100，200 and 400 ng/ml) for 24 hours. 
Cells were harvested and 25 jug of total proteins were used for western blot analysis. 
5.3.1 HDAC inhibitors induced acetylation of histone H3 
Acetylated histone H3-specific antibody were used to show the level of acetylation 
in histone H3 when cells were cultured with SAHA and TSA (Figure 18). The density of 
acetylated histone H3 was higher in protein extracted from either SAHA or TSA treated 
AGS cells than that from untreated cells. Increased histone acetylation could be detected 
in A G S cells treated with as less as 1 |LIM of SAHA and 25 ng/ml of TSA. The levels of 
histone acetylation gradually increased as the dosage of these HDAC inhibitors 
increased. At 8 jiM of SAHA and 50 ng/ml of TSA, the acetylated histone H3 protein 
levels markedly increased. The levels of acetylated Histone H3 observed at 15 |iM of 
SAHA and 400 ng/ml of TSA were 3-fold and 10-fold greater than control respectively. 
SAHA and TSA induced the accumulation of acetylated histone H3 in a dose-dependent 
effect. 
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5.3.2 HDAC inhibitors induced acetylation of histone H4 
Western blot analysis showed that before incubation with SAHA and TSA, the 
levels of acetylated histone H4 in AGS cells were low (Figure 19). When cells were 
cultured with SAHA or TSA, the level of acetylated histone H4 increased. The 
acetylated histone H4 start to be detected at SAHA concentrations of 1 |LIM and at TSA 
concentrations of 25 ng/ml. At 2 |LIM of SAHA and 100 ng/ml of TSA, the acetylated 
histone H4 protein levels markedly increased. The acetylated histone H4 expression ! 
gradually increased in both HDAC inhibitors as the concentrations increased. At 15 jiiM 
of SAHA and 400 ng/ml of TSA the level of acetylated histone H4 were 2-fold and 
4-fold greater than control respectively. The level of acetylated histone H4 was induced 
in a dose-dependent fashion when exposed to SAHA and TSA treatment. 
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Figure 18 Western blot analysis of acetylated-histone H3 expression in AGS 
cells. AGS cells were treated with various concentrations of (A) SAHA and (B) 
TSA for 24 hours. 25|ig of total proteins were loaded on each lane of 12% 
SDS-PAGE. Acetylated-histone H3 expression was probed with an 
anti-acetylated histone H3 polyclonal antibody (Upstate; 1: 50 000). Each blot is 
a representative of duplicate experiments. 
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Figure 19 Western blot analysis of acetylated-histone H4 expression in AGS cells. 
AGS cells were treated with various concentrations of (A) SAHA and (B) TSA for 24 
hours. 25|xg of total proteins were loaded on each lane of 12% SDS-PAGE. 
Acetylated-histone H4 expression was probed with an anti-acetylated histone H4 
polyclonal antibody (Upstate; 1:1000). Each blot is a representative of duplicate 
experiments. 
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5.4 SAHA- and TSA-induced gene expression 
profiles 
In this study, we used CodeLink^"^ Microarray platform to analyze the gene 
expression profile before and after the treatment of SAHA and TSA in AGS gastric 
cancer cells. The experiments indented to identify differential expressed genes. We 
repeated the microarray analysis independently twice for each agent and analyzed the 
results by comparing the normalized intensity of the treated cells to those from the 
untreated cells. A threshold value of 2.5 fold gene expression level was used as a cutoff 
for the microarray analysis. When AGS cells were treated with SAHA, a total of 369 
(~2%) genes were found with expression changes of more than 2.5 fold in the duplicate 
experiments. Among these 369 genes, 229 genes were up-regulated and 140 genes were 
down-regulated. Upon the treatment of TSA, a total of 508 (�30/0) genes were found to 
have altered expression above 2.5 fold differences. Among these 508 genes, 298 were 
up-regulated and 210 were down-regulated. When SAHA expression profile was 
compared with the TSA expression profile, a total of 258 (�1.3%) genes have altered 
gene expressions of at least 2.5 fold differences were found to overlap in these two sets 
of experiments. Among these 258 genes, 174 were up-regulated and 84 were 
down-regulated. These common genes account for 73% and 53% of altered gene 
expression above 2.5 fold in SAHA and TSA treatment experiments respectively. These 
findings suggested that these two structurally similar HDAC inhibitors may regulate a 
set of common target genes and pathways. Altered expression of these common genes 
may also likely related to the effect of inhibitory action on HDAC from these two 
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HDAC inhibitors. 
These 258 overlapped genes with altered expression from SAHA and TSA 
treatments have been categorized into different groups in terms of their major function 
(Figure 20) including apoptosis (5 genes), cell structure/ morphogenesis (6 genes), signal 
transduction (26 genes), transcription (12 genes), proliferation (4 genes), metabolism (15 
genes), cell-cell communication (1 genes), tumorgenesis/ oncogenesis/ tumor suppressor 
(4 genes), cell growth/ cell maintenance (11 genes), others (33 genes) and unknown (141 
genes). The detail listing of these genes are summarized in Appendix IV. It appeared that 
genes involved in multiple cellular pathways could be altered upon HDAC inhibitor 
treatment. 
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5.5 Verification of gene expression by 
quantitative RT-PCR 
We performed quantitative RT-PCR on selected genes whose expression 
was altered by SAHA and TSA, in order to verify changes in gene expression 
detected by the microarray analysis. We focus on the common genes that are 
up-regulated after treatments, which may be more likely the targets gene being 
down-regulated by HDAC. 
Since both SAHA and TSA exert anti-proliferative, apoptosis induction and 
cell cycle arrest effects on AGS cells, genes that involved in these pathways will 
be of particular relevant. These genes were also selected in light of genes 
alterations upon treatment with HDAC inhibitors reported in other studies. For 
selected up-regulated genes also reported in other gastric cancer cell line model 
are listed in Table 6A. For selected up-regulated genes reported in other 
non-gastric cancer cell line model are listed in Table 6B. For selected 
up-regulated genes not previously reported upon HDAC inhibitors treatment are 
listed in Table 6C. In addition, several highly induced genes upon treatment with 
SAHA and TSA were also selected for RT-PCR analysis. In total, there were 28 
genes selected for quantitative RT-PCR analysis. 
Based on microarray analysis, genes expression levels were similar in both 
SAHA and TSA treatments. The RT-PCR results appeared concordant with the 
microarray studies. The results are summarized in Table 6. Cell cycle regulators, 
like p21 ^^^^ was mildly up-regulated while Cyclin A and Cylcin E were 
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not up-regulated. Genes related to proliferation and apoptosis, including 
BCL2-interacting killer {BIK), BCL2- antagonist/killer 1 (BAKl)’ B-cell 
translocation gene 1 (BTGl), thioredoxin interacting protein (TXNIP), quiescin 6 
(QSCN6) were up-regulated while B-cell CLL/lymphoma 2, alpha (BCL-2) and 
BCL2-associated X protein (BAX) were not up-regulated but for BAKl was only 
mildly up-regulated. In addition, genes involving in these pathways but have not 
been reported to be up-regulated upon HDAC inhibitors treatment, including 
signal-induced proliferation-associated gene 1 (SIPAl), cell death-inducing 
DFFA-like effector b (CIDEB), cysteine-rich, angiogenic inducer, 61 (CYR61) 
and Metallothionein 2A (MT2A) were also up-regulated in our experiments. 
Other selected genes including glia maturation factor-gamma (GMFG)’ v-fos 
FBJ murine osteosarcoma viral oncogene homolog (FOS)，interleukin 8 (IL-8)， 
insulin-like growth factor binding protein- 2 (IGFBP2) and integrin alpha chain 7 
(ITGA 7) as well as the highly induced genes including aldo-keto reductase 
family 1, member C3 (AKR1C3), GPI-anchored metastasis-associated protein 
homolog (C4.4A), serine (or cysteine) proteinase inhibitor, clade I，member 1 
(SERPINIl)，serine (or cysteine) proteinase inhibitor, clade E，member 1 
(SERPINEl), adrenomedullin (ADM), dehydrogenase/reductase member 
2 (HEP27), cholecystokinin (CCK) and silver homolog (mouse) (SILV) were all 
confirmed to be up-regulated. 
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Common altered genes categorized in terms 
of function 
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Figure 20 A total of 258 overlapped genes with altered expression upon 
SAHA and TSA treatment were categorized into different groups in terms of their 
major function. 
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T a b l e 6 Quantitative RT-PCR analyzed on 28 selected genes expression 
after SAHA and TSA treatments. Microarray analysis results were also listed for 
comparison. These genes are selected based on four criteria: (1) genes that were 
previously identified as HDAC inhibitors up-regulated genes in gastric cancer 
cells, (2) up-regulated genes that were previously identified in non-gastric cancer 
cells, (3) genes that not reported to be regulated by HDAC inhibitors but are 
apoptosis and/or proliferative-related gene and (4) genes that highly induced after 
SAHA and TSA treatment in this current study. These genes were categorized by 
their function. 
A. HDAG inhibitor Rx up-regulated genes (reported in gastric cell line) 
SAHA 4nM TSA lOOfiM 
ACCN# OGS Gene name References 
RT-PCR Microarray RT-PCR Microarray 
(])Apoptosis / Proliferative related genes 
(Litvak D A.’ Hwang K. O et al. 
2000) (gastric) 
(Suzuki T., Yokozaki H ct al. 2000) 
(gastric) 
NM_000389 CDKNIA p21WAFl 186 1.625 3.65 1.62 二 � ^ 1 ’ Bang S H. c, „/. 2005) 
(Moore P. S., Barbi S. et d. 2004) 
(pancreas) 
(Richon V. M.’ SandhoffT. W. ct iil. 
2000) (bladder) 
(Litvak D A., Hwang K O et al. 
2000) (gastric) 
(Richon V. M.’ SandhoffT W ct al. 
NM_004064 CDKN1B cyclin-dependent kinase inhibitor lB(p27, Kipl) -0.46 1.75 ^ 1.2 2000) (bladder) 
(Suzuki T.’ Yokozaki H ct al. 2000) 
(gastric) 
(Peart M. J , Smyth G K. ct al. 
NM_001238 CCNEl cyclin E1, transcript variant 1 -4.06 0.91 -1.66 0.78 2005) (leukemia) 
(Suzuki T., Yokozaki H ct ni 2000) 
NM_001237 CCNA2 cyclin A2 -4.74 0.25 -4.18 0.25 (gastric) 
(Litvak D A , Hwang K. O. ct al. 
NM_001197 BIK BCL2-interacting killer 6.57 3.9 5.3 2000) (gastric) 
(Litvak D A., Hwang K O ct al. 
2000) (gastric) 
(Peart M J., Smyth G K ct al. 
NM_001188 BAKl BCL2-antagonist/killer 1 1 46 1 92 M 2 1.15 2005) (leukemia) 
(Litvak D A.’ Hwang K. O et al. 
2000) (gastric) 
(Suzuki T., Yokozaki H. et al. 2000) 
NM_004324 BAX BCL2-associated X protein -3.82 0.94 -2.44 1 [(gastric) 
(2) Other genes 
\ ‘ “ (Lee H. S., Park M. H. et al. 2004) 
NM 004877 GMFG glia.maturation factor’ gamma 4 1 8 4.06 5.22 5.35 . (gastric) 
B. HDAC inhibitor Rx up-regulated genes (reported in non-gastric cell line) , . . : : : : . : : " � 
(J) Apoptosis / Proliferative related genes 
(Peajt M. J., Smyth G K et <iL 
NM_000633 BCL2 B-cell CLL/lymphoma 2, alpha 0.28 1.13 1.84 1.23 2005) (leukemia) 
(Peart M. J , Smyth G K et al. 
NM 001731 BTGl B-cell translocation gene 1 i J S 3.55 2005) (leukemia) 
(Butler L. M., Zhou X. ct ai 2002) 
NM 006472 TXNIP thioredoxin interacting protein 5.92 12.72 7 21.44 (bladder, breast, prostate) 
(Chiba T , Yokosuka O et al. 2004) 
NM 002826 QSCN6 Quiescin Q6 1.9 1 46 2.56 1.47 | (hepatoma) 
(2) Other genes 
v-fos FBJ murine osteosarcoma viral oncogene (Chiba T., Yokosuka O ct al. 2004) 
NM 0052521 FOS |homology 10.93 5.5 11 01 9.26 |(hepatoma) | 
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N M _ 0 0 0 5 8 4 (Chiba T , Yokosuka O et al. 2004) 
- lL-8 interleukin 8 7.32 8.66 ^ 16.64 (hepatoma) 
(Chiba T.’ Yokosuka O. ct al. 2004) 
N M _ 0 0 0 5 9 7 1GFBP2 insulin-l ike growth gactor binding protein 2 3.98 2.68 6 88 1 88 (hepatoma) 
(Chiba T.’ Yokosuka O et al. 2004) 
N M _ 0 0 2 2 0 6 1TGA7 Integrin, a lpha 7 3.22 3.03 5.36 4.51 | (hepatoma) 
C Apoptosis / Proliferative related genes (not reported to be up-regulated by HDAC inhibitor) 
(Kurachi H.’ Wada Y. ct al. 1997) 
( leukemia, lymphoma) , 
(Farina A.，Hattori M. et al. 2004) 
N M _ 0 0 6 7 4 7 S I P A l s ignal- induced prol iferat ion-associated gene 1 9.78 8.01 ^ 6.11 [ 
(Erdtmann L.，Franck N. ct al. 2003) 
(cervix, hepatoma), 
(Lugovskoy A. A., Zhou P. ct al. 
N M _ 0 1 4 4 3 0 C I D E B cell death- inducing DFFA-l ike effector b 2.48 7.52 ^ 7.56 1999) 
(Tong X., Xie D et al. 2001) (lung) 
N M OO1554 C Y R 6 1 cysteine-rich, angiogenic inducer. 61 11.96 3.62 5 1 6 A ^ 
(Lee C, H , Bang S. H ct at. 2005) 
N M _ 0 0 5 9 5 3 M T 2 A |metal lothionein 2A 2.86 2.47 6.18 2.78 [(gastric) 
D. Highly ap-r^uiated genes after HDAC inhibitor Rx in current study , � . 
N M 003739 A K R 1 C 3 aldo-keto reductase family 1, member C3 12.67 15.21 12.61 22.79 
N M _ 0 1 4 4 0 0 C4.4A GPl -anchored metastasis-associated protein homology 13.01 9.85 9_5 11.54 
serine (or cysteine) proteinase inhibitor, clade I 
N M 005025 S E R P I N l l (neuroserpin), member 145vv / Neuroseipin / PI 12 ^ 19.36 13.84 32.47 
serine (or cysteine) proteinase inhibitor, member 1/ 
N M 000602 S E R P I N E l Plasminogen Act ivator Inhibitor 1 / PAI-1 10.68 20.54 11.6 36.86 
N M _ 0 0 1 1 2 4 A D M adrenomedull in IJ 10.73 10.87 12.89 
N M 005794 H E P 2 7 short-chain alcohol dehydrogenase family member ^ 18 96 12：6 28.02 
N M _ 0 0 0 7 2 9 C C K H o m o s叩 iens cholecystokinin 14.82 16.52 17.84 39.33 
N M _ 0 0 6 9 2 8 SILV | silver homolog (mouse) 16.84 36.63 19.36 43.97 
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5.6 Methylation study 
Aberrant gene promoter methylation was detected in 9 out of 11 (82%) 
cancer-related genes in AGS cells. Among these 9 genes, 6 (67%) genes 
(included COX-2, DOC-2, hMLHl, PTEN’ RASSFIA and TSLC-1) were found to 
be partially methylated whereas the 3 other genes (included, p i p i and 
SOCS-l) were completely methylated based on MSP analysis. Two out of the 11 
(18%) genes which included MGMT and 口15隱48 ^o promoter methylation 
detected. Treatment of 5-aza-2'deoxycytidine causing demethylation with 
re-appearing of the unmethylated genes detected by MSP, especially for pi4詹, 
pi 6職 and SOCS-L 
To investigate whether histone acetylation might also be involved in gene 
alternations on these genes in AGS cells, gene expression levels after treatment 
with SAHA and TSA for 24 hours were investigated and verified by quantitative 
real time RT-PCR. The microarray results indicated that the expression levels of 
these genes of SAHA-treated AGS cells were similar to those of TSA-treated 
AGS cells. The RT-PCR results appeared concordant with microarray results. 
Among these 11 genes, SOCS-l and TSLC-1 were up-regulated upon both SAHA 
and TSA treatments. For SOCS-l based on the RT-PCR result, there was � 4 - f o l d 
increased and �10-fold increased after SAHA and TSA treatment respectively. 
For TSLC-1, there was � 4 - f o l d and � 7 - f o l d increase after SAHA and TSA 
treatment respectively. The observations suggested that apart from gene 
methylation, histone deacetylation may also involved in the epigenetic regulation 
of SOCS-l and TSLC-1 expressions in AGS cells. For p l S !匪 ,m i l d 
up-regulation was observed in RT-PCR analysis, but not seen in microarray 
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studies and the possible significance may need further elucidation. 
Up-regulation of genes expression was not observed in other 9 genes after 
HDAC inhibitors treatment. In particular, no gene expression was detected for 
pi 6函 and RASSFIA in quantitative RT-PCP results. The results 
suggested that histone deacetylation probably not involved in epigenetic 
regulation of expression of these genes in AGS cells. 
Our study demonstrated that piG!脇"was hypermethylated in AGS cells. No 
expression of was detected in RT-PCR analysis and no induction of this 
gene was observed from the microarray profile after the treatment of SAHA and 
TSA. Thus p i 6 腿 m i g h t be regulated by methylation but not by histone 
deacetylation. 
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Table 7 Methylation-specific P C R (MSP) and quantitative R T - P C R were 
performed on 11 genes in gastric cancer A G S cells. The methylation status before 
and after 5 -aza-2' deoxycytidine treatment were accessed by MSP. Real-time 
R T - P C R was performed to examine m R N A expression levels of each gene after 
H D A C inhibitors treatments. The microarray results were listed for comparison. 
A C C N # Gene Name Methylation Status R T - P C R Microarray 
AGS 5'aza SAHA TSA SAHA TSA 
1 NM_000963 COX-2 partial partial 0.96 1.28 0.54 0.25 
2 NM_001343 DOC-2 partial partial 0.48 0.78 0.45 0.4 
3 NM_000249 MGMT complete U complete U 1.01 0.73 0.45 0.8 
4 NM—000249 hMLHl partial complete U 0.29 0.56 0.9 0.72 
5 NM_000077 p i严 ( C D K N 2 A ) complete M partial / / 0.62 0.8 
6 NM_004936 plS"""'® (iso 1 )(CDKN2B) complete U complete U 2.20 1.75 1.79 0.88 
7 NM_000077 p i ( C D K N 2 A ) complete M partial / / 0.62 0.8 
8 NM_000314 PTEN partial partial 0.64 0.49 1.58 0.9 
9 NM_007182 RASSFIA partial partial / / 0.25 0.42 
10 NM_003745 SOCS-1 complete M partial 3.94 9.68 2.67 2.82 
11 NM_014333 TSLC-1 partial partial 4.14 6.59 2.93 2.96 
M , Methylated; U, Unmethylated. 
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Chapter 6 Discussion 
6.1 Improved treatment strategy is needed for gastric 
cancer 
Gastric cancer is the second most common cancer world-wide (Bozzetti R, 
Marubini E. et al. 1999). Patients with gastric cancer often presented with 
advanced stage and the prognosis is poor. Despite the advancement in treatment, 
the mortality rate has remained relatively unchanged over the past 30 years and 
the overall 5-years survival rate is only 10-20% (Msika S., Benhamiche A. M. et 
al 2000; Green D., Ponce de Leon S. et al 2002). Surgical resection remains the 
primary treatment for patients with gastric cancer. However, surgical resection 
only can apply on patients with resectable gastric cancer and greater than 50% of 
patients suffered from unresectable locally advanced or metastatic disease 
(Dicken B. J., Bigam D. L. et al. 2005). Adjuvant treatments including 
chemotherapy, chemoradiotherapy or even immunotherapy have been 
investigated. However, the results of these treatments remain disappointing 
(Dicken B. J., Bigam D. L. et al 2005). Two randomized trials for neoadjuvant 
therapy (included radiotherapy, immunotherapy, chemotherapy, 
chemoradiotherapy) have been performed and neither of them convincingly 
demonstrated therapeutic benefit (Dicken B. J., Bigam D. L. et al. 2005). Thus 
new therapeutic approaches are urgently needed. 
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6.2 HDAC inhibitors as potential anti-cancer agents 
There are several potential advantages of histone deacetylase (HDAC) 
inhibitors as new therapeutic agents especially as compare with conventional 
chemotherapy. Conventional chemotherapeutic agents target proliferating cells 
based on small differences in drug sensitivity of tumor cells as compare to 
normal cells to deliver therapeutic benefit. These drugs have limited efficacy 
against non-proliferating tumor cells compare to rapidly proliferating tumor cells 
(Burgess A.，Ruefli A. et al. 2004). However, HDAC inhibitors appear having 
similar effectiveness in killing non-proliferating and proliferating tumor cells 
(Burgess A., Ruefli A. et al 2004). Furthermore, HDAC inhibitors are selectively 
cytotoxic to tumor cells while normal cells appear resistant to the agents. 
Therefore HDAC inhibitors as a potential new treatment option for gastric cancer 
deserved investigations. 
Previous evidences suggested that there is an interaction between DNA 
methylation and histone modifications. For example, Methyl-CpG binding 
protein (MeCP2) has been found to be associated with histone deacetylases 3 
(HDAC3) which histone modification can be induced by DNA methylation 
changes (Jones P. L., Veenstra G J. et al. 1998). Recent studies also demonstrated 
that HDAC inhibitors act synergistically with demethylating agent, 
5-aza-2 ‘-deoxycytidine (5-aza-CdR), on the re-activation of tumor suppressor 
genes (Kishikawa S., Ugai H. et al 2002). 5-aza-CdR in combination with 
HDAC inhibitors such as PB, TSA, SAHA and FK-228 is very effective and 
synergistic with regards to cell differentiation and/or cell growth arrest, apoptosis 
and cytotoxicity, and produced a greater reactivation silenced gene as compared 
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to each agent alone (Cameron E. E.，Bachman K. E. et al 1999; Zhu W. G., 
Lakshmanan R. R. et al. 2001; Boivin A. J., Momparler L. R et al. 2002; 
Klisovic M. I., Maghraby E. A. et al 2003; Primeau M.，Gagnon J. et al 2003). 
Thus, understanding the relationship between DNA methylation and histone 
modification may provide further insights in carcinogenesis. 
Human gastric adenocarcinoma cell line AGS was used in this study. AGS is 
a hyperdiploid, adherent epithelial cell line which can induce tumor formation in 
athymic BALB/c mice. AGS is a rapid growing and easy-to-handle cell line 
which has a doubling time less than 20 hours. Therefore, AGS is a suitable cell 
line model for in vitro and future in vivo study. 
Currently, there are limited data on HDAC inhibitors' effect in gastric 
cancer cell lines. There are only four previous studies reported. These studies 
include TSA treatment in SNU-16 reported by Lee HS et al (Lee H. S., Park M. 
H. et al. 2004), TSA treatment in 8 gastric cancer lines (MKN-1,-7, -28, -74, -45， 
TMK-1, KATO-III, HSC-39) reported by Suzuki T et al (Suzuki T., Yokozaki H. 
et al. 2000), TSA treatment in MKN-28 reported by Kaneda R et al (Kaneda R., 
Toyota M. et al. 2004) and Sodium butyrate treatment in SUA reported by Litvak 
DA et al (Litvak D. A., Hwang K. O. et al. 2000).To our knowledge, AGS cells 
have not been used to examine the potential efficacy of HDAC inhibitors. 
Trichostatin A (TSA) is commonly used in cell line studies, including gastric 
cancer cell lines. (Melnick A. and Licht J. D. 2002). But data on Suberoylanilide 
Hydroxamic Acid (SAHA) in gastric cancer cell line is lacking. 
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HDAC inhibitors are anti-cancer agents that can induce growth arrest, 
differentiation, and/or apoptotic cell death in a wide variety of transformed cells 
which include melanoma, leukemia (Vrana J. A., Decker R. H. et al 1999; Zhang 
X. D., Gillespie S. K. et al 2003), urinary bladder, breast, cervix and gastric 
cancer (Han J. W., Ahn S. H. et al 2000; Richon V. M.，Sandhoff T. W. et al 
2000). TSA can induce apoptotic cell death of human gastric caner cell lines such 
as MKN-1, MKN-7, MKN-28 and SNU-16 (Suzuki T., Yokozaki H. et al 2000; 
Lee K. H., Bae S. H. et al 2004). SAHA is a synthetic product while TSA is a 
natural product. Although TSA is more potent than SAHA, TSA is inappropriate 
for clinical use due to its marked toxicity whereas SAHA showed little in the 
way of toxic effects and have already entered into phase I and phase II clinical 
trial. SAHA demonstrated a broad range of anti-tumor activity, low toxicity, 
linear pharmacokinetics and good bioavailability (Kelly W. K.，O'Connor O. A. 
et al 2005). SAHA can induce apoptotic death in human prostate cell lines 
(LNCaP) and human breast cells (MCF7) (Butler L. M.，Zhou X. et al. 2002). 
However, the effects of SAHA to gastric cancer cells have not yet been studied. 
SAHA and TSA share some similarity due to their structural homology and 
they also have similar mechanisms on acetylation. In the current study, both 
SAHA and TSA were investigated. Thus, the consistent anti-cancer effects being 
observed and the common gene expression being altered may be more likely 
related to their inhibitory effect on HDAC activity. 
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6.3 Potential anti-cancer effect of TSA and SAHA on 
AGS cells 
I. Morphological changes of AGS gastric cancer cells 
Recently, HDAC inhibitors including Apicidin and TSA have shown to 
induce morphological changes in HeLa cervix cancer cells (Han J. W., Ahn S. H. 
et al 2000) and MKN-28 gastric cancer cells (Suzuki T., Yokozaki H. et al 2000) 
respectively. These observations prompted us to examine the effects of SAHA 
and TSA on the induction of morphological changes in AGS gastric cancer cells. 
In the current study, SAHA and TSA induced cell elongation and cell-to-cell 
detachment. The precise mechanisms underlying such morphological changes are 
unclear. These morphological alterations may be related to alterations of cell 
structure-regulating genes for example, KLK5 and C0L1A2 upon treatment with 
SAHA and TSA. 
II. Inhibition of cell proliferation 
Studies have investigated the anti-proliferative effects of SAHA and TSA. 
Induction of G1 and G2 cell cycle arrest, differentiation and apoptosis of 
transformed cells (Richon V. M., Emiliani S. et al 1998; Butler L. M., Agus D. B. 
et al 2000) have been reported. In this study, the effects of SAHA and TSA on 
cell growth and death of gastric carcinoma cell line, AGS were examined. 
From our results, SAHA and TSA successfully inhibited cell proliferation of 
AGS cells with I C 5 0 approximately 4 |iM and 100 ng/ml, respectively. The higher 
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the concentrations of the drug, the higher the percentage of growth inhibition was 
observed. Thus, the effects of these agents on proliferation appeared 
dose-dependent. It is possible that the effect of HDAC inhibitors may be 
dependent or independent of their HDAC inhibitory activity. However, as HDAC 
activity is over-expressed in various cancers and the cell growth inhibition ability 
of different HDAC inhibitors are associated with their HDAC inhibitory potency, 
thus scientists widely believed that the cell growth inhibition ability of a HDAC 
inhibitor is depends on it's ability to inhibit HDAC activity (Marks P. A., Richon 
V. M. et al 2004). 
III. Induction of cell cycle arrest 
In this study, SAHA at concentrat ion�or = 4 j^ M, induced G2/M phase 
arrest at both 24 and 48 hours time points. TSA at concentrations > or = 100 
ng/ml also induced G2/M phase arrest at 24 hours and 48 hours. Thus, at I C 5 0 of 
4 |iM of SAHA and 100 ng/ml of TSA, the accumulation of AGS cells in G2/M 
phase have increased at both 24 and 48 hours. However, apoptotic cells that 
treated for 48 hours were greatly induced at 4 |iM of SAHA and 100 ng/ml of 
TSA which resulted in large amounts of aggregates in the culture. Nevertheless, 
it appears that the predominant effect of TSA and SAHA on cell cycle is 
induction of G2/M phase arrest in AGS cells. 
Although HDAC inhibitors presumably act by similar mechanisms, they 
have different effects on cell cycle arrest in different cell lines. Cell cycle could 
be arrested at GO/Gl or at G2/M (most frequently) phase upon HDAC inhibitors 
treatment (Villar-Garea A. and Esteller M. 2004). For example, TSA induced 
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G2/M cell cycle arrest in osteosarcoma cell line HOS (Roh M. S., Kim C. W. et 
al 2004) and hepatoma cells HepG2 (Herold C., Ganslmayer M. et al. 2002) and 
induced GO/Gl arrest in cervix cancer HeLa cells (Han J. W., Ahn S. H. et al. 
2000). It is well known that G1 phase cell cycle arrest correlated with increased 
p2jWAFi expression but the precise mechanism causing G2/M phase arrest by 
HDAC inhibitors in cancer cells still remain to be elucidated (Roh M. S., Kim C. 
W. et al 2004). 
IV. Induction of apoptosis 
There are two major distinctive pathways of programmed cell death, the 
death receptor pathway and the mitochondria/ cytochrome c-mediated pathway. 
The first pathway involves ligation of death receptors such as Fas and tumor 
necrosis factor receptor to induce a cascade of protein-protein interactions 
mediated by pro-apoptotic caspases. The cytochrome c-mediated pathway 
usually stimulated by stress stimuli and cause cytochrome c release to cytoplasm 
and regulated by BCL-2 family of proteins (Darzynkiewicz Z., Juan G. et al. 
1997; Shao Y., Gao Z. et al 2004). However, the mechanisms by which HDAC 
inhibitors induce apoptosis are not well understood. 
Recently, scientists have proposed a novel mechanism of apoptosis induced 
by HDAC inhibitors. They showed that SAHA induced death of acute T cell 
leukemia cell line CEM through the intrinsic apoptosis pathway (Peart M. J., 
Tainton K. M. et al. 2003). Over-expression of BCL-2 suppressed apoptosis 
mediated by SAHA and resulted in the accumulation of cells in G2/M phase 
(Peart M. J., Smyth G. K. et al. 2005). However, the ultimate mechanism behind 
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the actions of HDAC inhibitors on apoptosis induction was still unclear. 
TSA induces apoptosis in pancreatic (Moore P. S.，Barbi S. et al 2004), 
hepatoma (Chiba T.，Yokosuka O. et al 2004), colon (Saito A., Yamashita T. et al 
1999) and gastric (Suzuki T., Yokozaki H. et al 2000) cancer cell lines at 
submicromolar to nanomolar concentrations. Whereas our data on AGS gastric 
cancer cells showed that the actions of TSA was effective even at lower 
concentrations. Treatment of TSA initiated apoptosis at 25 ng/ml and at the I C 5 0 
dosage of 100 ng/ml, TSA induced approximately 58% 土 16o/o apoptotic cells at 
24 hours and 60% 土 l?� /�apoptotic cells at 48 hours. SAHA has been reported to 
induce apoptosis in cell lines such as acute T-cell leukemia (Peart M. J., Tainton 
K. M. et al 2003) and cervix cancer (Shao Y., Gao Z. et al 2004). The dosage 
being employed usually ranging from 2.5 [iM to 5 jLiM of SAHA and treated for 
24 to 48 hours. For example, in HeLa cells (cervix cancer cell line), after 
treatment with micromolar-level of SAHA, massive cell death was observed at 
48 hours (Shao Y., Gao Z. et al 2004). From our data, SAHA induced apoptosis 
at concentration as low as 1 |iM and at I C 5 0 of 4 |iM, induced 43% 土 6o/o of cell 
death at 24 hours and 40% 土 9o/o at 48 hours. Apoptosis reflected by Annexin V 
staining correlated with the cell viability accessed by MTT assay, which showed 
approximately 50% apoptotic cells upon SAHA and TSA treatment at 48 hours. 
Thus, both TSA and SAHA appear effective in inducing apoptosis in AGS cells 
and the effect seemingly is in a dose-dependent manner at both 24 and 48 hours 
treatment experiments. 
In conclusion, HDAC inhibitors including TSA and SAHA can effectively 
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induced growth inhibition, cell cycle arrest and apoptosis in gastric cancer cell 
line AGS. The observations support the potential anti-cancer effect of HDAC 
inhibitors in gastric cancer. 
6.4 Expression of acetylated histones upon treatment 
with TSA and SAHA 
SAHA and TSA are known to alter the expression of a variety of genes by 
modulating the histone acetylation (Yoshida M.，Kijima M. et al 1990; Richon V. 
M., Sandhoff T. W. et al. 2000). Both SAHA and TSA have shown to inhibit 
HDAC, leading to hyperacetylation of histone proteins H3 and H4 in other cell 
lines (Richon V. M., Sandhoff T. W. et al. 2000). In our study, SAHA and TSA 
demonstrated their ability to inhibit the HDAC activity in gastric cancer cells 
which resulted in increased accumulation of acetylated histone H3 and H4. The 
levels of acetylation in histone H3 and H4 after treatment were induced in a 
dose-dependent manner. The increased expression of acetylated histone H3 and 
H4 indicated that SAHA and TSA effectively inhibited HDAC activity in AGS 
cell line. These observations provided indirect evidence to support the 
anti-cancer effects of TSA and SAHA in AGS cells were related to their HDAC 
inhibitory activity. 
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6.5 Identify potential target genes upon treatment 
with TSA and SAHA 
Carcinogenesis is considered as a multi-step process with abnormal 
expression of tumor-related genes or inactivation of tumor suppressor genes. 
Over the past decades, researches in molecular pathology have identified 
multiple genetic and epigenetic abnormalities of cancer-related genes in the 
development and progression of gastric cancer (Tahara E. 1993). With the 
introduction of gene array, a large number of cDNA microarray studies have been 
applied on gene expression studies in cancer. Expression microarrays have been 
performed on gastric cancer research. For examples, to identify metastasis 
associated genes (Wang J. H. and Chen S. S. 2002), to established carcinogenesis 
models of gastric cancer (Abe M., Yamashita S. et al. 2003), to analyze the 
gastric cancer and compare it to its normal gastric mucosa (Boussioutas A., Li H. 
et al 2003) and to study the relationship between Helicobacter pylori and gastric 
cancer (Nardone G and Morgner A. 2003). 
With the microarray expression approach, Van Lint and his co-workers have 
shown that HDAC inhibitors selectively altered gene expressions instead of a 
global alteration in gene transcription (Van Lint C.’ Emiliani S. et al. 1996). 
Previous studies have also shown that inhibition of HDAC activity by TSA or 
SAHA resulted in only about 2-5% changes (increase or decrease) in gene 
expressions when compare to the untreated control cells (Van Lint C., Emiliani S. 
et al. 1996; Vrana J. A., Decker R. H. et al. 1999; Richon V. M., Sandhoff T. W. 
et al 2000; Butler L. M., Zhou X. et al. 2002). Other investigators also reported 
different set of genes altered by HDAC inhibitors. (Richon V. M•，Sandhoff T. W. 
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et al 2000; Suzuki T., Yokozaki H. et al 2000; Butler L. M., Zhou X. et al 2002; 
Chiba T., Yokosuka O. et al 2004; Hur J., Chesnes J. et al 2004; Moore P. S., 
Barbi S. et al. 2004; Peart M. J., Smyth G. K. et al. 2005). 
Using the microarray expression approach, we also try to identify genes that 
are being altered in AGS cells after treatment with TSA and SAHA. In the scope 
of the current study, we focused on the common genes that are up-regulated after 
treatments, which may be more likely the target genes being down-regulated by 
HDAC. Genes are also selected in light of other's observations on gene 
alterations upon treatment with HDAC inhibitors. In the selected genes for 
further analysis (Table 6), 16 HDAC inhibitors- regulated genes were reported by 
other investigators (Table 6，A & B) and 11 of them were involved in apoptosis 
or proliferation. We also identified other up-regulated genes related to 
anti-proliferation and apoptosis in AGS cells treated with TSA and SAHA (Table 
6 C). In addition, highly up-regulated genes upon treatment with HDAC 
inhibitors (Table 6 D) were also selected for confirmation by RT-PCR. The 
anti-proliferative and apoptosis induction effects of TSA and SAHA have been 
demonstrated in our studies. Thus, in accordance with these observations, 
alteration of genes involved in proliferation and apoptosis appears important in 
mediating the effects of HDAC inhibitors. 
6.5.1 Candidate genes involved in cell cycle 
g . p2 广 
Cyclin-dependent kinase inhibitor (CDKI) p2J 謂(CDKNIA) is the most 
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commonly induced genes in cell lines treated with HDAC inhibitors (Lee H. S., 
Park M. H. et al 2004; Moore P. S., Barbi S. et al. 2004). The expression of this 
gene have been found to be induced in transformed cells by various HDAC 
inhibitors including TSA and SAHA (Richon V. M.，Webb Y. et al 1996; Richon 
V. M., Sandhoff T. W. et al 2000). Upregulation 酬 was also reported in 
gastric cancer cell line treated with HDAC inhibitors by other investigators 
(Litvak D. A., Hwang K. O. et al. 2000; Suzuki T., Yokozaki H. et al 2000; Lee 
C. H., Bang S. H. et al. 2005). It is widely believed that p21 翻 plays an 
important role in GO/Gl phase arrest in cell cycle of transformed cells by HDAC 
inhibitors (Marks P. A., Richon V. M. et al. 2000). The increased expression of 
inhibits Gl-S phase cdk2 activity which was related to G1 phase arrest 
and anti-proliferation effect (Burgess A. J., Pavey S. et al. 2001). Others reported 
that increased p2严仆! expression was associated with apoptosis induction 
(Burgess A. J., Pavey S. et al. 2001). Scientists believed that the induction of 
by HDAC inhibitors are selective as the expression of was not 
altered (Richon V. M., Sandhoff T. W. et al 2000). 
From our results, p21 ^^^^ was mildly up-regulated in treated cells as 
compared to untreated cells. The observation is consistent with the others' studies 
in gastric and non-gastric cell lines. However in our studies, at IC50 or higher 
concentrations, G2/M phase arrest was the predominant effect of TSA and SAHA. 
The underlying explanations are unclear. Nevertheless, it appears that 




Another cyclin-dependent kinase inhibitor, (CDKNIB) shares a 
limited similarity with CDK inhibitor that mediate interaction between 
CDKI and cyclin-CDK complexes (Shin J. Y., Kim H. S. et al. 2000). p27_ is 
known to be involved in G1 arrest that encoded protein binds to and prevents the 
activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the 
cell cycle progression at G i . i s highly conserved and broadly expressed in 
human tissues, and its mRNA levels are similar in proliferating and quiescent 
cells (Sherr C. J. and Roberts J. M. 1999). Upregulation of>27吻^ was reported in 
gastric cancer cell line SUA treated with sodium butyrate (Litvak D. A., Hwang 
K. O. et al. 2000). But this was not observed in other study using eight gastric 
cancer cell lines treated with TSA (Suzuki T., Yokozaki H. et al 2000). Other 
studies which examined the effect of SAHA on the 卩27乂妒 gene expression levels 
also showed that p27啤丨 was not altered (Richon V. M., Sandhoff T. W. et al. 
2000). In our study, mild upregulation of /?27� '" was observed in microarray 
expression studies, but upregulation was not confirmed by real time RT-PCR. 
Thus, it appears that upregulation of may not be an important event in 
gastric cancer cell line treated with HDAC inhibitors. 
c. Cyclin E & Cyclin A 
Cyclin E (CCNEl) was found to be induced in acute T-cell leukemia cells 
after treatment of SAHA (Peart M. J., Smyth G. K. et al. 2005). Other study has 
also demonstrated the effect of SAHA on the expression of cell cycle regulators 
cyclin E and cyclin A in gastric cancer cell lines (Suzuki T., Yokozaki H. et al. 
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2000). Suzuki et al showed that TSA induced the protein expression of cyclin E 
and cyclin A in three gastric cancer cell lines (Suzuki T., Yokozaki H. et al 2000). 
However, other studies on gastric cancer cell line did not observe upregulation of 
cyclin E or cyclin A (Litvak D. A., Hwang K. O. et al 2000; Lee H. S., Park M. 
H. et al. 2004). In our study, cyclin E and cyclin A expressions were in fact, 
down- regulated upon treatment of TSA and SAHA. Thus, it is possible that 
different cell lines may response differently. Moreover, recent studies revealed 
that overexpression of cyclin E has been observed in several types of tumor, it 
may contribute to tumorigenesis through their resistance to the inhibitory 
activities o f p 2 1 似卩】andand caused chromosome instability (Wingate H., 
Zhang N. et al. 2005). Thus, downregulation of cyclin E and cyclin A as shown 
in AGS cells treated with TSA and SAHA may contribute to the anti-cancer 
effect of HDAC inhibitors and these observations warrant further investigations. 
cL Sisnal-induced proliferation-associated sene 1 (SIPAl) 
Signal-induced proliferation-associated gene 1 (SIPAl) encodes a protein 
called GTPase activating protein (GAP). In early studies, evidence suggested that 
SIPAl play a role in cell cycle progression. Recent studies demonstrated that 
when SIPAl was overexpressed, it exhibited inhibitory effect and caused a strong 
arrest at the G2 phase. In other words, SIPA1 exerts its negative effect on G2/M 
progression (Farina A., Hattori M. et al 2004). In our study, it appeared that TSA 
and SAHA treatment leaded to predominantly G2/M phase arrest. With 
treatments of these HDAC inhibitors, SIPAl expression levels were significantly 
up-regulated. Thus, it is possible that upregulation of SIPAl contribute to the 
G2/M phase arrest in our gastric cancer cell line model. The possible role of 
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SIPAl in gastric carcinogenesis and the epigenetic control of gene expression 
deserved further investigations. 
6.5.2 Candidate genes involved in apoptosis and 
anti-proliferation 
The intrinsic pathway is primarily regulated by the BCL-2 family, which 
includes anti-apoptotic， pro-apoptotic members and BH3 domain-only 
pro-apoptotic members. Anti-apoptotic genes suppress the release of cytochrome 
c from mitochondria, whereas the pro-apoptotic genes facilitate the process 
(Peart M. J., Tainton K. M. et al 2003). Gene expressions from these three 
groups of members were examined after the treatment of SAHA or TSA. Suzuki 
and his colleagues have demonstrated the effect of TSA on the expression of 
apoptosis-regulating proteins in gastric cancer cell lines. They found that TSA 
induced protein expression of BAK and BAX while Bad protein expression was 
not significantly altered in gastric cancer cell lines (Suzuki T., Yokozaki H. et al 
2000). In other study with gastric cancer cell line, BAK, BAX and BIK were 
up-regulated when treated with sodium butyrate (Litvak D. A., Hwang K. O. et al. 
2000). In study with leukemic cell line, BAKl was up-regulated while BCL-2 
was down-regulated in response to SAHA treatment (Peart M. J., Smyth G. K. et 
al 2005). They also found that overexpression of BCL-2 suppressed apoptosis 
mediated by SAHA and resulted in accumulation of cells in G2/M phase, which 
indicated that SAHA can program cells undergo apoptosis or arrest in G2/M 
phase (Peart M. J., Smyth G K. et al 2005). 
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In our data, when AGS cells were treated with SAHA or TSA, the treatment 
induced the expression of pro-apoptotic genes BIK and with mild up-regulation 
of BAK 1. But the pro-apoptotic gene expressions of BAX and BAD were 
down-regulated. BCL-2 appeared not significantly altered. Our findings are 
consistent with others' studies on gastric cancer cell lines, except BAX was not 
up-regulated. 
a, BCL2-interactins killer (apoptosis-inducins) (BIK) (Pro-apoptotic sene) 
In our study, BCL2-interacting killer (apoptosis-inducing) (BIK) was 
significantly up-regulated. BIK is a pro-apoptotic gene that promotes cell death in 
a manner similar to the BCL-2 related death. The death- promoting activity of 
BIK was suppressed by expression of BCL-2 and Bcl-XL which suggested that 
BIK may be a common target for anti-apoptotic proteins (Verma S., Budarf M. L. 
et al 2000; Zou Y.，Peng H. et al. 2002). BIK gene is a potent inducer for 
apoptosis and trigger apoptosis in a p53-independent manner which makes BIK a 
potentially useful anticancer agent (Zou Y., Peng H. et al 2002). The results in 
this study revealed that BIK expression was significantly up-regulated with 
SAHA and TSA treatments. These suggested that upregulation of BIK may be an 
important mediator for apoptosis induction by SAHA and TSA. 
b. Thioredoxin interactins protein (TXNIP) (Proapoptotic sene) 
Thioredoxin interacting protein (TXNIP) is also known as TBP-2 and 
VDUPl, is a regulator of the cellular redox state. TXNIP was found to be induced 
by HDAC inhibitors in several cancer cell lines, including prostate (LNCaP), 
breast (MCF7) and urinary bladder (T24) carcinoma cells (Butler L. M., Zhou X. 
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et al 2002). Studies revealed that TXNIP expression in colorectal and gastric 
cancers were significantly lower than that in the adjacent normal tissues and 
expression in stage II patients were significantly higher than that in stage III 
(Ikarashi M., Takahashi Y. et al 2002). These observations suggested that 
expression of TXNIP correlated with the pathogenesis of gastric cancer. 
Upregulation of TXNIP expression induced GO/Gl cell cycle arrest (Han S. H., 
Jeon J. H. et al 2003). Recent studies have also revealed that TXNIP is a novel 
proapoptotic gene as overexpression of TXNIP induced apoptosis when assessed 
by BAX, BCL-2, caspase-3, and cleaved caspase-9 (Minn A. H., Hafele C. et al 
2005). Studies also observed interaction between HDACl and TXNIP (Han S. H., 
Jeon J. H. et al 2003). From our data, TXNIP was induced with HDAC inhibitors 
treatments in gastric cancer cells. Thus, TXNIP could be a potential novel tumor 
suppressor gene in gastric cancer. 
c. Cell death-inducing DFFA-like effector b (CIDEB) (apoptosis induction) 
Cell death-inducing DFFA-like effector b (CIDEB) encodes protein with 
significant homology to the N-terminal region of DNA fragmentation factor 
(DFF) 45. CIDEB was found to activate apoptosis and appeared to serve as 
positive effectors of the apoptotic pathway (Inohara N., Koseki T. et al 1998; 
Lugovskoy A. A., Zhou P. et al 1999). In our study, significant upregulation of 
CIDEB was observed after treatment with TSA and SAHA. However, the 
function of CIDEB and its action in apoptosis induction have not been studied in 
detail in cancer research. More studies have to be done to identify the role of 
CIDEB in gastric cancer. 
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d. B-cell translocation sene 1 (BTGl) - (anti-proliferation) 
B-cell translocation gene 1 (BTGl) is a rapid up-regulation of 
antiproliferative/growth arrest genes (Peart M. J., Smyth G. K. et al. 2005). It is a 
member of the antiproliferative gene family that regulates cell growth and 
differentiation (Iwai K., Hirata K. et al 2004). Studies have demonstrated that 
overexpression of BTGl increased cell migration and inhibited network 
formation. These findings suggested that BTGl may play an important role in the 
process of angiogenesis (Iwai K., Hirata K. et al 2004). Recent studies also 
revealed that BTGl was one of the differentially expressed genes which believed 
to be involved in the tumorgenesis in ovarian cancer (Urzua U., Roby K. R et al 
2005). From our data, BTGl was induced after treatment of SAHA and TSA. The 
upregulation of this gene was consistent with the anti-proliferative effect of TSA 
and SAHA. Upregulation of BTGl upon treatment with HDAC inhibitors has not 
been identified in other studies on gastric cancer cells. However, BTGl was 
found to be rapidly up-regulated in response to the treatment of SAHA in a 
leukemic cell line (Peart M. J., Smyth G. K. et al 2005). Thus, further 
investigation in the possible role of BTGl in gastric carcinogenesis is warranted. 
e, Quiescin 6 (0SCN6) (anti-proliferation} 
Quiescin 6 (QSCN6) is located on human chromosome lq24, near the 
putative hereditary prostate cancer locus (HPCl) (Coppock D. L., Cina-Poppe D. 
et al. 1998). It is known as negative regulator of cell proliferation in human 
embryo lung fibroblasts (Coppock D. L., Kopman C. et al. 1993; Chiba T., 
Yokosuka O. et al 2004). QSCN6 was shown to be induced after the treatment 
with HDAC inhibitor in human liver cancer cell (Chiba T., Yokosuka O. et al. 
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2004). Our result is the first time to indicate that QSCN6 was also up-regulated 
with HDAC inhibitors treatment in gastric cancer cells. Upregulation of QSCN6 
may also be involved in the anti-proliferative effect of HDAC inhibitors. 
厂 Cysteine-ricK ansiosenic inducer, 61 (CYR61) (anti-proliferative) 
Cysteine-rich, angiogenic inducer, 61 (CYR61) is a secreted protein encoded 
by a growth factor-inducible immediate-early gene which regulates cell adhesion, 
migration, proliferation, differentiation and promote tumor growth. A study 
found that the mRNA expression of CYR61 was decreased markedly in human 
non- small cell lung cancers compared with their normal matched lung samples. 
Transfection of CYR61 into non-small cell lung cancer cell lines inhibited 
proliferation, caused G1 phase cell cycle arrest, induced p53 and 
expression and decreased cdk2 activity (Tong X.’ Xie D. et al 2001). Taken 
together, CYR61 may play a role as a tumor suppressor in non-small cell lung 
cancers. While some studies showed that transfection of CYR61 into gastric 
adenocarcinoma cell line RF-1 promoted tumor growth and vasculatization 
(Babic A. M., Kireeva M. L. et al 1998). In this study, CYR61 was induced with 
HDAC inhibitor treatments. Therefore, it may be a potential candidate tumor 
suppressor gene in gastric cancer. 
g. Metallothionein 2A (MT2A) (apoptosis induction and anti-proliferative) 
Metallothionein 2A (MT2A) was found to inhibit cell proliferation and 
induce apoptosis in esophageal cancer (Cui Y.，Wang J. et al 2003). Lee CH et al 
showed that MT2A was down regulated in gastric cancer (Lee C. H., Bang S. H. 
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et al 2005). However, recent nasopharyngeal cancer studies revealed that 
down-regulation of MT2A reduced cell viability and proliferation in NPC cells 
(Tan O. J., Bay B. H. et al 2005). Thus, the roles of MT2A may be different in 
different types of human cancer. Our results indicated for the first time, MT2A 
was up-regulated in gastric cancer cell line treated with HDAC inhibitors. Thus, 
it is possible that MT2A expression is down-regulated in gastric cancer and is 
related to epigenetic silencing mechanism. But whether MT2A may be a 
candidate tumor suppressor gene in gastric cancer will need further 
investigations. 
6.5.3 Other genes reported to be up-regulated with HDAC 
inhibitors treatment 
a, Glia maturation factor-samma (GMFG) 
Glia maturation factor-gamma (GMFG) can be phosphorylated by a variety 
of protein kinases and plays a role in intracellular signal transduction (Kawai Y., 
Asai K. et al 2003). GMFG was one of the up-regulated genes that have been 
identified in the gastric cancer cell line, SNU16, with TSA treatment (Lee H. S., 
Park M. H. et al. 2004). Due to the lack of cancer research of this gene, the 
function and potential role of GMFG in cancer remains unknown. In our AGS 
cell line, upregulation of GMFG have been observed both with SAHA and TSA 
treatments. The observation was consistent with the previous study. However, the 
functions and actions of this gene in gastric cancers remain unclear. 
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b, v-fos FBJ murine osteosarcoma viral oncogene homolos (FOS) 
v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) encodes 
leucine zipper proteins that can dimerize with proteins of the JUN family to form 
the transcription factor complex AP-1 (Finzer P., Soto U. et al 2000). Based on 
the results performed by Finland researchers, FOS is the primary target in human 
gastric cancer cells as the expression of FOS significantly increased after H. 
pylori infection (Myllykangas S., Monni O. et al. 2004). H. pylori infection may 
predispose the host cells for DNA damage by activating transcription and 
promoting histone removal from the chromosomal locations that specific to 
gastric cancer and exposing its target DNA to mutations (Myllykangas S.，Monni 
O. et al 2004). Studies also demonstrated that FOS expression was markedly 
induced after TSA treatment in human hepatoma cells (Chiba T., Yokosuka O. et 
al 2004). Our results also showed significant upregulation of FOS in AGS cells 
after TSA and SAHA treatment. Thus, the observations suggest that FOS may be 
regulated by epigenetic mechanism and contribute to gastric cancer development. 
c. Inter leu kin 8 (IL-8) 
Interleukin 8 (IL-8) is one of the highly induced genes detected after 
treatment with TSA and SAHA in AGS cells. IL-8 was originally identified as a 
neutrophil chemotactic factor in the supematants of activated human monocytes. 
It is known as one of the non-specific angiogenic factor in human malignancies 
(Lee K. H., Bae S. H. et al. 2004). Previous studies have reported that IL-8 
expression is higher in gastric cancer tissue than in corresponding normal 
mucosa and IL-8 mRNA levels associated with the vascularization in gastric 
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cancer (Lee K. H., Bae S. H. et al. 2004). Although gastric cancer tissues express 
higher IL-8 than normal tissues, there is no significant difference in the survival 
rates between patients with high and low IL-8 levels and IL-8 expression did not 
correlate with the pathological stage (Lee K. H., Bae S. H. et al 2004). In 
response to TSA treatment, IL-8 expression showed downregulation in multiple 
hepatoma cell lines (Chiba T., Yokosuka O. et al. 2004). However, in our data, 
IL-8 was dramatically up-regulated in response to SAHA and TSA treatments. 
The underlying mechanism and possible significance of theses observation are 
currently unclear. 
d. Insulin-like srowth factor binding protein- 2 (IGFBP2) 
Insulin-like growth factor binding protein- 2 (IGFBP2) is a member of the 
IGFBPs which regulate insulin-like growth factor (IGF) and associated with 
growth control and carcinogenesis (Grimberg A. and Cohen P. 2000). IGFBP has 
been considered previously as primarily inhibitory in action by sequestering free 
IGFs in several cell lines. However, the levels of IGFPP2 have been elevated in 
various cancers and found to have a positive correlation with the aggressiveness 
of some tumors, including prostate cancer (Moore M. G, Wetterau L. A. et al 
2003). The possible role of IGFBP2 may be difference in different types of 
cancers. Moreover, similar to our observations, with TSA treatment, the 
expressions of IGFBP2 have found to be up-regulated in hepatoma cells (Chiba 
T., Yokosuka O. et al 2004). Since IGFBP2 has not been studied in gastric 
cancer, its function remains to be explored. 
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e. Intesrin alpha chain 7 (ITGA 7) 
Integrin alpha chain 7 (ITGA 7) is mainly expressed in skeletal and cardiac 
muscle and have a prominent role in myogenesis, differentiation, cell migration 
and cell-cell interactions (Pegoraro E., Cepollaro F. et al 2002). However, the 
function of ITGA 7 in tumorgenesis has not been explored. Nevertheless, ITGA 7 
exhibited substantial induction after TSA treatment in multiple hepatoma cell 
lines (Chiba T., Yokosuka O. et al. 2004). Our study also revealed that ITGA7 
was up-regulated after SAHA and TSA treatments. Thus, ITGA 7 could be a 
cancer-related gene that modulated the activation of cell proliferation through 
cell-cell interactions. Further work is necessary to obtain more insight into the 
function of integrin-mediated interaction and signaling. 
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6.5.4 Selected highly up-regulated genes with HDAC inhibitors 
treatment 
a. Aldo-keto reductase family U member C3 (AKR1C3) 
Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) (AKR1C3) encodes a member of the aldo-keto reductase 
(AKR) superfamily. This gene contains enzymes that catalyze the conversion of 
aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or 
NADPH as cofactors. Studies showed that the expression of AKR1C3 is reduced 
in breast cancer tissues as compared to normal breast tissues (Lewis M. J., Wiebe 
J. P. et al 2004). Other studies also indicated that AKR associated with cell 
growth regulation and/or differentiation (Mills K. L, Gilkes A. F. et al. 1998). 
Interestingly, in our data, the expression of AKR1C3 was highly up-regulated 
with SAHA and TSA treatment. The role of AKR1C3 in gastric cancer remains to 
be elucidated. 
b. GPI-anchored metastasis-associated protein homolos (C4,4A) 
GPI-anchored metastasis-associated protein homolog (C4.4A) has recently 
identified to be involved in cell-cell and cell-matrix interactions. Studies have 
showed that C4.4A was up-regulated in the breast tumor samples relative to their 
matched normal tissues (Fletcher G C., Patel S. et al. 2003). As C4.4A interact 
with genes that involved in differentiation, C4AA may play a role in cell 
differentiation in cancer (Fletcher G. C., Patel S. et al. 2003). Limited researches 
have been preformed on C4.4A, the role of this gene on carcinogenesis remain to 
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be discovered. 
c. Serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1 
(SERPINIl) 
Serine (or cysteine) proteinase inhibitor, clade I (Neuroserpin / PI 12), 
member 1 (SERPINIl) is involved in many cellular processes and reacts 
preferentially with tissue-type plasminogen activator in the central nervous 
system (CNS) (Yepes M. and Lawrence D. A. 2004). Reduced expression has 
been observed in brain tumor, but increased expression was reported in prostate 
cancer (Chang W. S., Chang N. T. et al. 2000; Hasumi H., Ishiguro H. et al 
2005). Since lack of studies of this gene in gastric cancer, the roles in gastric 
cancer remain unknown. However, SERPINIl was highly induced in AGS in 
response to SAHA and TSA treatment. Its role in gastric cancer may deserve 
further studies. 
d. Serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminosen 
activator inhibitor type 1), member 1 (SERPINEl) 
Serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 (SERPINEl) was associated with tumor 
invasion and metastasis in gastric cancer. Previous studies have shown that the 
cellular motility of SERPINEl might determine penetration of lymphatic and 
blood vessels and the depth of cancer invasion in gastric cancer (Kawasaki K., 
Hayashi Y. et al 1998). SERPINEl expression has been induced to at least 
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10-fold after HDAC inhibitors treatments. Thus, more works should be done to 
characterize the role of SERPINEl in gastric cancer. The significance of this 
observation is currently unclear. 
e. A drenomedullin (ADM) 
Adrenomedullin (ADM) is a multifunctional peptide which is produced by a 
wide variety of tissues and cells. ADM is expressed in mucosa and possibly act as 
antimicrobial action in host defense. Studies have shown that gut epithelial cells 
secrete ADM basally and ADM production increased significantly upon exposure 
to a number of gastric pathogens such as H. pylori and E. coli. Similar results 
were observed as the ADM expression increased in AGS cells in response to 
inflammatory mediators. Therefore, it was hypothesized that ADM is an 
important host effector molecule that is quickly mobilized by the epithelium 
upon injury and may be useful in the gastric cancer prevention and treatment 
(Allaker R. R and Kapas S. 2003). ADM was considered as potential oncogene in 
cancers including prostate cancer (Mazzocchi G, Malendowicz L. K. et al. 2004) 
and adrenocortical cancer (Albertin G, Carraro G. et al 2005). However ADM 
was shown to cause inhibition of prostate cancer cell growth in another study 
(Abasolo I., Wang Z. et al. 2004). Thus, the roles of ADM may be different in 
different types of human cancer. In the current study, ADM was highly induced in 
response to SAHA and TSA treatments in gastric cancer AGS cells and suggested 
that ADM may be down-regulated by epigenetic mechanism in gastric cancer. 
The possible role of ADM in gastric carcinogenesis deserved further studies. 
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f- Dehydrosenase/reductase (SDR family) member 2 (HEP2 7) 
Dehydrogenase/reductase (SDR family) member 2 (HEP27) encodes a 
member of short chain alcohol dehydrogenase/reductase family. Previous studies 
have shown that treatment of butyrate induced growth arrest and synthesis of 
HEP27 in human hepatoblastoma cells (Pellegrini S., Censini S. et al. 2002). As 
butyrate is a well know HDAC inhibitors, the synthesis of HEP2 7 might be 
related to histone acetylation. In this study, with the treatment of HDAC 
inhibitors, SAHA and TSA, HEP2 7 was also induced in gastric cancer cell line 
AGS. More works need to be done to characterize the function of this gene in 
cancer. 
g. Ch olecystokin in (CCK) 
Cholecystokinin (CCK) is a brain / gut peptide. In the gut, it is a gut 
hormone and a neuropeptide that stimulate insulin secretion and contraction of 
gallbladder (Ahren B., Hoist J. J. et al 2000). Most of the studies reported on the 
role of gastrin and CCK receptors in cancer developments. Several evidences 
suggested that gastrin promote cancer progression via different CCK receptors in 
different regions of the gut (Aly A., Shulkes A. et al 2004). Nevertheless, Yasui 
et al have shown that proliferation of gastrin-dependent human gastric cancers 
may be suppressed by CCK (Yasui W., Sumiyoshi H. et al 1986). In our data, 
CCK was markedly induced in response to SAHA and TSA treatment in gastric 
cancer cells. Thus, CCK may be a potential candidate tumor suppressor gene in 
gastric cancer. 
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h. Silver homolos (mouse) (SILV) 
Silver homolog (mouse) (SILV) encodes melanosomal protein which plays 
important roles in melanogenesis. Although the function oiSILV is unclear, it has 
been proposed to function in polymerization or stabilization of melanin 
intermediates and/or in protecting pigmented cells from toxic melanin 
intermediates (Berson J. F., Harper D. C. et al. 2001). However, little is known 
about the role of this gene in cancer development. SILV w2ls highly induced gene 
in our experiments and confirmed by RT-PCR. The potential role of SILV in 
gastric cancer remains unclear. 
6.6 Genes regulated by gene promoter 
hypermethylation in AGS cells 
Hypermethylation of CpG islands in promoter region by transcriptional 
silencing is a common mechanism for the inactivation of tumor suppressor genes. 
Multiple genes hypermethylation is reported in gastric adenocarcinoma (GCA). 
In the current study, nine out of 11 (82%) selected genes examined showed gene 
methylation in AGS cell line. Among the 9 genes, 6 genes (included COX-2, 
DOC-2, hMLHl, PTEN’ RASSFIA and TSLC-1) were found to be partially 
methylated whereas the 3 other genes (included, pi严,pi6!態 and SOCS-1) 
were completely methylated based on MSP analysis. These findings were 
consistent with previous methylation studies. Notably, methylation of 
phosphatase and tensin homolog (PTEN) was noted in AGS cell. This tumor 
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suppressor gene located on 10q23.3 encodes a dual-specificity protein 
phosphatase (Byun D. S., Cho K. et al 2003). Recent studies revealed that no 
mutations were detected in 10 gastric cancer cell lines, similar levels of PTEN 
expression were observed and MSP analysis also indicated that PTEN promoter 
CpG islands remained unmethylated (Sato K., Tamura G. et al. 2002). 
The expression levels of these genes in AGS cells were also assessed after 
treatment with HDAC inhibitors. Most of the genes, including COX-2, DOC-2’ 
hMLHl, pi 严，pi 6!脳〜PTEN and RASSFIA showed no remarkable induction 
of the mRNA expression levels in both RT-PCR and microarray results. The 
results suggested that these genes were controlled by gene promoter 
hypermethylation and histone deacetylation seem not to be involved in the 
regulation of the gene expressions. No gene methylation was detected in MGMT 
and PI5I顏 in AGS cells. Expression of plS!隱 was slightly induced by 
RT-PCR analysis, the significance of the observation remains to be clarified. 
In particular, SOCS-1 and TSLC-\ genes were methylated and both were 
up-regulated after SAHA and TSA treatments. In previous study, CpG island of 
SOCS-1 was densely methylated in gastric cancer AGS cells and methylation of 
SOCS-1 was detected in 27.5% (11 of 40) of primary gastric adenocarcinoma (To 
K. F., Chan M. W. et al 2004). Beside that, we also demonstrated that 
downregulation of SOCS-1 was associated with interleukin-6 (IL-6) in the 
activation of JAK/STAT pathway in gastric cancer (To K. F.，Chan M. W. et al. 
2004). The results suggested that down-regulation of SOCS-1 was involved in a 
subset of GCA. Our present data were in keeping with previous finding that 
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SOCS-l was hypermethylated in the promoter region in AGS cells. Upon the 
treatment of SAHA and TSA, RT-PCR and microarray analysis indicated that 
SOCS-l expression was upregulated. Therefore, SOCS-l might be regulated not 
only by promoter hypermethylation but also histone deacetylation. Epigenetic 
regulation by histone deacetylation has not been reported for SOCS-\ gene. 
The expression of TSLC-1 was found to be lost in various cancers including 
human non-small cell lung cancer (NSCLC), esophageal cancer, gastric cancer, 
ovarian cancer, endometrial cancer, breast cancer, colorectal and small cell lung 
cancers. Combined analysis of promoter methylation and the allelic state 
demonstrated that beside mono-allelic methylation, bi-allelic methylation of the 
TSLC-1 gene occurred at high incidence in those cancer cell lines (Fukami T., 
Fukuhara H. et al. 2003). The methylation status of TSLC-\ has been studied in 
gastric cancer cell lines in previous studies such as KATO-III and ECCIO. To our 
knowledge, this was the first time the methylation status of TSLC-1 was 
examined in AGS cell line. TSLC-1 encodes an immunoglobulin (Ig)-like cell 
surface protein called Necl-2 which belongs to the Nectin and Nectin-like (Ned) 
family (Boles K. S., Barchet W. et al 2005). Neds contribute a variety of 
cell-cell junctions through homotypic contacts and/or heterotypic interactions 
with other Nectins and Neds which inhibits tumorgenesis by ensuring that 
epithelial cells grow in organized layers (Boles K. S., Barchet W. et al. 2005). 
Interestingly, studies demonstrated that tumor suppressor Necl-2 triggered 
natural killer (NK) cells and CD8+ T-cell response through their cell-surface 
receptor CRTAM and promoted immune response. Thus, it is possible that 
epithelial tumors such as NSCLC escape immune response by deleting TSLC-1 
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or inhibiting the transcription in order to silence Necl-2 (Boles K. S., Barchet W. 
et al 2005). Other gastric cancer studies have demonstrated that promoter 
methylation of TSLCl was a cancer-specific alteration as it was methylated in 2 
gastric cell lines and 16% of primary gastric cancer while non-cancerous gastric 
tissues had no methylation detected (Honda T., Tamura G. et al 2002). 
In our study, TSLCl was partially methylated. The possible involvement of 
histone deacetylation in the epigenetic control of TSLC-1 expression has not been 
reported before. Treatment with HDAC inhibitors, both SAHA and TSA, 
upregulated the TSLCl expression and was demonstrated in both microarray and 
real-time RT-PCR results. Thus, we speculated that the candidate tumor 
suppressor TSLCl might be regulated by both methylation and histone 
deacetylation epigenetic mechanisms. 
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Chapter 7 Conclusion 
1. Assess the potential anti-cancer effect of H D A C inhibitors in a gastric 
cancer cell line model. 
In the current study, a gastric cancer cell line AGS model is used to 
investigate the potential anti-cancer effect of HDAC inhibitors. The results 
indicated that both Suberoylanilide Hydroxamic Acid (SAHA) and Trichostatin A 
(TSA) exhibited anti-proliferative effect, apoptosis induction and G2/M phase 
cell cycle arrest in AGS cells. Theses observations suggested that HDAC 
inhibitors may have anti-cancer effects in gastric cancer. 
2. To explore the alterations of genes expressions upon treatment of H D A C 
inhibitors. 
(1) By microarray expression analysis, a small subset of genes were altered after 
treatment with HDAC inhibitors: around 2% in SAHA (at 4|LIM concentration 
and 24 hours treatment) and around 3% in TSA (at lOOng/ml concentration and 
24 hours treatment) experiments. Overlapping genes altered after treatment of 
SAHA and TSA constitute more than 1% of genome. Among these altered 
overlapping genes, more than half were hypothetical genes with unknown 
function while the remaining genes were related to various cellular pathways 
including anti-proliferation and apoptosis. The results suggested that a specific 
set of genes are being altered by HDAC inhibitors. Since a numbers of altered 
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genes were related to anti-proliferation or apoptosis induction, these may further 
provide insights into the underlying mechanisms of the anti-cancer effects of 
HDAC inhibitors. 
(2) Selected up-regulated genes after treatment of HDAC inhibitors were further 
confirmed by RT-PCR. 
a. In particular, after SAHA and TSA treatments, pro-apoptotic or apoptosis 
induction genes including BCL-2 interacting killer (BIK), BCL-2 
anatagonist/killer 1 (BAKl), cell death-inducing DFFA-like effector b (CIDEB), 
thioredoxin interacting protein {TXNIF) were up-regulated but not for BCL-2 or 
BAX. Anti-proliferating genes including B-cell translocation gene 1 {BTGl) 
quiescin 6 (QSCN6), cysteine-rich，angiogenic inducer, 61 {CYR61) and 
metallothionein 2A (MT2A) were up-regulated. Cell-cycle related genes 
including and signal-induced proliferation-associated gene 1 (SIPAl) 
were up-regulated b u t , cyclin A and cylin E were not up-regulated. 
b. Among these altered genes, pro-apoptotic/ apoptosis induction genes or 
anti-proliferative genes including TXNIP，QSCN6 and BTGl have been reported 
to be up-regulated after HDAC inhibitors treatment in non-gastric cell lines, but 
were first identified in gastric cancer cell line in the current study. 
c. Genes including CYR61’ MT2A, CIDEB and SIPAl have not been reported to 
be up-regulated after HDAC inhibitors treatment. In particular, SIPAl may be 
involved in G2/M phase arrest as observed in this study. The results suggested 
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that these genes may also be important targets for HDAC inhibitors. 
d. Most of the candidate tumor suppressor genes that frequently silenced by gene 
promoter methylation in gastric cancer, do not show up-regulation after SAHA or 
TSA treatments in AGS cells. The observations suggested that epigenetic 
mechanisms in silencing of these genes are related to gene methylation but 
probably not histone de-acetylation. However, TSLC 1 and SOCS-1 were 
up-regulated upon treatments of HDAC inhibitors, suggesting that both gene 
methylation and histone de-acetylation may involved in the epigenetic silencing 
of theses two genes. 
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Chapter 8 Further Studies 
Our study further supported the potential anti-cancer effect of HDAC 
inhibitors in gastric cancer cell line. In order to confirm the anti-cancer effect of 
HDAC inhibitors in vitro, animal studies will be conducted. Since AGS cell line 
is tumor forming in nude mice model, further studies on this animal model can 
also correlate with the current cell line model results. In particular, SAHA has 
been investigated in some other cancers and enters into phase I or II clinical trails. 
Thus, with further supporting evidence from in vitro study, SAHA may be 
feasible in entering into clinical trail for gastric cancer patients. On the other 
hand, AGS cell line and AGS tumor formation in nude mice may be suitable in 
vivo and in vitro models for investigating new and potential HDAC inhibitors. 
There are a number of potential target genes being identified. Further 
studies like chromatin immunoprecipitation (ChIP) assay can be applied to see 
whether there are direct HDAC inhibitory effects on those target genes. These 
studies will provide a better understanding of epigenetic gene regulation in 
gastric carcinogenesis. These genes may constitute a new group of cancer related 
or tumor suppressor genes in gastric cancer. Genes, like TSLCl and SOCS-1 are 
silenced by gene methylation in gastric cancers, the current studies suggested that 
these genes may also controlled by histone acetylation. Further studies on the 
potential synergic effect of both de-methylation agents and HDAC inhibitors on 
gene re-expression will be of interest to disclose a better picture of the epigenetic 
regulations of these genes. 
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Appendix I 
^^Real Time RT-PCR Primer Sequence 
Gene Primer Sequence (5'-3') ^ T e r ^ ^ ^ ^ ^ ! ^ 
F I G A C T T C G G A G T T T T G CCA T T 58。C … 
ADM 40 
R GAG CGA ACC CAG GTA CAT C 58 C 
F TCA TGC CTG AT TGG GAT TT 58�C 川 AKRIC3 — 40 
R GTC CAA CCT GCT CCT CAT TA 58 C 
F GGG ACG AAC TGG ACA GTA AC 58�C 川 BAKl ；—— 40 
R GAG TCA TAG CGT CGG TTG AT 58 C 
F GGG ACG AAC TGG ACA GTA AC 58°C 川 
B A X 1 — 4 0 
R ACT CGG AAA AAG ACC TCT CG 58 C 
F GCC CTG TGG ATG ACT GAG TA 58°C 
BCL-2 ； 40 
R GGC CGT ACA GTT CCA CAA 58 C 
F TTG ATG GAG ACC CTC CTG TA 58�C 仙 
B i k — 
R AAG TCC TCC ATA GGG TCC AG 58�C 
F TAG CAC TCA AAA CAG CAC CA 58°C 
B T G l - 7 4 U 
R TCC TCC TTA CAG CTG ATT CG 58 C 
F CCC TGC TGG CAA GAT ACA T 58t： 仙 
CCK 4U 
R CCA GGT TCT GCA GGT TCT TA 5 8 ^ 
F ACC ATT GGT CCC TCT TGA TT 58°C 
C C N A 2 4U 
R CAC TCA CTG GCT TTT CAT CTT 58 C 
F GGA CAC CAT GAA GGA GGA C 58�C 仙 CCNEl ^^ 
R CTT CAT CTG GAT CCT GCA A A 58°C 
F GAT GTC CGT CAG AAC CCA TG 58�C 仙 CDKNlA(p21) ; 4 � 
R TTA GGG CTT CCT CTT GGA GA 58_C 
F AGG AAT AAG GAA GCG ACC TG 58°C 仙 CDKNIB (p27) ： 4 � 
R GGG AAC CGT CTG AAA CAT T ^ 
F GTT CCA GGG AAG GAA CTC TC 5 8�C 仙 
C I D E B - r -
R GAT CAC AGA CAC GGA AAG GT 3 8 ^ 
F ACT TCA TGG TCC CAG TGC TC 58�C 仙 CYR61 ； 40 
R AAA TCC GGG TTT CTT TCA CA 一 
F ATC CTG GGC TCA GGT AAG AG 58°C 如 
C 4 4 A 叫 
• R CTT TCT GCA CGC AGC TGT A 
F C G G G G A T A G C C T C T C T T A C T 58°C 仙 FOS — 40 
R AAT GAA GTT GGC ACT GGA GA 
GMFG F CAG ACA ATG CAG CCA TCA TA SST 
I 
R[CTG AAA TTC TTC CTC CAG CA 58�C 
TTr— F CAT CCT GGT CTC TTC CAT TG 58°C 
HEP27 40 
R GTG TTC TAG TGA GAC CCA GCA 58�C 
^ F GAG GGC ACT TGT GAG AAG C 58�C 
IGFBP2 40 
R GCT CCT TCA TAG CCG ACT TG 58�C 
F TGT GCC TTG GTT TCT CCT TT 58°C 
IL-8 40 
R GCT TCC ACA TGT CCT CAC AA 58�C 
F GCT CGT CGA ACT GCT CTT CT 58°C 
ITGA7 40 
R CAG TCT CCT CCA GGC TCA AC 58�C 
F ATG GAT CCC AAC TGC TCC T 58�C 
MT2A 40 
R GCA TTT GCA CTC TTT GCA TT 58�C 
F AGT TCT TCG CCT CCT GGT G 58�C 
QSCN6 40 
R AGG CCT TGA AGA ACC TCA CA 58�C 
F AGC AGC TAT GGG ATT CAA GA 58�C 
SERPINE 1 40 
R GCT GAT CTC ATC CTT GTT CC 58°C 
F CGT GGC CAA CTA CAT CAA TA 58°C 
SERPINI 1 -� 40 
R TGG GGA TAC CAA ATC TTT CA 
F GCT GTG ATA GGT GCT TTG CT 58�C 
SILV -� 40 
R GGT TCT GAG TTG CCT TGA GA 58 C 
F GAC AGT GAG ACA CCC CTG AC 58°C 
SIPAl ； 40 
R ACA AGG TAC GTG GCA GAA AG 58 C 
F ACT CGT GTC AAA GCC GTT AG 58°C 
TXNIP -� 40 
R AGC TCA AAG CG AAC TTG TA 58 C 
F CTG GCA CCC AGC ACA ATG 58°C 
P- actin 40 




Gene Primer Sequence (5,-3，） Temperature Cycles 
^ 
FICCC T C C C T T A C C A T C A A A T C 58°C 
C O X - 2 40 
R T G A A G A T T A G T C C G C C G T A G 58°C 
F G G G T C A A C A T T T C C C T T T C T 58�C 
D O C - 2 40 
R A C G G G C A A T G A A A G A A A T C 58�C 
F T C A C C C T G T A C C A G T C C A A T 58�C 
G S T P I 40 
R C T G C T G G T C C T T C C C A T A G 58°C 
F A G T G G G A G G A G C A A T G A G A 58�C 
M G M T 40 
R C T G C T G C A G A C C A C T C T G T 58°C 
F G A T T C A G A T C C A A G A C A A T G G 58°C _ 
h M L H l 40 
R T C C T C A A A G G A C T G C A G T T T A 58°C 
F A C G G A G T C A A C C G T T T C G 58°C 
p 15 ( C D K N 2 B ) 40 
R G T G G G A A A T T G G G T A A G A A A 58。C 
F A C A T T A T G A C A C C G C C A A A T 58°C 
P T E N 40 
R T A G C T G T G G T G G G T T A T G G T 58°C 
F G G T A G C A C A C A A C C A G G T G 58°C 川 
SOCS-1 40 
R G A A G A G G A G G A A G G T T C T G G 58°C 
F C C A A C A G G A A G A C C A T T T A T 58。C 
TSLC-1 40 
R C A A C T G A A A C C T G C T G T C C T 58°C 
III 
Appendix III 
Gene P r — Sequence (5，-3’） 二H^^CC) 
COX-2 M F: TTA GAT ACG GCG GCG GCG GC 61 161 
(Akhtar M.，Cheng .......... .R： TCT TTA CCC GAA CGC TTC CG 
Y. et al. 2001) U F: ATA GAT TAG ATA TGG TGG TGG TGG T 61 171 
R： CAC AAT CTT TAC CCA AAC ACT TCC A 
DOC-2 M F: TTT GTA TTC GTT TTT CGT TCG 60 157 
R: TTA ACT CGC GCT ACA ACG AC 
U F: GTT GGT TTG GGG TTT TTG ATT 60 139 
R: TTT ATT AAC TCA CAC TAC AAC AAC ACA 
MGMT M F: TTT CGA CGT TCG TAG GTT TTC CG 59 81 
(Esteller M， GCA CTC TTC CGA AAA CGA AAC G 
^ ^ ' e l f l t T o O O r J U F: TTT GTG TTT TGA TGT TTG TAG GTT TTT GT 59 93 
R: AAC TCC ACA CTC TTC CAA CCC CAA AAC A 
hMLHl M F: ACG TAG ACG TTT TAT TAG GGT CGC 59 113 
(Fleisher A. S.， R: CCT CAT CGT AAC TAC CCG CG 
Esteller M. et al. 
1999) U F: TTT TGA TGT AGA TGT TTT ATT AGG GTT GT 59 93 
R: ACC ACC TCA TCA TAA CTA CCC ACA 
p i 4 (CDKN2A) M F: GTG TTA AAG GGC GGC GTA GC 64 122 
(Esteller M., R: AAA ACC CTC ACT CGC GAC GA 
Tortola S. et al. 
2000) U F: TTT TTG GTG TTA AAG GGT GGT GTA GT 64 122 
R: CAC AAA AAC CCT CAC TCA CAA CAA 
pi 5 (CDKN2B) M F: GCG TTC GTA TTT TGC GGT T 60 148 
(Herman J. G, R: CGT ACA ATA ACC GAA CGA CCG A 
1996) U F: TGT GAT GTC TTT GTA TTT TGT GGT T 60 154 
R: CCA TAC AAT AAC CAA ACA ACC AA 
p 16 (CDKN2A) M F: TTA TTA GAG GGT GGG GCG GAT CGC 60 150 
(Herman J. G.， R: GAC CCC GAA CCG CGA CCG TAA 
G r a f f / g g i ) � , "！' U F: TTA TTA GAG GGT GGG GTG GAT TGT 60 151 
R: CAA CCC CAA ACC ACA ACC ATA A 
PTEN M F: TTT AGC GTT TGT GAG TAG TCG C 142 55 
(Sato K., Tamura R: CCT TCC CTT TCA AAA AAA ACC G 
G. et al. 2002) ^ ^。丁丁 GTG AGG GAG ATG AGA GAT 192 55 
R: CAC CTT CCC TTT CAA AAA AAA CCA 
IV 
RASSFIA M F: GTG TTA ACG CGT TGC GTA TC 60 93 
(Burbee D. G., 
Forgacs E. et al. R: AAC CCC GCG AAC TAA AAA CGA 
2001) 
U F: TTT GGT TGG AGT GTG TTA ATG TG 60 105 
R: CAA ACC CCA CAA ACT AAA AAC AA 
SOCS-1 M F: TTC GCG TGT ATT TTT AGG TCG GTC 60 160 
(Yoshikawa H., R： CGA CAC AAC TCC TAC AAC GAC CG 
2001) U F: TTA TG A GTA TTT GTG TGT ATT TTT AGG TGG GTT 60 175 
R: CAC TAA CAA CAC AAC TCC TAC AAC AAC CA 
TSLC-1 M F: TTC GGG GAA AGT AAA ATT CG 58 107 
(Kuramochi M., R： CTA ACG CTA ACG TTC GAC GAC G 
Fukuhara H. et al. 
2001) U F: TTG ATT TGG GGA AAG TAA AAT TTG 58 115 
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